[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 7604
1. Tanaka A, Minoguchi K, Chen X, Oda N, Yokoe T, Yamamoto Y, Yamamoto M, Watanabe Y, Ohta S, Xu X, Adachi M: Activated protein C attenuates leukocyte elastase-induced lung injury in mice. Shock; 2008 Aug;30(2):153-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activated protein C attenuates leukocyte elastase-induced lung injury in mice.
  • The purpose of the current study was to (1) examine the relationship between LE-induced lung injury and specific markers of inflammation and cytokine/chemokine, and to (2) determine the potential of activated protein C (APC), a potent immunomodulator, to block the inflammatory response to LE.
  • Total cells, total protein, and neutrophils were increased and peaked at 16 h in bronchial alveolar lavage fluid.
  • Administration of LE up-regulated the synthesis of proinflammatory cytokines, IL-1beta and IL-6, chemokines, keratinocyte-derived chemokine, and macrophage inflammatory protein 2 in bronchial alveolar lavage fluid, and their peaks were at 6 h.
  • Furthermore, the mice were treated with APC at 0.2, 2.0, and 10 mg/kg (i.v.) after instillation of LE.
  • Therapeutic treatment of APC at 2.0 and 10 mg/kg significantly attenuated the increases in all these parameters.
  • Lung histology revealed that, in addition to inflammation, alveolar hemorrhage and alveolar wall destruction induced by LE were also attenuated by APC.
  • Finally, the expression of tissue plasminogen activator and plasminogen activator inhibitor in whole lung of mice exposed to LE, detected by means of reverse-transcriptase-polymerase chain reaction, were not influenced by the treatment with APC.
  • These data demonstrate that intratracheal administration of LE to mice causes a transient inflammatory response, and APC can play a protective role against LE-induced lung injury.
  • [MeSH-major] Inflammation Mediators / therapeutic use. Leukocyte Elastase / toxicity. Lung Diseases / chemically induced. Lung Diseases / pathology. Protein C / metabolism. Protein C / therapeutic use
  • [MeSH-minor] Animals. Enzyme Activation / physiology. Female. Fibrinolysis. Intubation, Intratracheal. Mice. Mice, Inbred C57BL. Neutrophil Activation / physiology. Neutrophil Infiltration / physiology. Neutrophils / pathology. Pulmonary Alveoli / drug effects. Pulmonary Alveoli / metabolism. Pulmonary Alveoli / pathology

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628688.001).
  • [ISSN] 1073-2322
  • [Journal-full-title] Shock (Augusta, Ga.)
  • [ISO-abbreviation] Shock
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Inflammation Mediators; 0 / Protein C; EC 3.4.21.37 / Leukocyte Elastase
  •  go-up   go-down


2. Berkhout M, Nagtegaal ID, Cornelissen SJ, Dekkers MM, van de Molengraft FJ, Peters WH, Nagengast FM, van Krieken JH, Jeuken JW: Chromosomal and methylation alterations in sporadic and familial adenomatous polyposis-related duodenal carcinomas. Mod Pathol; 2007 Dec;20(12):1253-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal and methylation alterations in sporadic and familial adenomatous polyposis-related duodenal carcinomas.
  • Primary carcinomas of the small intestine are rare and the mechanism of their pathogenesis is poorly understood.
  • Patients with familial adenomatous polyposis (FAP) have a high risk of developing duodenal carcinomas.
  • Therefore, five FAP-related duodenal carcinomas were characterized for chromosomal and methylation alterations, which were compared to those observed in sporadic duodenal carcinomas.
  • Comparative genomic hybridization (CGH) and methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) was performed in 10 primary sporadic and five primary FAP-related duodenal carcinomas.
  • In the FAP-related carcinomas, frequent gains were observed on chromosomes 8, 17 and 19, whereas in sporadic carcinomas they occurred on chromosomes 8, 12, 13 and 20.
  • In 60% of the sporadic carcinomas, gains in the regions of chromosome 12 were observed which were absent in the FAP-related carcinomas (P=0.04).
  • Hypermethylation was observed in the immunoglobulin superfamily genes member 4 (IGSF4), TIMP metallopeptidase inhibitor 3 (TIMP3), Estrogen receptor 1 (ESR1), adenomatous polyposis coli (APC), H-cadherin (CDH13) and paired box gene 6 (PAX6) genes.
  • Hypermethylation of PAX6 was only observed in FAP-related carcinomas (3/5) and not in sporadic carcinomas (P=0.02).
  • In conclusion, in contrast to sporadic duodenal carcinomas, gains on chromosome 12 were not observed in duodenal carcinomas of patients with FAP.
  • Identification of the genes in these regions of chromosome 12 could lead to a better understanding of the carcinogenesis pathways leading to sporadic and FAP-related duodenal carcinomas.
  • Furthermore, hypermethylation seems to be a general feature of both FAP-related duodenal carcinomas as well as sporadic duodenal carcinomas with the exception of the PAX6 gene, which is methylated only in FAP-related carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Adenomatous Polyposis Coli / genetics. Chromosome Aberrations. DNA Methylation. Duodenal Neoplasms / genetics


3. Lee SH, Kang HJ, Shin DH, Cho DY, Song JM, Lee HC, Kim GH, Song GA, Sol MY, Kim JY, Choi KU, Lee CH, Huh GY, Park DY: Expression of beta-catenin and its mechanism of delocalization in intestinal-type early gastric cancer based on mucin expression. Histol Histopathol; 2009 07;24(7):831-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of beta-catenin and its mechanism of delocalization in intestinal-type early gastric cancer based on mucin expression.
  • The biological characteristics of intestinal-type early gastric cancers (ICs) differ based on mucin phenotypes.
  • There was increased cytoplasmic and nuclear beta-catenin expression (delocalization) in ICs with a predominant intestinal mucin phenotype (ICIP; 46.3% [25/54 cases]) compared to ICs with a predominant gastric mucin phenotype (ICGP; 20% [11/55 cases]).
  • There were no beta-catenin or APC mutations in ICs.
  • APC promoter hypermethylation was present in 49 of 105 (46.7%) cases of ICs.
  • There was a significant relationship between APC promoter hypermethylation and beta-catenin delocalization in ICs, especially in ICIPs.
  • There was no relationship between beta-catenin delocalization and APC gene loss of heterozygosity in ICs.
  • In conclusion, we showed that beta-catenin delocalization was more evident in ICIPs, and APC promoter hypermethylation might play a role in delocalization of beta-catenin, especially in ICIPs.
  • [MeSH-minor] Adult. Aged. Alleles. Base Sequence. Cell Nucleus / metabolism. DNA Methylation. DNA Mutational Analysis. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Female. Gastrectomy. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Genes, APC. Humans. Immunohistochemistry. Loss of Heterozygosity. Male. Middle Aged. Molecular Sequence Data. Mutation. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Polymorphism, Single-Stranded Conformational. Promoter Regions, Genetic. Retrospective Studies. Sequence Analysis, DNA. Time Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19475529.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / DNA, Neoplasm; 0 / Mucins; 0 / beta Catenin
  •  go-up   go-down


Advertisement
4. Leal RF, Ayrizono Mde L, Milanski M, Fagundes JJ, Moraes JC, Meirelles LR, Velloso LA, Coy CS: Detection of epithelial apoptosis in pelvic ileal pouches for ulcerative colitis and familial adenomatous polyposis. J Transl Med; 2010;8:11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of epithelial apoptosis in pelvic ileal pouches for ulcerative colitis and familial adenomatous polyposis.
  • BACKGROUND: Ileal pouch-anal anastomosis (IPAA) is the surgical procedure of choice for patients with refractory ulcerative colitis (UC) and for familial adenomatous polyposis (FAP) with many rectal polyps.
  • Pouchitis is one of the more frequent complications after IPAA in UC patients; however, it is rare in FAP.
  • OBJECTIVE: Evaluate pro-apoptotic activity in endoscopically and histological normal mucosa of the ileal pouch in patients with UC and FAP.
  • METHODS: Eighteen patients (nine with UC and nine with FAP) with J pouch after total rectocolectomy were studied.
  • The specimens were snap-frozen and the expressions of Bax and Bcl-2 were determined by immunoblot of protein extracts and by immunohistochemistry analysis.
  • FADD, Caspase-8, APAF-1 and Caspase-9 were evaluated by immunoprecipitation and immunoblot.
  • RESULTS: Patients with UC had significantly higher protein levels of Bax and APAF-1, Caspase-9 than patients with FAP, but were similar to controls.
  • Immunohistochemistry for Bax showed less intensity of immunoreactions in FAP than in UC and Controls.
  • CONCLUSION: Patients with FAP present lower levels of pro-apoptotic proteins in all methods applied, even in the absence of clinical and endoscopic pouchitis and dysplasia in the histological analysis.
  • However, FAP patients had low pro-apoptotic activity in the mucosa, and it could explain the tendency to low cell turn over and presence of adenomas in this syndrome.
  • [MeSH-major] Adenomatous Polyposis Coli / surgery. Apoptosis / physiology. Colitis, Ulcerative / surgery. Colonic Pouches / pathology. Intestinal Mucosa / pathology
  • [MeSH-minor] Animals. Apoptosis Regulatory Proteins / metabolism. Apoptotic Protease-Activating Factor 1 / metabolism. Caspase 8 / metabolism. Caspase 9 / metabolism. Humans. Ileum / anatomy & histology. Ileum / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):691-9 [14644193.001]
  • [Cites] Acta Haematol. 2004;111(1-2):7-27 [14646342.001]
  • [Cites] Br Med J. 1978 Jul 8;2(6130):85-8 [667572.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Ann Surg. 1990 May;211(5):622-7; discussion 627-9 [2339922.001]
  • [Cites] Mayo Clin Proc. 1994 May;69(5):409-15 [8170189.001]
  • [Cites] Dig Dis Sci. 1994 Jul;39(7):1525-31 [8026266.001]
  • [Cites] Dis Colon Rectum. 1995 May;38(5):526-9 [7736885.001]
  • [Cites] Dis Colon Rectum. 1995 May;38(5):543-4 [7736887.001]
  • [Cites] Dis Colon Rectum. 1995 Aug;38(8):831-7 [7634977.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12490-5 [8901609.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):7141-7 [9507028.001]
  • [Cites] World J Surg. 1998 Apr;22(4):347-51 [9523515.001]
  • [Cites] Gut. 1998 Jul;43(1):48-55 [9771405.001]
  • [Cites] Int J Colorectal Dis. 1998;13(5-6):196-207 [9870162.001]
  • [Cites] Endocrinology. 2005 Mar;146(3):1428-37 [15550510.001]
  • [Cites] Scand J Gastroenterol. 2005 Jan;40(1):43-51 [15841713.001]
  • [Cites] Inflamm Bowel Dis. 2005 May;11(5):447-54 [15867584.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):469-75 [15747080.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2248-53 [16181377.001]
  • [Cites] Ann Hematol. 2005 Oct;84(10):627-39 [16041532.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jan;4(1):81-9; quiz 2-3 [16431309.001]
  • [Cites] World J Gastroenterol. 2006 Feb 21;12(7):1056-62 [16534846.001]
  • [Cites] Gut. 2006 Jun;55(6):833-41 [16401690.001]
  • [Cites] Int J Colorectal Dis. 2006 Oct;21(7):711-20 [16437210.001]
  • [Cites] Fam Cancer. 2006;5(3):241-60; discussion 261-2 [16998670.001]
  • [Cites] J Surg Res. 2007 May 1;139(1):143-56 [17257621.001]
  • [Cites] Dis Colon Rectum. 2007 Jun;50(6):832-8 [17309000.001]
  • [Cites] Dis Colon Rectum. 2007 Jun;50(6):825-31 [17429711.001]
  • [Cites] Br J Surg. 2007 Jul;94(7):812-23 [17571291.001]
  • [Cites] Tech Coloproctol. 2008 Mar;12(1):33-8 [18512010.001]
  • [Cites] Inflamm Bowel Dis. 2000 Aug;6(3):157-64 [10961587.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):360-4 [11224623.001]
  • [Cites] J Surg Res. 2001 Jun 1;98(1):27-32 [11368534.001]
  • [Cites] Dis Colon Rectum. 2002 Jun;45(6):776-86; discussion 786-8 [12072630.001]
  • [Cites] Scand J Gastroenterol. 2003 Oct;38(10):1055-8 [14621280.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • (PMID = 20113505.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / APAF1 protein, human; 0 / Apoptosis Regulatory Proteins; 0 / Apoptotic Protease-Activating Factor 1; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9
  • [Other-IDs] NLM/ PMC2843649
  •  go-up   go-down


5. Aizu K, Li W, Yajima T, Arai T, Shimoda K, Nimura Y, Yoshikai Y: An important role of Tyk2 in APC function of dendritic cells for priming CD8+ T cells producing IFN-gamma. Eur J Immunol; 2006 Nov;36(11):3060-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An important role of Tyk2 in APC function of dendritic cells for priming CD8+ T cells producing IFN-gamma.

  • MedlinePlus Health Information. consumer health - Listeria Infections.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17048270.001).
  • [ISSN] 0014-2980
  • [Journal-full-title] European journal of immunology
  • [ISO-abbreviation] Eur. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Cytokines; 0 / HLA-A Antigens; 0 / HLA-B Antigens; 0 / OVA-8; 0 / Peptide Fragments; 82115-62-6 / Interferon-gamma; 9006-59-1 / Ovalbumin; EC 2.7.10.2 / TYK2 Kinase; EC 2.7.10.2 / Tyk2 protein, mouse
  •  go-up   go-down


6. Takamori N, Shimomura A, Senda T: Microtubule-bundling activity of APC is stimulated by interaction with PSD-95. Neurosci Lett; 2006 Jul 31;403(1-2):68-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microtubule-bundling activity of APC is stimulated by interaction with PSD-95.
  • Adenomatous polyposis coli (APC) tumor suppressor protein binds to microtubules, leading to microtubule bundling and stabilization.
  • The protein also interacts with postsynaptic density (PSD)-95, a major scaffolding protein in neurons.
  • Here, we analyzed the effects of PSD-95 on the microtubule-bundling activity of APC.
  • The coexpression of APC and PSD-95 in COS-7 cells enhanced microtubule-bundle formation compared with the expression of APC alone.
  • A mutant APC variant that does not associate with PSD-95 did not enhance microtubule bundling, despite coexpression with PSD-95.
  • Immunoelectron microscopy showed that the APC-PSD-95 complex sometimes colocalized on microtubules in processes of cultured neurons.
  • These results suggest that the microtubule-bundling activity of APC is regulated by its interaction with PSD-95, which might modulate microtubule architecture and dynamics in neurons.
  • [MeSH-major] Adenomatous Polyposis Coli Protein / physiology. Microtubules / metabolism. Nerve Tissue Proteins / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16701944.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Nerve Tissue Proteins; 0 / postsynaptic density proteins
  •  go-up   go-down


7. Nielsen M, de Miranda NF, van Puijenbroek M, Jordanova ES, Middeldorp A, van Wezel T, van Eijk R, Tops CM, Vasen HF, Hes FJ, Morreau H: Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas. BMC Cancer; 2009;9:184
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas.
  • BACKGROUND: MUTYH-associated polyposis (MAP) is a recessively inherited disorder which predisposes biallelic carriers for a high risk of polyposis and colorectal carcinoma (CRC).
  • Since about one third of the biallelic MAP patients in population based CRC series has no adenomas, this study aimed to identify specific clinicopathological characteristics of MAP CRCs and compare these with reported data on sporadic and Lynch CRCs.
  • METHODS: From 44 MAP patients who developed > or = 1 CRCs, 42 of 58 tumours were analyzed histologically and 35 immunohistochemically for p53 and beta-catenin.
  • KRAS2, the mutation cluster region (MCR) of APC, p53, and SMAD4 were analyzed for somatic mutations.
  • RESULTS: MAP CRCs frequently localized to the proximal colon (69%, 40/58), were mucinous in 21% (9/42), and had a conspicuous Crohn's like infiltrate reaction in 33% (13/40); all of these parameters occurred at a higher rate than reported for sporadic CRCs.
  • Tumour infiltrating lymphocytes (TILs) were also highly prevalent in MAP CRCs.
  • Somatic APC MCR mutations occurred in 14% (5/36) while 64% (23/36) had KRAS2 mutations (22/23 c.34G>T).
  • CONCLUSION: MAP CRCs show some similarities to micro-satellite unstable cancers, with a preferential proximal location, a high rate of mucinous histotype and increased presence of TILs.
  • These features should direct the practicing pathologist towards a MAP aetiology of CRC as an alternative for a mismatch repair deficient cause.
  • High frequent G>T transversions in APC and KRAS2 (mutated in early tumour development) but not in P53 and SMAD4 (implicated in tumour progression) might indicate a predominant MUTYH effect in early carcinogenesis.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Adenomatous Polyposis Coli / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. DNA Glycosylases / genetics. Microsatellite Instability
  • [MeSH-minor] Adult. Aged. Alleles. Cohort Studies. Female. Genetic Predisposition to Disease. Humans. Immunohistochemistry. Lymphocytes, Tumor-Infiltrating / immunology. Male. Middle Aged. Mutation. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2001 Feb;158(2):527-35 [11159189.001]
  • [Cites] Cancer Lett. 2008 Sep 18;268(2):308-13 [18495334.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):692-6 [11531254.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):227-32 [11818965.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):469-77 [12547705.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7595-9 [14633673.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):972-80 [14871975.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):493-501 [14968119.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1591-3 [15083190.001]
  • [Cites] Carcinogenesis. 2004 Jul;25(7):1219-26 [14976131.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):9-16 [15236166.001]
  • [Cites] Hum Mol Genet. 2004 Oct 1;13(19):2303-11 [15294875.001]
  • [Cites] Mod Pathol. 1990 May;3(3):332-5 [2362940.001]
  • [Cites] Hum Mol Genet. 1992 Jul;1(4):229-33 [1338904.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3011-20 [8187091.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):682-7 [8608876.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1805-13 [10362805.001]
  • [Cites] Gastroenterology. 1958 Jan;34(1):85-98 [13501357.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 3;96(21):1631-4 [15523092.001]
  • [Cites] Am J Hum Genet. 2005 Jul;77(1):112-9 [15931596.001]
  • [Cites] Hum Mutat. 2005 Aug;26(2):63-8 [15977173.001]
  • [Cites] Microsc Res Tech. 2005 May;67(1):15-21 [16025486.001]
  • [Cites] J Med Genet. 2005 Sep;42(9):e54 [16140997.001]
  • [Cites] Biochim Biophys Acta. 2005 Nov 25;1756(2):83-96 [16219426.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):807-14 [16557584.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1960-4 [17008531.001]
  • [Cites] J Clin Pathol. 2006 Nov;59(11):1212-5 [16943222.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1239-43 [17031395.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):874-9; discussion 879-80 [17122612.001]
  • [Cites] Mol Cancer Res. 2007 Feb;5(2):165-70 [17293392.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Mar;5(3):379-87 [17368238.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):139-42 [18172263.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):772-81 [18245538.001]
  • [Cites] Cancer Biomark. 2008;4(2):55-61 [18503156.001]
  • [Cites] J Pathol. 2008 Sep;216(1):25-31 [18506705.001]
  • [Cites] Histopathology. 2008 Aug;53(2):184-94 [18564191.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):297-304 [11438476.001]
  • (PMID = 19527492.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / mutY adenine glycosylase
  • [Other-IDs] NLM/ PMC2706846
  •  go-up   go-down


8. Inoue K, Koike E, Takano H, Yanagisawa R, Ichinose T, Yoshikawa T: Effects of diesel exhaust particles on antigen-presenting cells and antigen-specific Th immunity in mice. Exp Biol Med (Maywood); 2009 Feb;234(2):200-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study characterized more precisely which pathways and cellular events of the allergic response are amplified by DEP in view of the maturation/activation/function of antigen-presenting cells (APC) and the antigen-specific Th response.
  • We evaluated the effects of DEP on the phenotype and function of bone marrow-derived dendritic cells (BMDC) in vitro and on the expression pattern of APC-related molecules in the murine lung in the presence or absence of antigen in vivo.
  • In addition, an in vivo experiment showed that repetitive pulmonary exposure to DEP plus antigen (OVA) increased the numbers of MHC class II+cells and those expressing CD11c, DEC205 (DC markers), CD80, CD86 (co-stimulatory molecules), F4/80 (a macrophage marker), and CD19 (a B-cell differentiation antigen) in the lung as compared to that of others (vehicle, DEP, or OVA).
  • In conclusion, enhancement of allergic responses by DEP can be explained via two novel mechanisms, i.e., enhancement effects on APC including DC and on antigen-specific Th response, which culminate in the promotion of local and systemic dysregulated Th immunity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064938.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antigens; 0 / Epitopes; 0 / Histocompatibility Antigens Class II; 0 / Immunoglobulins; 0 / Particulate Matter; 0 / Vehicle Emissions; 9006-59-1 / Ovalbumin
  •  go-up   go-down


9. Wu YM, Yan J, Chen LL, Gu ZY: Association between infection of different strains of Porphyromonas gingivalis and Actinobacillus actinomycetemcomitans in subgingival plaque and clinical parameters in chronic periodontitis. J Zhejiang Univ Sci B; 2007 Feb;8(2):121-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Two multiplex polymerase chain reaction (PCR) assays were developed to detect the 16SrDNA, collagenase (prtC) and fimbria (fimA) genes of P. gingivalis and the 16SrDNA, leukotoxin (lktA) and fimbria-associated protein (fap) genes of A. actinomycetemcomitans in 60 sulcus samples from 30 periodontal healthy subjects and in 122 subgingival plaque samples from 61 patients with CP.
  • RESULTS: The 16SrDNA, prtC and fimA genes of P. gingivalis were detected in 92.6%, 85.2% and 80.3% of the subgingival plaque samples respectively, while the 16SrDNA, lktA and fap genes of A. actinomycetemcomitans were in 84.4%, 75.4% and 50.0% respectively.
  • Nucleotide sequence analysis showed 98.62%~100% homology of the PCR products in these genes with the reported sequences. P. gingivalis strains with prtC+/fimA+ and A. actinomycetemcomitans with lktA+ were predominant in deep pockets (>6 mm) or in sites with attachment loss > or =5 mm than in shallow pockets (3~4 mm) or in sites with attachment loss < or =2 mm (P<0.05). P. gingivalis strains with prtC+/fimA+ also showed higher frequency in gingival index (GI)=3 than in GI=1 group (P<0.05).
  • CONCLUSION: Infection of P. gingivalis with prtC+/fimA+ and A. actinomycetemcomitans with lktA+ correlates with periodontal destruction of CP in Chinese.
  • Nonetheless P. gingivalis fimA, prtC genes and A. actinomycetemcomitans lktA gene are closely associated with periodontal destruction, while A. actinomycetemcomitans fap gene is not.
  • [MeSH-minor] Adult. Aged. China / epidemiology. Chronic Disease. Female. Humans. Male. Middle Aged. Prevalence. Risk Assessment / methods. Risk Factors. Species Specificity. Statistics as Topic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Dent Res. 2001 Oct;80(10):1930-4 [11706954.001]
  • [Cites] J Periodontal Res. 2004 Apr;39(2):136-42 [15009522.001]
  • [Cites] J Clin Microbiol. 2004 Sep;42(9):4141-6 [15365002.001]
  • [Cites] J Bacteriol. 1992 Jun;174(12):3889-95 [1317840.001]
  • [Cites] J Dent Res. 1993 Jun;72(6):1040-4 [8388414.001]
  • [Cites] Oral Microbiol Immunol. 1994 Jun;9(3):161-5 [7936722.001]
  • [Cites] FEMS Microbiol Lett. 1994 Dec 15;124(3):333-41 [7851739.001]
  • [Cites] Clin Infect Dis. 1995 Jun;20 Suppl 2:S304-7 [7548580.001]
  • [Cites] J Clin Periodontol. 1996 Mar;23(3 Pt 1):212-9 [8707980.001]
  • [Cites] Microb Pathog. 1997 Aug;23(2):63-9 [9245617.001]
  • [Cites] J Clin Microbiol. 1999 May;37(5):1426-30 [10203499.001]
  • [Cites] Acta Odontol Latinoam. 2004;17(1-2):15-21 [15584257.001]
  • [Cites] Eur J Oral Sci. 2005 Feb;113(1):28-33 [15693826.001]
  • [Cites] J Periodontal Res. 2005 Jun;40(3):258-68 [15853973.001]
  • [Cites] J Periodontol. 2005 May;76(5):674-9 [15898925.001]
  • [Cites] Eur J Oral Sci. 2005 Jun;113(3):197-202 [15953243.001]
  • [Cites] J Periodontol. 2005 Feb;76(2):204-9 [15974843.001]
  • [Cites] Chin Med J (Engl). 2005 Jun 5;118(11):915-21 [15978192.001]
  • [Cites] J Clin Periodontol. 2005 Aug;32(8):860-6 [15998269.001]
  • [Cites] Ann Periodontol. 1999 Dec;4(1):1-6 [10863370.001]
  • [Cites] J Dent Res. 2000 Sep;79(9):1664-8 [11023261.001]
  • [Cites] Oral Microbiol Immunol. 2000 Feb;15(1):33-9 [11155162.001]
  • [Cites] J Periodontal Res. 2001 Feb;36(1):18-24 [11246700.001]
  • [Cites] Periodontol 2000. 2000 Oct;24:153-92 [11276866.001]
  • [Cites] Crit Rev Oral Biol Med. 2001;12(2):116-24 [11345522.001]
  • [Cites] Clin Microbiol Infect. 2001 Apr;7(4):213-7 [11422244.001]
  • [Cites] J Clin Periodontol. 2001 Sep;28(9):886-90 [11493360.001]
  • [Cites] J Periodontol. 2001 Oct;72(10):1354-63 [11699477.001]
  • [Cites] J Clin Periodontol. 2001 Dec;28(12):1163-71 [11737515.001]
  • [Cites] Eur J Oral Sci. 2002 Jun;110(3):212-7 [12120706.001]
  • [Cites] J Periodontol. 2003 Jan;74(1):90-6 [12593602.001]
  • [Cites] J Periodontal Res. 2003 Jun;38(3):276-81 [12753365.001]
  • [Cites] Acta Odontol Scand. 2003 Apr;61(2):115-22 [12790510.001]
  • [Cites] J Periodontol. 2003 Jul;74(7):1000-6 [12931762.001]
  • [Cites] Eur J Oral Sci. 2003 Oct;111(5):390-4 [12974681.001]
  • [Cites] J Clin Microbiol. 2003 Oct;41(10):4829-32 [14532234.001]
  • [Cites] Curr Protein Pept Sci. 2003 Dec;4(6):443-50 [14683429.001]
  • [Cites] FEMS Microbiol Lett. 2004 Mar 12;232(1):31-7 [15019731.001]
  • (PMID = 17266188.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC1791058
  •  go-up   go-down


10. Tanaka M, Jin G, Yamazaki Y, Takahara T, Takuwa M, Nakamura T: Identification of candidate cooperative genes of the Apc mutation in transformation of the colon epithelial cell by retroviral insertional mutagenesis. Cancer Sci; 2008 May;99(5):979-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of candidate cooperative genes of the Apc mutation in transformation of the colon epithelial cell by retroviral insertional mutagenesis.
  • The mutation of Apc is an important early genetic event in colon carcinogenesis.
  • To identify cooperative genes for the Apc(Min) mutation the authors carried out retroviral insertional mutagenesis (RIM) using Min mouse-derived IMCE colon epithelial cells.
  • Anchorage-independent transformed colonies were induced by retroviral infection only in IMCE cells, while no transformation was found in young adult mouse colon (YAMC) cells that are normal for Apc.
  • These data suggest the importance of cytoskeletal function in Apc-related tumor development and the usefulness of RIM in non-hematopoietic tissues, providing new insight into the early stage of colon carcinogenesis.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Colon / pathology. Genes, APC. Mutagenesis, Insertional. Mutation. Retroviridae / genetics
  • [MeSH-minor] Animals. Cell Line. Dyneins / genetics. Epithelial Cells / pathology. Membrane Proteins / genetics. Mice. Microtubules / metabolism. Neoplasm Proteins / genetics. Up-Regulation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294281.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ahnak protein, mouse; 0 / Membrane Proteins; 0 / Neoplasm Proteins; EC 3.6.4.2 / Dnah3 protein, mouse; EC 3.6.4.2 / Dyneins
  •  go-up   go-down


11. Tighe A, Ray-Sinha A, Staples OD, Taylor SS: GSK-3 inhibitors induce chromosome instability. BMC Cell Biol; 2007 Aug 14;8:34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While several lines of evidence suggest that mutations in adenomatous polyposis coli (APC) may promote chromosome instability, at least in colon cancer, the underlying mechanisms remain unclear.
  • Here, we turn our attention to GSK-3 - a protein kinase, which in concert with APC, targets beta-catenin for proteolysis - and ask whether GSK-3 is required for accurate chromosome segregation.
  • Analysis of synchronised HeLa cells shows that GSK-3 inhibitors do not prevent G1/S progression or cell division.
  • CONCLUSION: Thus, not only do our observations indicate a role for GSK-3 in accurate chromosome segregation, but they also raise the possibility that, if used as therapeutic agents, GSK-3 inhibitors may induce unwanted side effects by inducing chromosome instability.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2003 Feb 15;116(Pt 4):637-46 [12538764.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4365-70 [15767571.001]
  • [Cites] Science. 2005 Mar 25;307(5717):1904-9 [15790842.001]
  • [Cites] J Cell Sci. 2005 Aug 15;118(Pt 16):3639-52 [16046481.001]
  • [Cites] Mol Biol Cell. 2005 Oct;16(10):4609-22 [16030254.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):773-85 [16195750.001]
  • [Cites] J Cell Sci. 2005 Oct 15;118(Pt 20):4889-900 [16219694.001]
  • [Cites] J Cell Biol. 2005 Oct 24;171(2):197-200 [16247021.001]
  • [Cites] J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86 [12615961.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):267-80 [12719470.001]
  • [Cites] EMBO J. 2003 Jun 2;22(11):2752-63 [12773390.001]
  • [Cites] Science. 2003 Sep 12;301(5639):1547-50 [12970569.001]
  • [Cites] Mol Cell. 2003 Aug;12(2):381-92 [14536078.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45937-45 [12928438.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):672-83 [14644191.001]
  • [Cites] J Cell Biol. 2003 Dec 8;163(5):949-61 [14662741.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51786-95 [14523000.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6 [14698171.001]
  • [Cites] Genes Dev. 2004 Jan 1;18(1):48-61 [14724178.001]
  • [Cites] Gene. 2005 Nov 21;361:1-12 [16185824.001]
  • [Cites] Trends Cell Biol. 2005 Nov;15(11):589-98 [16214339.001]
  • [Cites] Nature. 2006 Apr 13;440(7086):954-8 [16612388.001]
  • [Cites] EMBO J. 2006 Jun 21;25(12):2814-27 [16763565.001]
  • [Cites] J Cell Sci. 2006 Sep 1;119(Pt 17):3664-75 [16912073.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] J Cell Biol. 2007 Jan 15;176(2):183-95 [17227893.001]
  • [Cites] Trends Cell Biol. 2005 Sep;15(9):486-93 [16084093.001]
  • [Cites] Cell. 2003 Feb 21;112(4):407-21 [12600307.001]
  • [Cites] Diabetes. 2003 Mar;52(3):588-95 [12606497.001]
  • [Cites] J Cell Biol. 2004 Jan 19;164(2):243-53 [14734535.001]
  • [Cites] J Cell Sci. 2004 Mar 1;117(Pt 7):1117-28 [14970257.001]
  • [Cites] J Cell Sci. 2004 Mar 15;117(Pt 8):1577-89 [15020684.001]
  • [Cites] Trends Biochem Sci. 2004 Feb;29(2):95-102 [15102436.001]
  • [Cites] Bioorg Med Chem. 2004 Jun 15;12(12):3167-85 [15158785.001]
  • [Cites] Mol Biol Cell. 2004 Jun;15(6):2978-91 [15075372.001]
  • [Cites] EMBO J. 2004 Jun 2;23(11):2235-45 [15152189.001]
  • [Cites] Nat Rev Drug Discov. 2004 Jun;3(6):479-87 [15173837.001]
  • [Cites] Chromosoma. 2004 Jun;112(8):389-97 [15156327.001]
  • [Cites] Chromosome Res. 2004;12(6):599-616 [15289666.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:337-66 [15473844.001]
  • [Cites] J Cell Sci. 2004 Nov 1;117(Pt 23):5461-77 [15509863.001]
  • [Cites] Eur J Biochem. 1983 Jan 17;130(1):227-34 [6402364.001]
  • [Cites] J Cell Sci. 1992 Nov;103 ( Pt 3):665-75 [1478963.001]
  • [Cites] Mol Cell Biol. 1994 Jan;14(1):831-9 [8264650.001]
  • [Cites] J Cell Biol. 1994 Dec;127(5):1301-10 [7962091.001]
  • [Cites] Nature. 1995 Feb 16;373(6515):630-2 [7854422.001]
  • [Cites] J Cell Biol. 1995 Jun;129(5):1195-204 [7775567.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):2972-7 [7606712.001]
  • [Cites] J Cell Biol. 1995 Aug;130(4):941-8 [7642709.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8455-9 [8710892.001]
  • [Cites] Curr Biol. 1996 Dec 1;6(12):1664-8 [8994831.001]
  • [Cites] Science. 1997 Jan 31;275(5300):632-7 [9005842.001]
  • [Cites] Cell. 1997 May 30;89(5):727-35 [9182760.001]
  • [Cites] J Cell Sci. 1998 Mar;111 ( Pt 5):557-72 [9454730.001]
  • [Cites] J Cell Sci. 2004 Dec 15;117(Pt 26):6339-53 [15561772.001]
  • [Cites] J Cell Biol. 2000 May 15;149(4):761-6 [10811817.001]
  • [Cites] Nature. 2000 Jul 6;406(6791):86-90 [10894547.001]
  • [Cites] Chem Biol. 2000 Oct;7(10):793-803 [11033082.001]
  • [Cites] Mol Med Today. 2000 Dec;6(12):462-9 [11099951.001]
  • [Cites] Curr Biol. 2001 Jan 9;11(1):44-9 [11166179.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):429-32 [11283619.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):433-8 [11283620.001]
  • [Cites] Diabetes. 2001 May;50(5):937-46 [11334436.001]
  • [Cites] EMBO Rep. 2001 Jul;2(7):609-14 [11454737.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Oct;2(10):769-76 [11584304.001]
  • [Cites] J Cell Sci. 2001 Dec;114(Pt 24):4385-95 [11792804.001]
  • [Cites] J Med Chem. 2002 Mar 14;45(6):1292-9 [11881998.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 May;3(5):328-38 [11988767.001]
  • [Cites] Bioorg Med Chem Lett. 2002 Jun 3;12(11):1525-8 [12031334.001]
  • [Cites] Diabetes. 2002 Oct;51(10):2903-10 [12351425.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Oct;3(10):731-41 [12360190.001]
  • [Cites] Curr Biol. 2002 Dec 10;12(23):2055-9 [12477396.001]
  • (PMID = 17697341.001).
  • [ISSN] 1471-2121
  • [Journal-full-title] BMC cell biology
  • [ISO-abbreviation] BMC Cell Biol.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / beta Catenin; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3
  • [Other-IDs] NLM/ PMC1976608
  •  go-up   go-down


12. Gaspar C, Cardoso J, Franken P, Molenaar L, Morreau H, Möslein G, Sampson J, Boer JM, de Menezes RX, Fodde R: Cross-species comparison of human and mouse intestinal polyps reveals conserved mechanisms in adenomatous polyposis coli (APC)-driven tumorigenesis. Am J Pathol; 2008 May;172(5):1363-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross-species comparison of human and mouse intestinal polyps reveals conserved mechanisms in adenomatous polyposis coli (APC)-driven tumorigenesis.
  • The majority of sporadic colorectal cancers are triggered by mutations in the adenomatous polyposis coli (APC) tumor suppressor gene, leading to the constitutive activation of the Wnt/beta-catenin signaling pathway and formation of adenomas.
  • Despite this common genetic basis, colorectal cancers are very heterogeneous in their degree of differentiation, growth rate, and malignancy potential.
  • Here, we applied a cross-species comparison of expression profiles of intestinal polyps derived from hereditary colorectal cancer patients carrying APC germline mutations and from mice carrying a targeted inactivating mutation in the mouse homologue Apc.
  • This comparative approach resulted in the establishment of a conserved signature of 166 genes that were differentially expressed between adenomas and normal intestinal mucosa in both species.
  • Functional analyses of the conserved genes revealed a general increase in cell proliferation and the activation of the Wnt/beta-catenin signaling pathway.
  • Moreover, the conserved signature was able to resolve expression profiles from hereditary polyposis patients carrying APC germline mutations from those with bi-allelic inactivation of the MYH gene, supporting the usefulness of such comparisons to discriminate among patients with distinct genetic defects.
  • [MeSH-major] Adenomatous Polyposis Coli / metabolism. Adenomatous Polyposis Coli Protein / metabolism. Cell Transformation, Neoplastic / metabolism. Colorectal Neoplasms / pathology. Intestinal Polyps / metabolism


13. De Groot CO, Jelesarov I, Damberger FF, Bjelić S, Schärer MA, Bhavesh NS, Grigoriev I, Buey RM, Wüthrich K, Capitani G, Akhmanova A, Steinmetz MO: Molecular insights into mammalian end-binding protein heterodimerization. J Biol Chem; 2010 Feb 19;285(8):5802-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular insights into mammalian end-binding protein heterodimerization.
  • Microtubule plus-end tracking proteins (+TIPs) are involved in many microtubule-based processes.
  • End binding (EB) proteins constitute a highly conserved family of +TIPs.
  • Here we used a combination of methods to investigate the dimerization properties of the three human EB proteins EB1, EB2, and EB3.
  • Based on Förster resonance energy transfer, we demonstrate that the C-terminal dimerization domains of EBs (EBc) can readily exchange their chains in solution.
  • We further document that EB1c and EB3c preferentially form heterodimers, whereas EB2c does not participate significantly in the formation of heterotypic complexes.
  • Fluorescence spectroscopy and nuclear magnetic resonance studies in the presence of the cytoskeleton-associated protein-glycine-rich domains of either CLIP-170 or p150(glued) or of a fragment derived from the adenomatous polyposis coli tumor suppressor protein show that chain exchange of EBc domains can be controlled by binding partners.
  • Extension of these studies of the EBc domains to full-length EBs demonstrate that heterodimer formation between EB1 and EB3, but not between EB2 and the other two EBs, occurs both in vitro and in cells as revealed by live cell imaging.
  • [MeSH-major] Microtubule-Associated Proteins / metabolism. Models, Molecular. Protein Multimerization / physiology
  • [MeSH-minor] Animals. CHO Cells. Cell Line. Cricetinae. Cricetulus. Humans. Kinetics. Magnetic Resonance Spectroscopy. Neoplasm Proteins / chemistry. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Protein Structure, Quaternary. Protein Structure, Tertiary. Recombinant Proteins / chemistry. Recombinant Proteins / genetics. Recombinant Proteins / metabolism. Spectrometry, Fluorescence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biol Cell. 2002 Oct;13(10):3627-45 [12388762.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2002 Nov;58(Pt 11):1948-54 [12393927.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36430-4 [12857735.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38926-34 [12860982.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):49721-31 [14514668.001]
  • [Cites] Neuron. 2004 Jun 24;42(6):897-912 [15207235.001]
  • [Cites] Nat Cell Biol. 2004 Sep;6(9):820-30 [15311282.001]
  • [Cites] Adv Protein Chem. 1966;21:287-386 [5333290.001]
  • [Cites] Annu Rev Biochem. 1972;41:903-24 [4563445.001]
  • [Cites] J Mol Biol. 1979 Oct 15;134(1):75-94 [537062.001]
  • [Cites] Biochemistry. 1988 Oct 18;27(21):8063-8 [3233195.001]
  • [Cites] Proteins. 1993 Sep;17(1):75-86 [8234246.001]
  • [Cites] J Mol Biol. 1993 Dec 5;234(3):779-815 [8254673.001]
  • [Cites] Adv Protein Chem. 1995;46:141-76 [7771317.001]
  • [Cites] J Mol Graph. 1996 Feb;14(1):51-5, 29-32 [8744573.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:83-117 [9442869.001]
  • [Cites] Biochemistry. 1999 Jan 19;38(3):870-80 [9893981.001]
  • [Cites] EMBO J. 2005 Jan 26;24(2):261-9 [15616574.001]
  • [Cites] J Cell Biol. 2005 Feb 14;168(4):587-98 [15699215.001]
  • [Cites] J Cell Biol. 2005 Sep 12;170(6):895-901 [16157700.001]
  • [Cites] Mol Cell. 2006 Sep 1;23(5):663-71 [16949363.001]
  • [Cites] Cell. 2006 Dec 29;127(7):1415-24 [17190604.001]
  • [Cites] PLoS Biol. 2007 Feb;5(2):e29 [17227146.001]
  • [Cites] Curr Biol. 2007 Jul 3;17(13):1134-9 [17600711.001]
  • [Cites] Curr Biol. 2007 Aug 7;17(15):1318-25 [17658256.001]
  • [Cites] Trends Biochem Sci. 2007 Sep;32(9):407-14 [17764955.001]
  • [Cites] Mol Cell. 2007 Sep 21;27(6):976-91 [17889670.001]
  • [Cites] Nat Struct Mol Biol. 2007 Oct;14(10):959-67 [17828277.001]
  • [Cites] Exp Cell Res. 2008 Jan 1;314(1):213-26 [17964570.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1100-5 [18059460.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Apr;9(4):309-22 [18322465.001]
  • [Cites] Nat Cell Biol. 2008 Apr;10(4):415-21 [18364701.001]
  • [Cites] Oncogene. 2008 Apr 10;27(17):2494-500 [17968321.001]
  • [Cites] Nat Cell Biol. 2008 Oct;10(10):1181-9 [18806788.001]
  • [Cites] Trends Biochem Sci. 2008 Nov;33(11):535-45 [18835717.001]
  • [Cites] J Cell Biol. 2008 Dec 29;183(7):1223-33 [19103809.001]
  • [Cites] Neuron. 2009 Jan 15;61(1):85-100 [19146815.001]
  • [Cites] J Cell Biol. 2009 Mar 9;184(5):691-706 [19255245.001]
  • [Cites] Mol Biol Cell. 2009 Jun;20(11):2684-96 [19369422.001]
  • [Cites] Cell. 2009 Jul 23;138(2):366-76 [19632184.001]
  • [Cites] J Biol Chem. 2009 Oct 9;284(41):28367-81 [19696028.001]
  • [Cites] Oncogene. 2000 Jan 13;19(2):210-6 [10644998.001]
  • [Cites] J Cell Biol. 2000 May 15;149(4):761-6 [10811817.001]
  • [Cites] Genomics. 2001 Jan 15;71(2):142-9 [11161807.001]
  • [Cites] Cell. 2001 May 18;105(4):421-4 [11371339.001]
  • [Cites] Biotechniques. 2001 Jul;31(1):88-90, 92 [11464525.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):753-8 [12700769.001]
  • (PMID = 20008324.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MAPRE1 protein, human; 0 / MAPRE3 protein, human; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Recombinant Proteins; 144198-36-7 / dynactin; 148349-95-5 / cytoplasmic linker protein 170
  • [Other-IDs] NLM/ PMC2820806
  •  go-up   go-down


14. Sinicrope FA: Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. Mol Carcinog; 2006 Jun;45(6):447-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A causal link for COX-2 in epithelial tumorigenesis was shown in genetically manipulated animal models of colon and breast carcinoma.
  • COX enzymes are targets for cancer prevention as shown by the observation that nonselective COX and selective COX-2 inhibitors have been reported to effectively prevent experimental colon cancer and can regress colorectal polyps in patients with familial adenomatous polyposis.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16688727.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Prostaglandins; EC 1.14.99.1 / Cyclooxygenase 2
  • [Number-of-references] 53
  •  go-up   go-down


15. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR: Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res; 2006 Feb 1;66(3):1354-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.
  • Roughly 40% of ovarian endometrioid adenocarcinomas (OEA) have constitutive activation of Wnt signaling as a result of oncogenic mutations in the beta-catenin protein or inactivating mutations in key negative regulators of beta-catenin, such as the adenomatous polyposis coli and Axin tumor suppressor proteins.
  • Using microarray and quantitative PCR-based approaches, we found that fibroblast growth factor (FGF9) expression was increased >6-fold in primary OEAs with Wnt/beta-catenin pathway defects compared with OEAs lacking such defects.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Fibroblast Growth Factor 9 / genetics. Ovarian Neoplasms / genetics. Wnt1 Protein / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452189.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / PHS HHS / / NIH P30 46952; United States / NCI NIH HHS / CA / R01 CA 85463; United States / NCI NIH HHS / CA / R01 CA 94172; United States / NCI NIH HHS / CA / U19 CA 84953
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FGF9 protein, human; 0 / Fibroblast Growth Factor 9; 0 / RNA, Messenger; 0 / Wnt1 Protein; 0 / beta Catenin
  •  go-up   go-down


16. Wu JQ, Kornbluth S: Not-so-pseudo a substrate: Acm1-mediated inhibition of the APC. Mol Cell; 2008 Jun 6;30(5):543-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Not-so-pseudo a substrate: Acm1-mediated inhibition of the APC.
  • In a recent issue of Molecular Cell, Enquist-Newman et al. (2008) demonstrate that Acm1 is ubiquitinated by APC(Cdc20).
  • By contrast, the high-affinity interaction between Acm1 and APC(Cdh1) renders it a poor substrate, but a specific inhibitor, of the APC(Cdh1) complex.
  • [MeSH-major] Repressor Proteins / metabolism. Saccharomyces cerevisiae / metabolism. Saccharomyces cerevisiae Proteins / metabolism. Ubiquitin-Protein Ligase Complexes / antagonists & inhibitors. Ubiquitin-Protein Ligase Complexes / metabolism
  • [MeSH-minor] Anaphase-Promoting Complex-Cyclosome. Cdc20 Proteins. Cdh1 Proteins. Cell Cycle Proteins / metabolism. Mitosis. Substrate Specificity. Ubiquitination

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Mol Cell. 2008 May 23;30(4):437-46 [18498748.001]
  • (PMID = 18538651.001).
  • [ISSN] 1097-4164
  • [Journal-full-title] Molecular cell
  • [ISO-abbreviation] Mol. Cell
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acm1 protein, S cerevisiae; 0 / CDC20 protein, S cerevisiae; 0 / CDH1 protein, S cerevisiae; 0 / Cdc20 Proteins; 0 / Cdh1 Proteins; 0 / Cell Cycle Proteins; 0 / Repressor Proteins; 0 / Saccharomyces cerevisiae Proteins; EC 6.3.2.19 / Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Ubiquitin-Protein Ligase Complexes
  •  go-up   go-down


17. Fouladkhah A, Avens JS: Effects of combined heat and acetic acid on natural microflora reduction on cantaloupe melons. J Food Prot; 2010 May;73(5):981-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High level of nutrients and water activity, direct contact with soil, and lack of thermal procedures during primary processing make fresh produce a potential food safety hazard.
  • Aerobic plate counts (APC) of dilutions were determined.
  • Statistical analysis (least significant difference-based analysis of variance) showed that there were no significant (P > 0.05) differences in APC among control, water at 25 degrees C, and 5% acetic acid at 25 degrees C.
  • Thermal treatments with water at 95 degrees C, and 5% acetic acid at 95 degrees C, were both significantly (P < 0.05) more effective in APC reduction than were nonthermal treatments, but were not significantly different from each other.
  • Results indicated that a thermal water immersion intervention in primary processing of fresh melons can result in a 3-log reduction of natural microflora surface contamination, but 5% acetic acid will not significantly augment this reduction.

  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • Hazardous Substances Data Bank. ACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501053.001).
  • [ISSN] 0362-028X
  • [Journal-full-title] Journal of food protection
  • [ISO-abbreviation] J. Food Prot.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; Q40Q9N063P / Acetic Acid
  •  go-up   go-down


18. Hosseini BH, Louban I, Djandji D, Wabnitz GH, Deeg J, Bulbuc N, Samstag Y, Gunzer M, Spatz JP, Hämmerling GJ: Immune synapse formation determines interaction forces between T cells and antigen-presenting cells measured by atomic force microscopy. Proc Natl Acad Sci U S A; 2009 Oct 20;106(42):17852-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This recognition results in the formation of a so-called immune synapse (IS) at the T-cell/APC interface, which is crucial for T-cell activation.
  • Dynamic analysis of T-cell/APC interaction by AFM revealed that in the presence of antigen interaction forces increased from 1 to 2 nN at early time-points to a maximum of approximately 14 nN after 30 min and decreased again after 60 min.
  • Because the integrin lymphocyte function antigen-1 (LFA-1) and its counterpart intercellular adhesion molecule-1 (ICAM-1) are prominent members of a mature IS, the effect of a small molecular inhibitor for LFA-1, BIRT377, was investigated.
  • BIRT377 almost completely abolish the interaction forces, emphasizing the importance of LFA-1/ICAM-1-interactions for firm T-cell/APC adhesion.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1999 Nov 15;163(10):5173-7 [10553036.001]
  • [Cites] Nat Cell Biol. 2000 Jun;2(6):313-7 [10854320.001]
  • [Cites] Curr Biol. 2000 Dec 14-28;10(24):R923-33 [11137031.001]
  • [Cites] Biophys J. 2002 Oct;83(4):2270-9 [12324444.001]
  • [Cites] Cells Tissues Organs. 2002;172(3):174-89 [12476047.001]
  • [Cites] J Leukoc Biol. 2003 Jan;73(1):30-48 [12525560.001]
  • [Cites] Eur J Immunol. 2003 Feb;33(2):411-21 [12645938.001]
  • [Cites] Nat Rev Immunol. 2003 Nov;3(11):867-78 [14668803.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2801-9 [15256430.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):25864-72 [1464601.001]
  • [Cites] Blood. 1993 Jan 15;81(2):419-23 [8422461.001]
  • [Cites] J Exp Med. 1993 Oct 1;178(4):1453-8 [7690835.001]
  • [Cites] Science. 1994 Oct 14;266(5183):257-9 [7939660.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3477-81 [8622961.001]
  • [Cites] Nature. 1998 Sep 3;395(6697):82-6 [9738502.001]
  • [Cites] Science. 1999 Jul 9;285(5425):221-7 [10398592.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4753-60 [15550395.001]
  • [Cites] PLoS Biol. 2005 Jun;3(6):e150 [15857154.001]
  • [Cites] Nat Rev Immunol. 2005 Jul;5(7):546-59 [15965491.001]
  • [Cites] Eur J Immunol. 2005 Jun;35(6):1741-53 [15909310.001]
  • [Cites] Semin Immunol. 2005 Dec;17(6):442-51 [16263308.001]
  • [Cites] Exp Biol Med (Maywood). 2006 Sep;231(8):1306-12 [16946399.001]
  • [Cites] Biophys J. 2008 Aug;95(3):1448-59 [18456832.001]
  • [Cites] Nat Nanotechnol. 2008 May;3(5):261-9 [18654521.001]
  • [Cites] Nature. 2008 Oct 9;455(7214):764-9 [18843362.001]
  • [Cites] Curr Opin Cell Biol. 2006 Oct;18(5):579-86 [16904883.001]
  • [Cites] Biomacromolecules. 2006 Nov;7(11):3188-95 [17096550.001]
  • [Cites] Immunity. 2007 Jan;26(1):17-27 [17241958.001]
  • [Cites] Science. 2007 Jan 26;315(5811):528-31 [17185562.001]
  • [Cites] J Immunol. 2007 Mar 15;178(6):3637-47 [17339461.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1519-29 [17392507.001]
  • [Cites] J Cell Sci. 2008 Jun 1;121(11):1785-91 [18492792.001]
  • [Cites] J Immunol Methods. 2008 Jul 31;336(2):91-7 [18539294.001]
  • [ErratumIn] Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2373
  • (PMID = 19822763.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / PN2 EY016586
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRT 377; 0 / Imidazolidines; 0 / Lymphocyte Function-Associated Antigen-1; 0 / Peptide Fragments; 126547-89-5 / Intercellular Adhesion Molecule-1; EC 3.2.1.- / hen egg lysozyme; EC 3.2.1.17 / Muramidase
  • [Other-IDs] NLM/ PMC2764924
  •  go-up   go-down


19. Lyons LC, Collado MS, Khabour O, Green CL, Eskin A: The circadian clock modulates core steps in long-term memory formation in Aplysia. J Neurosci; 2006 Aug 23;26(34):8662-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated whether the circadian clock modulated core molecular processes necessary for memory formation in vivo by analyzing circadian regulation of basal and LTS-induced levels of phosphorylated mitogen-activated protein kinase (P-MAPK) and Aplysia CCAAT/enhancer binding protein (ApC/EBP).
  • In contrast, the circadian clock regulated basal levels of ApC/EBP protein with peak levels at night, antiphase to the rhythm in LTS.
  • Importantly, LTS training during the (subjective) day produced greater increases in P-MAPK and ApC/EBP than training at night.
  • Thus, circadian modulation of LTS occurs, at least in part, by suppressing changes in key proteins at night.
  • Rescue of long-term memory formation at night required both facilitation of MAPK and transcription in conjunction with LTS training, confirming that the circadian clock at night actively suppresses MAPK activation and transcription involved in memory formation.
  • The circadian clock appears to modulate LTS at multiple levels.
  • Together, our studies suggest that the circadian clock modulates LTS at multiple steps and locations during the formation of long-term memory.
  • [MeSH-minor] Animals. CCAAT-Enhancer-Binding Proteins / metabolism. Electric Stimulation / methods. Enzyme Activation / physiology. Ganglia, Invertebrate / enzymology. Hemolymph / metabolism. Mitogen-Activated Protein Kinases / metabolism. Phosphorylation. Serotonin / metabolism

  • MedlinePlus Health Information. consumer health - Memory.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928854.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS050589
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Proteins; 333DO1RDJY / Serotonin; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


20. Favory R, Lancel S, Maréchal X, Tissier S, Neviere R: Cardiovascular protective role for activated protein C during endotoxemia in rats. Intensive Care Med; 2006 Jun;32(6):899-905
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiovascular protective role for activated protein C during endotoxemia in rats.
  • OBJECTIVE: We examined whether activated protein C (APC) treatment improves cardiovascular inflammation and dysfunction in endotoxemic rats.
  • DESIGN AND SETTING: Randomized, controlled trial in an experimental laboratory of a university physiology department SUBJECTS: Male Sprague Dawley rats.
  • INTERVENTIONS: Internal carotid artery and external jugular vein were catheterized under sterile conditions in rats.
  • Instrumented rats infused or not with APC (240 microg/kg per hour) were challenged with E. coli endotoxin (10 mg/kg).
  • MEASUREMENTS AND RESULTS: Endotoxin administration induced systemic hypotension, depression of myocardial systolic performance and reduction in capillary density of the small intestine muscularis layer.
  • Plasma levels of nitrite/nitrate, tumor necrosis factor alpha and macrophage migration inhibitory factor, mesentery venule leukocyte-endothelium interactions, heart and small intestine myeloperoxidase activities were increased in endotoxin-treated rats.
  • APC largely prevented endotoxin-induced cardiovascular dysfunction with improved systemic hemodynamics, functional capillary density, and myocardial contractile performance.
  • Beneficial cardiovascular effects of APC were associated with attenuation of entotoxin-induced inflammatory response in terms of plasma levels of nitrite/nitrate, tumor necrosis factor alpha, macrophage migration inhibitory factor, and endothelial cell-leukocyte activation.
  • CONCLUSION: APC reduces systemic and tissue inflammation and preserves cardiovascular function during experimental endotoxemia.
  • [MeSH-major] Cardiovascular System / drug effects. Endotoxemia. Protein C Inhibitor / pharmacology. Serine Proteinase Inhibitors / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Anaesth. 2004 Jul;93(1):114-20 [15121730.001]
  • [Cites] Circ Res. 2005 May 27;96(10):1095-102 [15879312.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11199-203 [11278252.001]
  • [Cites] Neuron. 2004 Feb 19;41(4):563-72 [14980205.001]
  • [Cites] Crit Care Med. 2004 Apr;32(4):1011-7 [15071394.001]
  • [Cites] Circulation. 2001 Sep 4;104(10):1171-5 [11535575.001]
  • [Cites] Lancet. 2005 Jan 1-7;365(9453):63-78 [15639681.001]
  • [Cites] Curr Opin Infect Dis. 2004 Jun;17(3):205-11 [15166822.001]
  • [Cites] N Engl J Med. 1989 Aug 3;321(5):280-7 [2664516.001]
  • [Cites] Trends Immunol. 2004 Oct;25(10):536-42 [15364056.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3781-7 [10845910.001]
  • [Cites] Nat Med. 2004 Dec;10(12):1379-83 [15516929.001]
  • [Cites] Shock. 2004 Mar;21(3):222-9 [14770034.001]
  • [Cites] Intensive Care Med. 2005 Nov;31(11):1573-6 [16175347.001]
  • [Cites] Nat Med. 2003 Mar;9(3):338-42 [12563316.001]
  • [Cites] Crit Care Med. 2003 Mar;31(3):834-40 [12626993.001]
  • [Cites] N Engl J Med. 2001 Mar 8;344(10 ):699-709 [11236773.001]
  • [Cites] Biochem Soc Trans. 2005 Apr;33(Pt 2):401-5 [15787615.001]
  • [Cites] N Engl J Med. 2003 Jan 9;348(2):138-50 [12519925.001]
  • [Cites] Crit Care Med. 2005 Feb;33(2):368-72 [15699841.001]
  • [Cites] J Am Coll Cardiol. 2004 Jun 16;43(12):2348-58 [15193704.001]
  • (PMID = 16601957.001).
  • [ISSN] 0342-4642
  • [Journal-full-title] Intensive care medicine
  • [ISO-abbreviation] Intensive Care Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein C Inhibitor; 0 / Serine Proteinase Inhibitors
  •  go-up   go-down


21. Kalchayanand N, Arthur TM, Bosilevac JM, Brichta-Harhay DM, Guerini MN, Shackelford SD, Wheeler TL, Koohmaraie M: Microbiological characterization of lamb carcasses at commercial processing plants in the United States. J Food Prot; 2007 Aug;70(8):1811-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address this missing information, a total of 2,548 sponge samples from pelts, preevisceration carcasses, and postintervention carcasses were collected from multiple large commercial lamb processing plants to determine aerobic plate counts, the prevalences of Escherichia coli O157:H7, non-O157 Shiga toxin-producing E. coli (STEC), and Salmonella.
  • The prevalences of E. coli O157:H7 from the pelts, the preevisceration carcasses, and the postintervention carcasses were 12.8, 1.6, and 2.9%, respectively.
  • The average Salmonella prevalences were 14.4, 4.3, and 1.8% for pelts, preevisceration carcasses, and postintervention carcasses, respectively.
  • A small number of STEC serotypes associated with severe human illness were isolated from postintervention carcasses.
  • The results of this study establish a baseline for microbiological quality and prevalences of Salmonella, E. coli O157:H7, and STEC in U.S. lamb processing plants.
  • [MeSH-major] Escherichia coli / isolation & purification. Food Contamination / analysis. Food-Processing Industry / standards. Salmonella / isolation & purification. Sheep / microbiology
  • [MeSH-minor] Abattoirs. Animals. Colony Count, Microbial. Consumer Product Safety. Escherichia coli O157 / isolation & purification. Food Microbiology. Humans. Meat / microbiology. Prevalence. Serotyping. United States

  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17803136.001).
  • [ISSN] 0362-028X
  • [Journal-full-title] Journal of food protection
  • [ISO-abbreviation] J. Food Prot.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Lefevre JH, Parc Y, Svrcek M, Kernéis S, Colas C, Shields C, Flejou JF, Parc R, Tiret E: APC, MYH, and the correlation genotype-phenotype in colorectal polyposis. Ann Surg Oncol; 2009 Apr;16(4):871-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] APC, MYH, and the correlation genotype-phenotype in colorectal polyposis.
  • BACKGROUND: Familial adenomatous polyposis (FAP) has been divided into two entities: classical (CFAP) and attenuated (AFAP).
  • With the discovery of MYH associated polyposis (MAP) syndrome, the clinical differences have become unclear.
  • The aim of our study was to investigate patients with polyposis treated in our institution for a correlation between genotype and phenotype.
  • Four groups were identified: AFAP, CFAP, MAP, and no-mutation patients.
  • RESULTS: Patient breakdown was CFAP patients (n = 322/294), AFAP patients (n = 13/41), MYH patients (n = 17) and no-mut patients (n = 32).
  • Patients not tested for APC mutation (n = 131) were excluded.
  • Major differences were found for MYH patients: later age at diagnosis, more cancers, fewer polyps, and more located in the right part of the colon.
  • For phenotype/genotype correlation, patients aged more than 35 years at the time of colectomy and with fewer than 100 polyps had significantly more mutation found on MYH.
  • CONCLUSIONS: This two-way analysis did not show any correlation that might help to identify a subgroup of patients with APC mutation that may be considered attenuated.
  • It is more likely that the MAP syndrome is the real AFAP.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. DNA Glycosylases / genetics. Genes, APC
  • [MeSH-minor] Adolescent. Adult. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Mutation. Phenotype. Syndrome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169759.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / mutY adenine glycosylase
  •  go-up   go-down


23. Cheah PY, Wong YH, Loi C, Koh PK, Eu KW: Novel human pathological mutations. Gene symbol: APC. Disease: adenomatous polyposis coli. Hum Genet; 2009 Apr;125(3):352
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel human pathological mutations. Gene symbol: APC. Disease: adenomatous polyposis coli.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Genes, APC. INDEL Mutation

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19320041.001).
  • [ISSN] 1432-1203
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ HX080001
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Codon; 0 / Codon, Nonsense
  •  go-up   go-down


24. Holler E, Landfried K, Meier J, Hausmann M, Rogler G: The role of bacteria and pattern recognition receptors in GVHD. Int J Inflam; 2010;2010:814326
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Graft-versus-Host Disease (GvHD) is the most serious complication of allogeneic stem cell transplantation (SCT) and results from an activation of donor lymphocytes by recipient antigen-presenting cells (APCs).
  • For a long time, it has been postulated that the intestinal microflora and endotoxin exert a crucial step in this APC activation, as there is early and severe gastrointestinal damage induced by pretransplant conditioning.
  • With the detailed description of pathogen-associated molecular patterns and pathogen recognition receptors single nucleotide polymorphisms of TLRs and especially NOD2 have been identified as potential risk factors of GvHD and transplant related complications thus further supporting the crucial role of innate immunity in SCT, related complications.
  • Gastrointestinal decontamination and neutralization of endotoxin have been used to interfere with this early axis of activation with some success but more specific approaches of modulation of innate immunity are needed for further improvement of clinical outcome.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21188220.001).
  • [ISSN] 2042-0099
  • [Journal-full-title] International journal of inflammation
  • [ISO-abbreviation] Int J Inflam
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3003997
  •  go-up   go-down


25. Marrocco K, Bergdoll M, Achard P, Criqui MC, Genschik P: Selective proteolysis sets the tempo of the cell cycle. Curr Opin Plant Biol; 2010 Dec;13(6):631-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is achieved by the action of ubiquitin ligases (E3s), which remove both negative and positive regulators of the cell cycle.
  • Though our current understanding of the plant cell cycle has improved a lot these recent years, the identity of the E3s regulating it and their mode of action is still in its infancy.
  • Thus the anaphase promoting complex/cyclosome (APC/C) not only controls mitotic events, but is also important in post-mitotic cells for normal plant development and cell differentiation.
  • [MeSH-minor] Anaphase-Promoting Complex-Cyclosome. Models, Biological. Plant Growth Regulators / metabolism. Ubiquitin-Protein Ligase Complexes / genetics. Ubiquitin-Protein Ligase Complexes / metabolism. Ubiquitin-Protein Ligases / genetics. Ubiquitin-Protein Ligases / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20810305.001).
  • [ISSN] 1879-0356
  • [Journal-full-title] Current opinion in plant biology
  • [ISO-abbreviation] Curr. Opin. Plant Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Plant Growth Regulators; EC 6.3.2.19 / Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Ubiquitin-Protein Ligase Complexes; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


26. Yoshida K: Cell-cycle-dependent regulation of the human and mouse Tome-1 promoters. FEBS Lett; 2005 Feb 28;579(6):1488-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In turn, Tome-1 itself is targeted for degradation by APC in the G1 phase of the cell cycle.
  • [MeSH-major] Cell Cycle / genetics. Cell Cycle Proteins / genetics. Promoter Regions, Genetic / genetics
  • [MeSH-minor] 5' Flanking Region / genetics. Animals. Base Sequence. Cell Division. Down-Regulation / genetics. G2 Phase. Humans. Mice. Molecular Sequence Data. Mutation / genetics. NIH 3T3 Cells. Sequence Alignment. Transcriptional Activation / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15733861.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CDCA3 protein, human; 0 / Cell Cycle Proteins; 0 / Tome-1 protein, mouse
  •  go-up   go-down


27. Chambers WM, McC Mortensen NJ: Should ileal pouch-anal anastomosis include mucosectomy? Colorectal Dis; 2007 Jun;9(5):384-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Debate exists as to the benefits of performing mucosectomy as part of pouch surgery for ulcerative colitis (UC) and familial adenomatous polyposis (FAP).
  • Potential reasons for functional problems were investigated, as were rates of 'cuffitis', dysplasia, polyposis and cancer in the ileal pouch and anal canal.
  • Meta-analysis suggested that nighttime seepage of stool and resting and squeeze pressure were worse after mucosectomy.
  • Mucosectomy does seem to confer benefit in terms of disease control but this benefit does not reach statistical significance.
  • Performing mucosectomy results in some clinical benefits in terms of lower rates of inflammation and dysplasia in the retained mucosa in UC patients and lower rates of cuff polyposis in FAP patients.
  • However, on the basis of available evidence mucosectomy is only indicated in those cases where the patient is at a high risk of disease in the retained rectal cuff.
  • [MeSH-major] Colonic Pouches / adverse effects. Intestinal Mucosa / surgery. Proctocolectomy, Restorative / adverse effects
  • [MeSH-minor] Adenocarcinoma / prevention & control. Adenomatous Polyposis Coli / surgery. Anastomosis, Surgical / adverse effects. Anastomosis, Surgical / methods. Anus Neoplasms / prevention & control. Arsenates. Colitis, Ulcerative / surgery. Humans. Ileal Neoplasms / prevention & control. Randomized Controlled Trials as Topic

  • Hazardous Substances Data Bank. ARSENIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504334.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arsenates; N7CIZ75ZPN / arsenic acid
  • [Number-of-references] 70
  •  go-up   go-down


28. Mozaffarian N, Wiedeman AE, Stevens AM: Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1. Rheumatology (Oxford); 2008 Sep;47(9):1335-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1.
  • OBJECTIVE: Antigen-presenting cells (APC) play critical roles in establishing and maintaining peripheral tolerance.
  • This is accomplished in part via expression of negative co-stimulatory molecules such as programmed death ligand-1 (PD-L1) on tolerogenic APC, such as immature myeloid dendritic cells (mDC).
  • Several studies have strongly linked dysfunction of APC, including mDC, to the pathogenesis of SLE.
  • The objective of this study was to determine whether APC expressed PD-L1 protein at normal levels during active lupus.
  • In contrast, both mDC and Mo from patients with active SLE failed to up-regulate PD-L1 over a 5 day time course, expressing this protein only during disease remissions.
  • CONCLUSIONS: These data are the first to link active lupus with reversibly decreased PD-L1 expression on professional APC, suggesting a novel mechanism for loss of peripheral tolerance in SLE.

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 2007 Mar 27;83(6):774-82 [17414712.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1365-9 [10581077.001]
  • [Cites] Lupus. 2000;9(6):445-50 [10981649.001]
  • [Cites] J Exp Med. 2000 Oct 2;192(7):1027-34 [11015443.001]
  • [Cites] Genes Immun. 2007 Jun;8(4):279-87 [17344889.001]
  • [Cites] Immunity. 2007 Jul;27(1):111-22 [17629517.001]
  • [Cites] J Virol. 2007 Sep;81(17):9249-58 [17567698.001]
  • [Cites] Rheumatology (Oxford). 2007 Sep;46(9):1492-4 [17673480.001]
  • [Cites] Mol Immunol. 2008 Jan;45(1):259-65 [17570528.001]
  • [Cites] Clin Exp Immunol. 2008 Jan;151(1):86-93 [18005363.001]
  • [Cites] Arthritis Rheum. 2007 Dec 15;57(8):1530-8 [18050226.001]
  • [Cites] Nat Immunol. 2001 Mar;2(3):261-8 [11224527.001]
  • [Cites] Science. 2001 Nov 16;294(5546):1540-3 [11711679.001]
  • [Cites] Nat Med. 2002 Aug;8(8):793-800 [12091876.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):666-9 [12402038.001]
  • [Cites] J Immunol. 2003 Feb 1;170(3):1257-66 [12538684.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2514-20 [12468426.001]
  • [Cites] Eur J Immunol. 2003 Oct;33(10):2706-16 [14515254.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10691-6 [15249675.001]
  • [Cites] Arthritis Rheum. 2004 Aug;50(8):2590-7 [15334473.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Jul;75(7):3464-8 [150602.001]
  • [Cites] Arthritis Rheum. 1997 Sep;40(9):1725 [9324032.001]
  • [Cites] J Exp Med. 1998 Oct 5;188(7):1359-68 [9763615.001]
  • [Cites] J Immunol. 1998 Oct 15;161(8):3966-73 [9780165.001]
  • [Cites] Scand J Immunol. 1999 Jan;49(1):82-7 [10023862.001]
  • [Cites] Immunity. 1999 Aug;11(2):141-51 [10485649.001]
  • [Cites] Eur Cytokine Netw. 2004 Jul-Sep;15(3):222-30 [15542447.001]
  • [Cites] J Immunol. 2005 Feb 15;174(4):1888-97 [15699115.001]
  • [Cites] Nat Immunol. 2005 Mar;6(3):280-6 [15685176.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3417-23 [16116236.001]
  • [Cites] J Immunol. 2006 Mar 15;176(6):3480-9 [16517716.001]
  • [Cites] J Leukoc Biol. 2006 Apr;79(4):686-95 [16461745.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):883-95 [16606670.001]
  • [Cites] Br J Ophthalmol. 2006 Aug;90(8):1040-5 [16613922.001]
  • [Cites] Rheumatology (Oxford). 2006 Sep;45(9):1087-95 [16527880.001]
  • [Cites] J Immunol. 2006 Sep 15;177(6):3606-14 [16951320.001]
  • [Cites] J Immunol. 2006 Sep 15;177(6):4196-202 [16951385.001]
  • [Cites] Diabet Med. 2006 Oct;23(10):1145-50 [16978382.001]
  • [Cites] Arthritis Rheum. 2006 Sep;54(9):2951-62 [16947629.001]
  • [Cites] J Autoimmun. 2006 Sep;27(2):110-8 [16890406.001]
  • [Cites] J Viral Hepat. 2006 Nov;13(11):725-33 [17052271.001]
  • [Cites] J Immunol. 2006 Nov 1;177(9):5878-89 [17056512.001]
  • [Cites] J Clin Immunol. 2006 Nov;26(6):506-11 [17024563.001]
  • [Cites] J Exp Med. 2006 Nov 27;203(12):2737-47 [17116737.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8291-5 [17142723.001]
  • [Cites] J Neuroimmunol. 2007 Jan;182(1-2):124-34 [17182110.001]
  • [Cites] J Immunol. 2007 Feb 15;178(4):2579-88 [17277168.001]
  • [Cites] Nat Immunol. 2007 Mar;8(3):239-45 [17304234.001]
  • [Cites] Eur J Hum Genet. 2007 Mar;15(3):336-41 [17228327.001]
  • [Cites] J Rheumatol. 2007 Apr;34(4):721-5 [17343323.001]
  • [Cites] Immunobiology. 2007;212(3):159-65 [17412283.001]
  • (PMID = 18650228.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000037; United States / NIAMS NIH HHS / AR / T32 AR007108; United States / NCRR NIH HHS / RR / M01-RR-00037
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / CD274 protein, human
  • [Other-IDs] NLM/ PMC2722808
  •  go-up   go-down


29. Alferez DG, Ryan AJ, Goodlad RA, Wright NA, Wilkinson RW: Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model. Int J Oncol; 2010 Oct;37(4):767-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.
  • The Apc(MIN/+) mouse is a well-characterised model of intestinal tumourigenesis in which animals develop macroscopically detectable adenomas.
  • However, most of the adenomas are formed in the small intestine and resolution of events in the colon, the most relevant site for human disease, is limited.
  • Inducing colitis with dextran sodium sulphate (DSS) can selectively enhance the development of lesions in the colon.
  • We demonstrated that a DSS pre-treatment is well tolerated and effective at inducing colon adenomas in an Apc(MIN/+) mouse model.
  • We then investigated the effect of inhibiting vascular endothelial growth factor (VEGFR)- and epidermal growth factor receptor (EGFR)-dependent signalling pathways on the development of adenomas induced in DSS-pretreated (DSS/Apc(MIN/+)) or non-DSS-pretreated (Apc(MIN/+)) mice using vandetanib (ZD6474), a potent and selective inhibitor of VEGFR and EGFR tyrosine kinase activity.
  • Eight-week old Apc(MIN/+) mice were given either drinking water or 1.8% DSS and then vandetanib (ZD6474) (50 mg/kg/day) or vehicle by oral gavage for 28 days and sacrificed 24 h after the last dose and assessed for adenoma formation in the intestines.
  • DSS pre-treatment was well tolerated and significantly enhanced formation of adenomas in the colon of control Apc(MIN/+) mice.
  • Vandetanib treatment significantly reduced adenoma formation in the small intestine by 68% (P=0.001) and the colon by 77% (from 13.8 to 3.1, P=0.01) of DSS-pretreated Apc(MIN/+) mice.
  • In the Apc(MIN/+) group, vandetanib also reduced the mean number of adenomas in the small intestine by 76% (P<0.001) and in the colon by 60% (from 3.9 to 1.5, P=0.1).
  • DSS-pre-treatment increased the resolution of the model, allowing us to confirm statistically significant effects of vandetanib on the development and growth of colon adenomas in the Apc(MIN/+) mouse.
  • Moreover these preclinical data provide a rationale for studying the effects of vandetanib in early stages of intestinal cancer in the clinic.
  • [MeSH-major] Adenoma / prevention & control. Antineoplastic Agents / pharmacology. Colitis / chemically induced. Colonic Neoplasms / prevention & control. Dextran Sulfate. Genes, APC. Piperidines / pharmacology. Protein Kinase Inhibitors / pharmacology. Quinazolines / pharmacology
  • [MeSH-minor] Animals. Disease Models, Animal. Intestine, Small / drug effects. Intestine, Small / enzymology. Intestine, Small / pathology. Mice. Mice, Inbred C57BL. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism. Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors. Vascular Endothelial Growth Factor Receptor-2 / metabolism. beta Catenin / metabolism

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20811697.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CTNNB1 protein, mouse; 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / Piperidines; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / beta Catenin; 9042-14-2 / Dextran Sulfate; EC 2.7.10.1 / EGFR protein, mouse; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


30. Voutsadakis IA: Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med; 2007 Mar-Apr;11(2):252-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathways of the molecular pathogenesis of colorectal carcinoma have been extensively studied and molecular lesions during the development of the disease have been revealed.
  • High up in the list of colorectal cancer lesions are APC (adenomatous polyposis coli), K-ras, Smad4 (or DPC4-deleted in pancreatic cancer 4) and p53 genes.
  • The ubiquitin-proteasome system (UPS) is comprised of a multi-unit cellular protease system that regulates several dozens of cell proteins after their ligation with the protein ubiquitin.
  • Given that among these proteins are regulators of the cell cycle, apoptosis, angiogenesis, adhesion and cell signalling, this system plays a significant role in cell fate and carcinogenesis.
  • UPS inhibition has been found to be a pre-requisite for apoptosis and is already clinically exploited with the proteasome inhibitor bortezomib in multiple myeloma.
  • Inhibition of Cox-2 by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been found to inhibit proliferation of colorectal cancer cells and in epidemiologic studies has been shown to reduce colon polyp formation in genetically predisposed populations and in the general population.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488476.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Ubiquitin; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Number-of-references] 298
  • [Other-IDs] NLM/ PMC3822826
  •  go-up   go-down


31. Heng W, Huang JA, Shen WH, Dai L, Bai X, Wang ZY: [Expression of endothelial protein C receptor in tumor cell lines and It's significance]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Aug;26(8):761-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of endothelial protein C receptor in tumor cell lines and It's significance].
  • AIM: To detect the role of activated protein C(APC) on proliferation of endothelial cell and investigate the expression of endothelial protein C receptor( EPCR) in variety of tumor cell lines.
  • METHODS: The effect of APC on endotheliocyte proliferation was determined by MTT colorimetry.
  • RESULTS: APC can increase the proliferation of EC significantly.
  • CONCLUSION: APC can stimulate the proliferation of endothelial cell.
  • High expression of EPCR in tumor cell lines provides a potential biological marker for malignancies.
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Humans. Interleukin-6 / metabolism. Interleukin-8 / metabolism. Protein C / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20619102.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Interleukin-6; 0 / Interleukin-8; 0 / PROCR protein, human; 0 / Protein C; 0 / Receptors, Cell Surface
  •  go-up   go-down


32. Kryczek I, Wei S, Gong W, Shu X, Szeliga W, Vatan L, Chen L, Wang G, Zou W: Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development. J Immunol; 2008 Nov 1;181(9):5842-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development.
  • However, Th1, Th17, and memory but not naive T cells are colocalized in an inflammatory environment.
  • We show that IFN-gamma stimulates B7-H1 expression on APC subsets and abates their Th1 polarization capacity in a B7-H1-dependent manner.
  • Interestingly, IFN-gamma triggers APCs to produce IL-1 and IL-23 and enables them to induce memory Th17 expansion via IL-1 and IL-23 in a B7-H1-independent manner.
  • We propose a novel dynamic between Th1 and Th17 in the course of inflammation as follows: Th1-mediated inflammation is attenuated by IFN-gamma-induced B7-H1 on APCs and is evolved toward Th17-mediated chronic inflammation by IFN-gamma-induced, APC-derived IL-1 and IL-23.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941172.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA099985; United States / NCI NIH HHS / CA / CA123088
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / CD274 protein, human; 0 / Growth Inhibitors; 0 / Interleukin-1; 0 / Interleukin-17; 0 / Interleukin-23; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


33. Samuel MS, Suzuki H, Buchert M, Putoczki TL, Tebbutt NC, Lundgren-May T, Christou A, Inglese M, Toyota M, Heath JK, Ward RL, Waring PM, Ernst M: Elevated Dnmt3a activity promotes polyposis in Apc(Min) mice by relaxing extracellular restraints on Wnt signaling. Gastroenterology; 2009 Sep;137(3):902-13, 913.e1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated Dnmt3a activity promotes polyposis in Apc(Min) mice by relaxing extracellular restraints on Wnt signaling.
  • Here we use knock-in transgenic mice to investigate the consequences of intestinal epithelium-specific overexpression of de novo Dnmt3a.
  • METHODS: A novel gene targeting strategy, based on the intestinal epithelium-specific, uniform expression of the A33 glycoprotein, is employed to restrict Dnmt3a overexpression in homozygous A33(Dnmt3a) mutant mice.
  • RESULTS: A33(Dnmt3a) mice infrequently develop spontaneous intestinal polyps.
  • However, when genetically challenged, tumor multiplicity in A33(Dnmt3a);Apc(Min) compound mice is 3-fold higher than in Apc(Min) mice.
  • Although we observe a requirement for spontaneous loss of heterozygosity of the adenomatous polyposis coli (Apc) gene to trigger tumorigenesis in Apc(Min) mice, lesions in A33(Dnmt3a);Apc(Min) mice frequently retain the wild-type Apc allele.
  • However, epithelia from normal mucosa and polyps of A33(Dnmt3a);Apc(Min) mice show hypermethylation-mediated transcriptional silencing of the Wnt antagonists Sfrp5, and to a lesser extent, Sfrp1 and increased nuclear beta-catenin alongside activation of the Wnt-target gene Axin2/Conductin.
  • Conversely, enforced Sfrp5 expression suppresses canonical Wnt-signaling more effectively in wild-type than in Apc(Min) cells.
  • CONCLUSIONS: Aberrant activation of the canonical Wnt pathway, either by mono-allelic Apc loss or transcriptional silencing of Sfrp5 is largely insufficient to promote polyposis, but epistatic interactions between these genetic and epigenetic events enables initiation and promotion of disease.
  • [MeSH-major] Adenomatous Polyposis Coli / metabolism. DNA (Cytosine-5-)-Methyltransferase / metabolism. Genes, APC. Intestinal Mucosa / metabolism. Signal Transduction. Wnt Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454286.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gpa33 protein, mouse; 0 / Membrane Glycoproteins; 0 / Wnt Proteins; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA methyltransferase 3A
  •  go-up   go-down


34. Walker A, Acquaviva C, Matsusaka T, Koop L, Pines J: UbcH10 has a rate-limiting role in G1 phase but might not act in the spindle checkpoint or as part of an autonomous oscillator. J Cell Sci; 2008 Jul 15;121(Pt 14):2319-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] UbcH10 has a rate-limiting role in G1 phase but might not act in the spindle checkpoint or as part of an autonomous oscillator.
  • Ubiquitin-dependent proteolysis mediated by the anaphase-promoting complex/cyclosome (APC/C) ubiquitin ligase lies at the heart of the cell cycle.
  • The APC/C targets mitotic cyclins for destruction in mitosis and G1 phase and is then inactivated at S phase, thereby generating the alternating states of high and low cyclin-Cdk activity required for the alternation of mitosis and DNA replication.
  • Two key questions are how the APC/C is held in check by the spindle-assembly checkpoint to delay cells in mitosis in the presence of improperly attached chromosomes, and how the APC/C is inactivated once cells exit mitosis.
  • The ubiquitin-conjugating protein UbcH10 has been proposed to be crucial in the answers to both questions.
  • However, here we show that the behaviour of UbcH10 is inconsistent with both a crucial role in the spindle checkpoint and in inactivating the APC/C as part of an autonomous oscillator.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18559889.001).
  • [ISSN] 0021-9533
  • [Journal-full-title] Journal of cell science
  • [ISO-abbreviation] J. Cell. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin A; EC 6.3.2.19 / UBE2C protein, human; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes
  •  go-up   go-down


35. Tojo K, Sekijima Y, Kelly JW, Ikeda S: Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res; 2006 Dec;56(4):441-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis.
  • Transthyretin (TTR) tetramer dissociation, misfolding and misassembly are required for the process of amyloid fibril formation associated with familial amyloid polyneuropathy (FAP).
  • Here, we investigated the feasibility of using these molecules for the treatment of FAP utilizing serum samples from 37 FAP patients with 10 different mutations.
  • We demonstrated that the TTR heterotetramer structures in FAP patients serum are significantly less stable than that in normal subjects, indicating the instability of the variant TTR structure is a fundamental cause of TTR amyloidosis.
  • Trivalent chromium at levels obtained by oral supplementation did not stabilize TTR in a statistically significant fashion.
  • Importantly, diflunisal increased serum TTR stability in FAP patients beyond the level of normal controls.
  • [MeSH-major] Amyloid Neuropathies, Familial / metabolism. Amyloid beta-Peptides / biosynthesis. Amyloid beta-Peptides / genetics. Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Diflunisal / pharmacology. Prealbumin / biosynthesis. Prealbumin / genetics
  • [MeSH-minor] Adult. Aged. Chromium / pharmacology. Female. Flufenamic Acid / pharmacology. Humans. Hydrogen-Ion Concentration. Iron / physiology. Male. Middle Aged. Mutation / physiology. Protein Denaturation

  • Genetic Alliance. consumer health - Familial Amyloid Polyneuropathy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17028027.001).
  • [ISSN] 0168-0102
  • [Journal-full-title] Neuroscience research
  • [ISO-abbreviation] Neurosci. Res.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK046335
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Amyloid beta-Peptides; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Prealbumin; 0R0008Q3JB / Chromium; 60GCX7Y6BH / Flufenamic Acid; 7C546U4DEN / Diflunisal; E1UOL152H7 / Iron
  •  go-up   go-down


36. Langelaar MF, Hope JC, Rutten VP, Noordhuizen JP, van Eden W, Koets AP: Mycobacterium avium ssp. paratuberculosis recombinant heat shock protein 70 interaction with different bovine antigen-presenting cells. Scand J Immunol; 2005 Mar;61(3):242-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mycobacterium avium ssp. paratuberculosis recombinant heat shock protein 70 interaction with different bovine antigen-presenting cells.
  • Abstract Heat shock proteins (Hsp) can deliver antigen into the major histocompatibility complex class I presentation pathway of antigen-presenting cells (APC), a process called cross priming, thus stimulating antigen-specific CD8+ T-cell reactions.
  • Hsp were shown to elicit proinflammatory responses in APC.
  • Both processes require interaction of Hsp with APC via specific receptors.
  • Characterized monocyte-derived macrophages, monocyte-derived dendritic cells (DC) and BoMac, an immortalized bovine macrophage cell line, were used to investigate the interaction of rHsp70 with different bovine APC.
  • Involvement of CD91 as a cellular receptor for rHsp70 was demonstrated; however, competition studies with immature DC demonstrated that other receptors exist on bovine APC.
  • [MeSH-major] Antigen-Presenting Cells / immunology. Bacterial Proteins / immunology. HSP70 Heat-Shock Proteins / immunology. Mycobacterium avium subsp. paratuberculosis / immunology

  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15787741.001).
  • [ISSN] 0300-9475
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Bacterial Proteins; 0 / Bacterial Vaccines; 0 / HSP70 Heat-Shock Proteins; 0 / alpha-Macroglobulins
  •  go-up   go-down


37. Yamashita T, Ando Y, Ueda M, Okamoto S, Misumi Y, Nakamura M, Takashi O, Uchino M: A rapid and sensitive prenatal diagnosis of familial amyloidotic polyneuropathy ATTR Val30Met by mass spectrometry. Prenat Diagn; 2009 Oct;29(10):930-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rapid and sensitive prenatal diagnosis of familial amyloidotic polyneuropathy ATTR Val30Met by mass spectrometry.
  • OBJECTIVE: To make a prenatal diagnosis of familial amyloidotic polyneuropathy (FAP) by mass spectrometry with the amniotic fluid.
  • METHODS: Amniotic-fluid samples of three non-FAP pregnant women and six amniotic-fluid samples of fetal mice whose mother was a heterozygotic FAP amyloidgenic transthyretin (ATTR) Val30Met gene carrier were collected.
  • CONCLUSION: Mass spectrometry analysis of the amniotic fluid might be a useful tool to make a prenatal diagnosis of FAP ATTR Val30Met.
  • [MeSH-major] Amyloid Neuropathies, Familial / diagnosis. Mass Spectrometry / methods. Prealbumin / analysis. Prenatal Diagnosis / methods

  • MedlinePlus Health Information. consumer health - Prenatal Testing.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • Hazardous Substances Data Bank. L-Valine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609897.001).
  • [ISSN] 1097-0223
  • [Journal-full-title] Prenatal diagnosis
  • [ISO-abbreviation] Prenat. Diagn.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Prealbumin; AE28F7PNPL / Methionine; HG18B9YRS7 / Valine
  •  go-up   go-down


38. Dalby M, Kharbanda R, Ghimire G, Spiro J, Moore P, Roughton M, Lane R, Al-Obaidi M, Teoh M, Hutchison E, Whitbread M, Fountain D, Grocott-Mason R, Mitchell A, Mason M, Ilsley C: Achieving routine sub 30 minute door-to-balloon times in a high volume 24/7 primary angioplasty center with autonomous ambulance diagnosis and immediate catheter laboratory access. Am Heart J; 2009 Nov;158(5):829-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Achieving routine sub 30 minute door-to-balloon times in a high volume 24/7 primary angioplasty center with autonomous ambulance diagnosis and immediate catheter laboratory access.
  • Using autonomous ambulance diagnosis with open access to the myocardial infarction center catheter laboratory, we compared reperfusion times and clinical outcomes for the final 2 years of TL with the first 3 years of PPCI.
  • RESULTS: Comparison was made between TL (2002-2004, n = 185) and PPCI (2004-2007, n = 704); all times are medians in minutes (interquartile range): for TL, symptom to needle 153 (85-225), call to needle 58 (49-73), first professional contact (FPC) to needle 47 (39-63), door to needle 18 (12-30) (mortality: 7.6% at 30 days, 9.2% at 1 year); for interhospital transfer PPCI (n = 227), symptom to balloon 226 (175-350), call to balloon 135 (117-188), FPC to balloon 121 (102-166), first door-to-balloon 100 (80-142) (mortality: 7.0% at 30 days, 12.3% at 1 year); for direct-access PPCI (n = 477), symptom to balloon 142 (101-238), call to balloon 79 (70-93), FPC to balloon 69 (59-82), door to balloon 20 (16-29) (mortality: 4.6% at 30 days, 8.6% at 1 year).
  • With autonomous ambulance diagnosis and open access direct to the catheter laboratory, a median door-to-balloon time of <30 minutes day and night was achieved, and >95% of patients were reperfused within 1 hour.

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am Heart J. 2010 Feb;159(2):330
  • (PMID = 19853705.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents
  •  go-up   go-down


39. Wen K, Azevedo MS, Gonzalez A, Zhang W, Saif LJ, Li G, Yousef A, Yuan L: Toll-like receptor and innate cytokine responses induced by lactobacilli colonization and human rotavirus infection in gnotobiotic pigs. Vet Immunol Immunopathol; 2009 Feb 15;127(3-4):304-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We demonstrated that LAB induced strong TLR2-expressing APC responses in blood and spleen, HRV induced a TLR3 response in spleen, and TLR9 responses were induced by either HRV (in spleen) or LAB (in blood).
  • LAB and HRV have an additive effect on TLR2- and TLR9-expressing APC responses, consistent with the adjuvant effect of LAB.
  • LAB enhanced the IFN-gamma and IL-4 responses in serum, but it had a suppressive effect on the TLR3- and TLR9-expressing CD14- APC responses in spleen and the serum IFN-alpha response induced by HRV.

  • MedlinePlus Health Information. consumer health - Rotavirus Infections.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Immunol. 2008 Sep;128(3):400-8 [18565796.001]
  • [Cites] Antonie Van Leeuwenhoek. 1999 Jul-Nov;76(1-4):383-9 [10532394.001]
  • [Cites] Dig Dis Sci. 1999 Oct;44(10):2119-23 [10548366.001]
  • [Cites] Immunology. 2001 Apr;102(4):396-404 [11328373.001]
  • [Cites] Immunology. 2001 Oct;104(2):175-84 [11683958.001]
  • [Cites] Vet Immunol Immunopathol. 2002 Sep 10;87(3-4):147-60 [12072229.001]
  • [Cites] Ann Allergy Asthma Immunol. 2002 Jun;88(6):543-7; quiz 548-50, 583 [12086359.001]
  • [Cites] Antonie Van Leeuwenhoek. 2002 Aug;82(1-4):341-52 [12369201.001]
  • [Cites] Vet Immunol Immunopathol. 2003 Jan 10;91(1):1-12 [12507844.001]
  • [Cites] Science. 2003 Aug 1;301(5633):640-3 [12855817.001]
  • [Cites] J Immunol. 2003 Sep 15;171(6):3154-62 [12960343.001]
  • [Cites] Immunology. 2003 Dec;110(4):440-9 [14632641.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):520-8 [14762789.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3516-21 [14993594.001]
  • [Cites] Nat Rev Immunol. 2004 Jul;4(7):499-511 [15229469.001]
  • [Cites] J Clin Microbiol. 1982 Feb;15(2):312-9 [6279693.001]
  • [Cites] Am J Vet Res. 1986 Aug;47(8):1697-703 [3019187.001]
  • [Cites] Pediatr Res. 1992 Aug;32(2):141-4 [1324462.001]
  • [Cites] Lancet. 1994 Oct 15;344(8929):1046-9 [7934445.001]
  • [Cites] FEMS Immunol Med Microbiol. 1994 Nov;10(1):55-63 [7874079.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1995 Apr;20(3):333-8 [7608829.001]
  • [Cites] Vaccine. 1995 Feb;13(3):310-2 [7631519.001]
  • [Cites] J Virol. 1996 May;70(5):3075-83 [8627786.001]
  • [Cites] J Gen Virol. 1996 Jul;77 ( Pt 7):1431-41 [8757984.001]
  • [Cites] Arch Virol Suppl. 1996;12:153-61 [9015112.001]
  • [Cites] Pediatr Infect Dis J. 1997 Dec;16(12):1103-7 [9427453.001]
  • [Cites] Clin Exp Immunol. 1999 May;116(2):283-90 [10337020.001]
  • [Cites] Appl Microbiol. 1964 Jul;12:295-300 [14199016.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):3906-12 [15671160.001]
  • [Cites] J Virol. 2005 May;79(9):5428-36 [15827157.001]
  • [Cites] Eur J Nutr. 2005 Oct;44(7):406-13 [15578195.001]
  • [Cites] J Virol. 2006 Jan;80(1):372-82 [16352562.001]
  • [Cites] Folia Biol (Praha). 2005;51(6):188-97 [16419614.001]
  • [Cites] Clin Vaccine Immunol. 2006 Feb;13(2):219-26 [16467329.001]
  • [Cites] Cell Res. 2006 Feb;16(2):141-7 [16474426.001]
  • [Cites] Immunity. 2006 Feb;24(2):153-63 [16473828.001]
  • [Cites] Emerg Infect Dis. 2006 Feb;12(2):304-6 [16494759.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Mar;21(3):521-30 [16638093.001]
  • [Cites] J Allergy Clin Immunol. 2006 May;117(5):979-87; quiz 988 [16675322.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Jun 1;23(11):1567-74 [16696804.001]
  • [Cites] Clin Exp Immunol. 2006 Jun;144(3):376-81 [16734605.001]
  • [Cites] Vet Res. 2006 Nov-Dec;37(6):791-812 [16973119.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Jan;23(1):39-43 [17133083.001]
  • [Cites] Vet Immunol Immunopathol. 2007 Feb 15;115(3-4):309-19 [17178162.001]
  • [Cites] Nutrition. 2007 Mar;23(3):254-60 [17352961.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4548-56 [17372013.001]
  • [Cites] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2007 Mar;21(1):38-40 [17429531.001]
  • [Cites] Immunol Invest. 2007;36(4):413-21 [17691023.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Oct;22(10):1627-32 [17845690.001]
  • [Cites] J Gen Virol. 2007 Oct;88(Pt 10):2749-61 [17872528.001]
  • [Cites] J Anim Sci. 2007 Dec;85(12):3256-66 [17785595.001]
  • [Cites] Acta Pharmacol Sin. 2008 Feb;29(2):239-44 [18215354.001]
  • [Cites] Vet Immunol Immunopathol. 2008 Feb 15;121(3-4):222-31 [18006076.001]
  • [Cites] Vet Immunol Immunopathol. 2008 Mar 15;122(1-2):175-81 [18023882.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2993-8 [18287072.001]
  • [Cites] AIDS. 2008 Mar 30;22(6):685-94 [18356597.001]
  • [Cites] Asia Pac J Clin Nutr. 2008;17(1):30-4 [18364323.001]
  • [Cites] PLoS Negl Trop Dis. 2008;2(4):e215 [18398488.001]
  • [Cites] PLoS Pathog. 2008 Jun;4(6):e1000079 [18535658.001]
  • [Cites] Vaccine. 2008 Jul 4;26(29-30):3655-61 [18524434.001]
  • (PMID = 19054578.001).
  • [ISSN] 0165-2427
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI033561-11; United States / NIAID NIH HHS / AI / R01 AI033561; United States / NCCIH NIH HHS / AT / R21 AT002524-02; United States / NCCIH NIH HHS / AT / R21 AT002524; United States / NIAID NIH HHS / AI / AI033561-11; United States / NCCIH NIH HHS / AT / 1R21AT002524; United States / NIAID NIH HHS / AI / R01AI033561
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines; 0 / Toll-Like Receptors
  • [Other-IDs] NLM/ NIHMS89734; NLM/ PMC2653198
  •  go-up   go-down


40. Zurbuchen U, Kroesen AJ, Buhr HJ: [Continent ileoanal reservoir--a surgical challenge]. Urologe A; 2008 Jan;47(1):18-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nowadays, patients with ulcerative colitis or familial adenomatous polyposis of the colon undergo proctocolectomy as the definitive treatment for their underlying disease.
  • This contribution describes the surgical indications and pathophysiological changes for the colon J-pouch and ileoanal reservoir.
  • In addition, explanations of the surgical techniques for both procedures are presented.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1999 Jul;42(7):896-902 [10411436.001]
  • [Cites] Ann Surg. 1986 Oct;204(4):375-83 [3767475.001]
  • [Cites] Ann Surg. 2002 Feb;235(2):207-16 [11807360.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):978-80 [8813791.001]
  • [Cites] Int J Colorectal Dis. 1998;13(4):160-3 [9810519.001]
  • [Cites] Chirurg. 1993 Aug;64(8):601-13 [8404287.001]
  • [Cites] Int J Colorectal Dis. 1998;13(4):151-3 [9810516.001]
  • [Cites] Br J Surg. 1997 Oct;84(10):1437-41 [9361608.001]
  • [Cites] Dis Colon Rectum. 2001 Jan;44(1):37-42 [11805561.001]
  • [Cites] Dis Colon Rectum. 2002 May;45(5):660-7 [12004217.001]
  • [Cites] Dis Colon Rectum. 1998 Jul;41(7):817-22; discussion 822-3 [9678365.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):487-99 [11330575.001]
  • [Cites] Ann Surg. 2003 Aug;238(2):214-20 [12894014.001]
  • [Cites] Langenbecks Arch Surg. 2001 Apr;386(3):193-9 [11382321.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):30-4 [9102258.001]
  • [Cites] Ann Surg. 2001 Dec;234(6):788-94 [11729385.001]
  • [Cites] Surg Today. 2002;32(6):487-92 [12107771.001]
  • [Cites] Int J Colorectal Dis. 2000 Apr;15(2):114-7 [10855555.001]
  • [Cites] Int J Colorectal Dis. 1998;13(5-6):241-6 [9870169.001]
  • [Cites] Ann Surg. 1995 Aug;222(2):120-7 [7639579.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):575-84; discussion 584-6 [10522727.001]
  • [Cites] Zentralbl Chir. 1994;119(12):867-77 [7846969.001]
  • [Cites] Int J Colorectal Dis. 1999 Apr;14(2):114-8 [10367257.001]
  • [Cites] Int J Colorectal Dis. 1999 Nov;14 (4-5):237-44 [10647633.001]
  • [Cites] Int J Colorectal Dis. 1999 Aug;14(3):158-63 [10460907.001]
  • (PMID = 18210064.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


41. Bobe G, Wang B, Seeram NP, Nair MG, Bourquin LD: Dietary anthocyanin-rich tart cherry extract inhibits intestinal tumorigenesis in APC(Min) mice fed suboptimal levels of sulindac. J Agric Food Chem; 2006 Dec 13;54(25):9322-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary anthocyanin-rich tart cherry extract inhibits intestinal tumorigenesis in APC(Min) mice fed suboptimal levels of sulindac.
  • A promising approach for cancer chemoprevention might be a combination therapy utilizing dietary phytochemicals and anticarcinogenic pharmaceuticals at a suboptimal dosage to minimize any potential adverse side effects.
  • Mice that were fed anthocyanin-rich extract (at any dose) in combination with sulindac had fewer tumors and a smaller total tumor burden (total tumor area per mouse) in the small intestine when compared to mice fed sulindac alone.
  • These results suggest that a dietary combination of tart cherry anthocyanins and sulindac is more protective against colon cancer than sulindac alone.
  • [MeSH-major] Anthocyanins / administration & dosage. Antineoplastic Agents / administration & dosage. Fruit / chemistry. Intestinal Neoplasms / prevention & control. Prunus / chemistry. Sulindac / administration & dosage
  • [MeSH-minor] Adenomatous Polyposis Coli / genetics. Animals. Diet. Female. Male. Mice. Mice, Inbred C57BL. Mice, Mutant Strains. Mutation. Plant Extracts / administration & dosage. Plant Extracts / chemistry

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147414.001).
  • [ISSN] 0021-8561
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthocyanins; 0 / Antineoplastic Agents; 0 / Plant Extracts; 184SNS8VUH / Sulindac
  •  go-up   go-down


42. Terazaki H, Ando Y, Fernandes R, Yamamura K, Maeda S, Saraiva MJ: Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant. Lab Invest; 2006 Jan;86(1):23-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant.
  • The mechanism of amyloid formation in familial amyloidotic polyneuropathy (FAP), a hereditary disorder associated with mutant transthyretin (TTR), is still unknown.
  • To test whether TTR deposition in FAP can be counteracted by antibodies for cryptic epitopes, we immunized with TTR Y78F, transgenic mice carrying the most common FAP-associated TTR mutant--V30M (transthyretin mutant with methionine replacing valine at position 30)--at selected ages that present normally with either nonfibrillar or TTR amyloid deposition.
  • Compared to age-matched control nonimmunized mice, Y78F-immunized mice had a significant reduction in TTR deposition usually found in this strain, in particular in stomach and intestine; by contrast, animals immunized with V30M did not show differences in deposition in comparison with nonimmunized mice.
  • Immunohistochemical analyses of tissues revealed that immunization with Y78F lead to infiltration by lymphocytes and macrophages at common deposition sites, but not in tissues such as liver, choroid plexus, and Langerhans islets, in which TTR is produced.
  • Therefore, TTR immunization with selected TTR mutants has potential application in immune therapy for FAP.
  • [MeSH-major] Amyloid Neuropathies, Familial / prevention & control. Mutation. Prealbumin / administration & dosage

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357867.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prealbumin
  •  go-up   go-down


43. Dietrich KA, Schwarz R, Liska M, Grass S, Menke A, Meister M, Kierschke G, Längle C, Genze F, Giehl K: Specific induction of migration and invasion of pancreatic carcinoma cells by RhoC, which differs from RhoA in its localisation and activity. Biol Chem; 2009 Oct;390(10):1063-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These differences are not mediated by a different interaction with RhoGDIs.
  • [MeSH-major] Cell Movement. Neoplasm Invasiveness. Pancreatic Neoplasms / pathology. rho GTP-Binding Proteins / metabolism. rhoA GTP-Binding Protein / metabolism
  • [MeSH-minor] Cell Line, Tumor. Deep Brain Stimulation. Humans. Protein Isoforms / chemistry. Protein Isoforms / genetics. Protein Isoforms / metabolism. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. rap GTP-Binding Proteins / chemistry. rap GTP-Binding Proteins / genetics. rap GTP-Binding Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19642867.001).
  • [ISSN] 1437-4315
  • [Journal-full-title] Biological chemistry
  • [ISO-abbreviation] Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / RHOC protein, human; 0 / RNA, Messenger; EC 3.6.5.2 / rap GTP-Binding Proteins; EC 3.6.5.2 / rho GTP-Binding Proteins; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


44. Chen D, Kennedy A, Wang JY, Zeng W, Zhao Q, Pearl M, Zhang M, Suo Z, Nesland JM, Qiao Y, Ng AK, Hirashima N, Yamane T, Mori Y, Mitsumata M, Ghersi G, Chen WT: Activation of EDTA-resistant gelatinases in malignant human tumors. Cancer Res; 2006 Oct 15;66(20):9977-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of EDTA-resistant gelatinases in malignant human tumors.
  • Among the many proteases associated with human cancer, seprase or fibroblast activation protein alpha, a type II transmembrane glycoprotein, has two types of EDTA-resistant protease activities: dipeptidyl peptidase and a 170-kDa gelatinase activity.
  • To test if activation of gelatinases associated with seprase could be involved in malignant tumors, we used a mammalian expression system to generate a soluble recombinant seprase (r-seprase).
  • Proteins purified from experimental xenografts and malignant tumors using antibody- or lectin-affinity columns in the presence of 5 mmol/L EDTA were assayed for seprase activation in vivo.
  • Seprase expression and activation occur most prevalently in ovarian carcinoma but were also detected in four other malignant tumor types, including adenocarcinoma of the colon and stomach, invasive ductal carcinoma of the breast, and malignant melanoma.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2004 Oct 1;306(5693):108-11 [15459390.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34691-7 [15175333.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5657-61 [7911242.001]
  • [Cites] Int J Cancer. 1994 Aug 1;58(3):385-92 [7519584.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1150-60 [7747809.001]
  • [Cites] J Biol Chem. 1997 Mar 21;272(12):7595-601 [9065413.001]
  • [Cites] Biochim Biophys Acta. 1997 Jul 10;1361(1):11-9 [9247085.001]
  • [Cites] Eur J Biochem. 1998 Jun 15;254(3):650-4 [9688278.001]
  • [Cites] Mod Pathol. 1998 Sep;11(9):855-63 [9758365.001]
  • [Cites] Hepatology. 1999 Jun;29(6):1768-78 [10347120.001]
  • [Cites] J Biol Chem. 1999 Aug 27;274(35):24947-52 [10455171.001]
  • [Cites] Oncology. 2004;67(5-6):411-9 [15713998.001]
  • [Cites] Mol Cancer Ther. 2005 Mar;4(3):351-60 [15767544.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):19441-4 [15809306.001]
  • [Cites] Cancer Lett. 2005 Sep 28;227(2):229-36 [16196122.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5702-10 [7923219.001]
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36505-12 [10593948.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2554-9 [10644713.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):67-72 [11241314.001]
  • [Cites] J Biol Chem. 2002 Aug 9;277(32):29231-41 [12023964.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4767-72 [12183436.001]
  • [Cites] J Biol Chem. 1998 May 22;273(21):13366 [12755100.001]
  • [Cites] Anticancer Res. 2003 Jul-Aug;23(4):3195-8 [12926053.001]
  • [Cites] Oncology. 2003;65(4):363-70 [14707457.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2712-6 [15087384.001]
  • [Cites] Oncogene. 2004 Jul 15;23(32):5435-46 [15133496.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8296-300 [2172980.001]
  • (PMID = 17047060.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA039077; United States / NIBIB NIH HHS / EB / R01EB002065; United States / NIBIB NIH HHS / EB / R01 EB002065; United States / NCRR NIH HHS / RR / M01 RR010710; United States / NCRR NIH HHS / RR / M01RR10710; United States / NCI NIH HHS / CA / R01CA0039077
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Recombinant Proteins; 9G34HU7RV0 / Edetic Acid; EC 3.4.14.- / Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  • [Other-IDs] NLM/ NIHMS11890; NLM/ PMC1626657
  •  go-up   go-down


45. Morais-de-Sá E, Neto-Silva RM, Pereira PJ, Saraiva MJ, Damas AM: The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin. Acta Crystallogr D Biol Crystallogr; 2006 May;62(Pt 5):512-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin.
  • Systemic deposition of transthyretin (TTR) amyloid fibrils is always observed in familial amyloidotic polyneuropathy, senile systemic amyloidosis and familial amyloidotic cardiomyopathy patients.
  • The destabilization of a native protein with consequent conformational changes appears to be a common link in several human amyloid diseases.
  • Intensive research has been directed towards finding small molecules that could work as therapeutic agents for the prevention/inhibition of amyloid diseases through stabilization of the native fold of the potentially amyloidogenic protein.
  • This work provides insight into the structural determinants of the highly stabilizing effects of 2,4-dinitrophenol on wild-type TTR.
  • As a result of 2,4-dinitrophenol binding, the two dimers in the TTR tetramer become closer, increasing the stability of the protein.
  • The three-dimensional structures now determined allow a comprehensive description of key interactions between transthyretin and 2,4-dinitrophenol, a small compound that holds promise as a template for the design of a therapeutical drug for amyloid diseases.

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • Hazardous Substances Data Bank. 2,4-Dinitrophenol .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627944.001).
  • [ISSN] 0907-4449
  • [Journal-full-title] Acta crystallographica. Section D, Biological crystallography
  • [ISO-abbreviation] Acta Crystallogr. D Biol. Crystallogr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Peptides; 0 / Prealbumin; Q13SKS21MN / 2,4-Dinitrophenol
  •  go-up   go-down


46. Inoue K, Hiraoka T, Kanemitsu K, Takamori H, Tsuji T, Kawasuji M: Onset of liver metastasis after histologically curative resection of pancreatic cancer. Surg Today; 2006;36(3):252-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Onset of liver metastasis after histologically curative resection of pancreatic cancer.
  • PURPOSE: We assessed the possibility of predicting the time of onset of liver metastases by measuring the postoperative changes in serum carbohydrate antigen (CA)19-9 after curative resection of pancreatic cancers.
  • METHODS: Among 28 patients who underwent histologically defined curative resection of pancreatic cancer between 1984 and 1999, liver metastasis developed in 11 patients with elevated serum CA19-9 levels.
  • We plotted the serum CA19-9 levels against time on a semilogarithmic graph.
  • Over the linear part of the curve, the time when log[CA19-9] equaled zero was defined as the time of onset of liver metastases.
  • The log[CA19-9] level doubling time was then calculated and evaluated in relation to the survival period.
  • RESULTS: The serum CA19-9 levels increased linearly in 10 of the 11 patients.
  • The predicted time of onset of liver metastasis ranged from preoperative day 163.0 to postoperative day 27.1, being preoperative in eight patients.
  • The doubling time until death correlated strongly with survival in the eight patients with maintained log[CA19-9] linearity.
  • CONCLUSION: The onset of liver metastases might be preoperative in patients with advanced pancreatic cancer.
  • Therefore, neoadjuvant chemotherapy should be mandatory even if there is no sign of liver metastases.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Time Factors

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1998 Jan-Feb;45(19):253-9 [9496523.001]
  • [Cites] J Gastrointest Surg. 1998 Jan-Feb;2(1):28-35 [9841965.001]
  • [Cites] Int J Pancreatol. 1995 Apr;17(2):139-46 [7622937.001]
  • [Cites] Int J Biol Markers. 1999 Apr-Jun;14(2):99-105 [10399629.001]
  • [Cites] Ann Surg Oncol. 1997 Oct-Nov;4(7):551-6 [9367020.001]
  • [Cites] Int J Pancreatol. 1990 Aug-Nov;7(1-3):201-7 [1964472.001]
  • [Cites] Am J Surg. 1978 Sep;136(3):322-7 [707698.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1039-46 [10421536.001]
  • [Cites] Int J Biol Markers. 1994;9(1):33-7 [8051433.001]
  • [Cites] Cancer. 1987 Nov 15;60(10):2428-31 [3478117.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4A):2433-5 [10470171.001]
  • [Cites] J Surg Oncol. 1993 Mar;52(3):137-41 [8441267.001]
  • [Cites] HPB Surg. 1994;8(2):107-10 [7880768.001]
  • [Cites] Hepatogastroenterology. 1996 May-Jun;43(9):748-55 [8799425.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1991 Sep;92(9):1074-7 [1944157.001]
  • (PMID = 16493535.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


47. Cai H, Hua B, Fan L, Wang Q, Wang S, Zhao Y: A novel mutation (g2172--&gt;c) in the factor V gene in a Chinese family with hereditary activated protein C resistance. Thromb Res; 2010 Jun;125(6):545-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel mutation (g2172-->c) in the factor V gene in a Chinese family with hereditary activated protein C resistance.
  • BACKGROUND: Activated protein C resistance (APC-R) was a major risk factor for venous thromboembolism(VTE) in Caucasians, and at least 90% of APC-R were associated with the point mutation of factor V (FV) gene (Arg506-->Gln, FV Leiden).
  • OBJECTIVE: To identify the genetic defect of FV in a Chinese family with APC-R associated with VTE.
  • Blood samples were obtained from five family members (including the proband) for screening APC-R by coagulation assay and the genetic defect of FV using direct sequencing.
  • RESULTS: Four out of five members had APC-R.
  • We identified a novel mutation (G2172-->C) in exon 13 of the FV gene, which was present in all the individuals with APC-R but was absent in the individual without APC-R.
  • This mutation is predicted to result in the replacement of glutamate by aspartate at position 666, close to one of the APC cleavage sites.
  • CONCLUSIONS: We have identified, for the first time, a novel mutation (G2172-->C) of FV that was associated with APC-R in a Chinese family with VTE.
  • We speculate that this mutation interferes with cleavage at Arg679 by APC.
  • [MeSH-major] Activated Protein C Resistance / genetics. Factor V / genetics. Point Mutation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20304467.001).
  • [ISSN] 1879-2472
  • [Journal-full-title] Thrombosis research
  • [ISO-abbreviation] Thromb. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9001-24-5 / Factor V
  •  go-up   go-down


48. Sangha S, Yao M, Wolfe MM: Non-steroidal anti-inflammatory drugs and colorectal cancer prevention. Postgrad Med J; 2005 Apr;81(954):223-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently, the most effective strategy available for colon cancer prevention is endoscopic screening, with polypectomy or surgical resection for advanced lesions.
  • Data obtained from animal and epidemiological studies and most recently from randomised, placebo controlled trials, suggest that non-steroidal anti-inflammatory drugs may prove effective chemopreventive agents in different groups of people, from patients with familial adenomatous polyposis to those with sporadic adenomas.
  • [MeSH-minor] Colorectal Neoplasms, Hereditary Nonpolyposis / prevention & control. Humans. Randomized Controlled Trials as Topic. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Gut. 2002 Jun;50(6):857-60 [12010890.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):875-84 [8492316.001]
  • [Cites] J Natl Cancer Inst. 1993 Aug 4;85(15):1220-4 [8331682.001]
  • [Cites] Br J Surg. 1993 Dec;80(12):1618-9 [8298943.001]
  • [Cites] Ann Intern Med. 1994 Aug 15;121(4):241-6 [8037405.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5953-8 [7954428.001]
  • [Cites] Lancet. 1995 Apr 1;345(8953):855-6 [7898240.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2556-9 [7780968.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10):609-14 [7637720.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4566-9 [8840961.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1493-5 [12149237.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):879-80 [12621130.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):883-90 [12621132.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):919-32 [12621137.001]
  • [Cites] Trends Neurosci. 2003 Apr;26(4):207-14 [12689772.001]
  • [Cites] Arch Neurol. 2003 Dec;60(12):1685-91 [14676042.001]
  • [Cites] Neurology. 2004 Jul 13;63(1):33-9 [15249607.001]
  • [Cites] Nat New Biol. 1971 Jun 23;231(25):232-5 [5284360.001]
  • [Cites] Gut. 1982 Oct;23(10):835-42 [7117903.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] J Biol Chem. 1991 Jul 15;266(20):12866-72 [1712772.001]
  • [Cites] Gastroenterology. 1991 Sep;101(3):635-9 [1650315.001]
  • [Cites] N Engl J Med. 1991 Dec 5;325(23):1593-6 [1669840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 1;89(9):3917-21 [1570314.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3336-40 [9096394.001]
  • [Cites] Jpn J Cancer Res. 1997 Nov;88(11):1044-51 [9439679.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):409-12 [9458081.001]
  • [Cites] Ann Intern Med. 1998 May 1;128(9):713-20 [9556464.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):350-8 [10419916.001]
  • [Cites] Cancer. 1999 Dec 1;86(11 Suppl):2551-63 [10630181.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1960-8 [10874065.001]
  • [Cites] N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528 [11087881.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1733-40 [11245490.001]
  • [Cites] Neuron. 2001 Jun;30(3):665-76 [11430801.001]
  • [Cites] Lancet Oncol. 2002 Mar;3(3):166-74 [11902503.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • (PMID = 15811884.001).
  • [ISSN] 0032-5473
  • [Journal-full-title] Postgraduate medical journal
  • [ISO-abbreviation] Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Anticarcinogenic Agents
  • [Other-IDs] NLM/ PMC1743256
  •  go-up   go-down


49. Wick EC, Sears CL: Bacteroides spp. and diarrhea. Curr Opin Infect Dis; 2010 Oct;23(5):470-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: Bacteroides fragilis is the only strain of Bacteroides spp. associated with diarrheal disease.
  • Toxin-producing strains of B. fragilis, termed enterotoxigenic Bacteroides fragilis (ETBF), are an established cause of diarrheal disease in people.
  • The clinical syndrome associated with ETBF diarrheal disease encompasses abdominal pain, tenesmus and inflammatory diarrhea.
  • Two new studies conducted in mice have further defined the chronic inflammatory response associated with ETBF infection and observed that in the multiple intestinal neoplasia mouse strain, heterozygotes for the adenomatous polyposis coli gene, ETBF infection enhances development of colonic tumors.
  • SUMMARY: B. fragilis remains the leading anaerobe in human disease.
  • ETBF is emerging as an important cause of human diarrheal disease but additional epidemiologic studies are needed to better understand the role of ETBF human disease.

  • Genetic Alliance. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - Diarrhea.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Emerg Infect Dis. 2000 Mar-Apr;6(2):171-4 [10756151.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14919-24 [15466707.001]
  • [Cites] Dig Dis Sci. 2004 Sep;49(9):1425-32 [15481314.001]
  • [Cites] Ann Intern Med. 1977 May;86(5):569-71 [322563.001]
  • [Cites] Infect Immun. 1984 May;44(2):241-4 [6538870.001]
  • [Cites] J Diarrhoeal Dis Res. 1992 Mar;10(1):4-9 [1619243.001]
  • [Cites] Clin Infect Dis. 1995 Jun;20(6):1492-6 [7548498.001]
  • [Cites] Clin Infect Dis. 1999 Sep;29(3):590-4 [10530453.001]
  • [Cites] Science. 2005 Mar 4;307(5714):1463-5 [15746427.001]
  • [Cites] Cell. 2005 Jul 15;122(1):107-18 [16009137.001]
  • [Cites] Clin Microbiol Infect. 2006 Aug;12(8):782-6 [16842574.001]
  • [Cites] Clin Infect Dis. 2007 Apr 1;44(7):895-900 [17342637.001]
  • [Cites] Clin Microbiol Rev. 2007 Oct;20(4):593-621 [17934076.001]
  • [Cites] J Infect Dis. 2008 Feb 1;197(3):435-8 [18199029.001]
  • [Cites] Nature. 2008 May 29;453(7195):620-5 [18509436.001]
  • [Cites] Clin Infect Dis. 2008 Sep 15;47(6):797-803 [18680416.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13099-104 [18723678.001]
  • [Cites] Cancer Biol Ther. 2008 Dec;7(12):1919-25 [18927500.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):65-80 [19026645.001]
  • [Cites] Infect Immun. 2009 Apr;77(4):1708-18 [19188353.001]
  • [Cites] Exp Biol Med (Maywood). 2009 Apr;234(4):430-41 [19176868.001]
  • [Cites] Clin Microbiol Rev. 2009 Apr;22(2):349-69, Table of Contents [19366918.001]
  • [Cites] Nat Med. 2009 Sep;15(9):1016-22 [19701202.001]
  • [Cites] Science. 2009 Dec 18;326(5960):1694-7 [19892944.001]
  • [Cites] J Clin Microbiol. 2010 Apr;48(4):1417-9 [20107088.001]
  • [Cites] J Clin Gastroenterol. 2010 May-Jun;44(5):354-60 [20048681.001]
  • (PMID = 20697287.001).
  • [ISSN] 1473-6527
  • [Journal-full-title] Current opinion in infectious diseases
  • [ISO-abbreviation] Curr. Opin. Infect. Dis.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK045496-16; United States / NIDDK NIH HHS / DK / DK059655-01; United States / NIDDK NIH HHS / DK / R01 DK059655-03; United States / NIDDK NIH HHS / DK / R01 DK045496-13; United States / NIDDK NIH HHS / DK / DK045496-15; United States / NIDDK NIH HHS / DK / DK059655-02; United States / NIDDK NIH HHS / DK / R01 DK080817-01; United States / NIDDK NIH HHS / DK / DK080817-04; United States / NIDDK NIH HHS / DK / DK080817-01; United States / NIDDK NIH HHS / DK / R01 DK045496; United States / NIDDK NIH HHS / DK / R01 DK059655-02; United States / NIDDK NIH HHS / DK / R01 DK045496-17; United States / NIDDK NIH HHS / DK / R01 DK080817-02; United States / NIDDK NIH HHS / DK / DK045496-16; United States / NIDDK NIH HHS / DK / DK059655-03; United States / NIDDK NIH HHS / DK / DK045496-18; United States / NIDDK NIH HHS / DK / DK080817-02; United States / NIDDK NIH HHS / DK / DK045496-14; United States / NIDDK NIH HHS / DK / R01 DK080817-03; United States / NIDDK NIH HHS / DK / R01 DK059655; United States / NIDDK NIH HHS / DK / R01 DK045496-14; United States / NIDDK NIH HHS / DK / R01 DK045496-15; United States / NIDDK NIH HHS / DK / DK045496-13; United States / NIDDK NIH HHS / DK / R01 DK080817; United States / NIDDK NIH HHS / DK / R01 DK059655-01; United States / NIDDK NIH HHS / DK / DK080817-03; United States / NIDDK NIH HHS / DK / DK045496-17; United States / NIDDK NIH HHS / DK / R01 DK045496-18; United States / NIDDK NIH HHS / DK / R01 DK080817-04
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Bacterial Toxins; 0 / Virulence Factors
  • [Other-IDs] NLM/ NIHMS262792; NLM/ PMC3079340
  •  go-up   go-down


51. Winship IM, Dudding TE: Lessons from the skin--cutaneous features of familial cancer. Lancet Oncol; 2008 May;9(5):462-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons from the skin--cutaneous features of familial cancer.
  • As the molecular basis of disease continues to be elucidated, familial cancer syndromes, which consist of a range of neoplastic and non-neoplastic features, are emerging.
  • The usual pathway of referral to a genetics clinic or familial cancer centre is via an oncologist, when high-risk features that suggest a possible hereditary basis for the presenting cancer are recognised.
  • These features are effective in ascertaining a substantial proportion of families with hereditary breast and ovarian cancer due to a BRCA mutation, or the more common bowel-cancer predisposition syndromes, such as hereditary non-polyposis colon cancer and familial adenomatous polyposis.
  • However, there are a range of familial cancer syndromes that are not easily detected and that can remain undiagnosed when history and examination are not extended to include non-malignant features.
  • The identification of cutaneous signs associated with rare familial-cancer syndromes provides individuals and their families with the opportunity to undertake early surveillance for malignant and non-malignant complications that might in time be shown to improve outcomes.
  • [MeSH-major] Colonic Neoplasms / pathology. Endocrine Gland Neoplasms / pathology. Kidney Neoplasms / pathology. Neoplastic Syndromes, Hereditary / pathology. Skin / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adenomatous Polyposis Coli / pathology. Basal Cell Nevus Syndrome / pathology. Carcinoma, Renal Cell / pathology. Colorectal Neoplasms, Hereditary Nonpolyposis / pathology. Disease Progression. Gene Expression Regulation, Neoplastic. Genetic Testing. Hamartoma Syndrome, Multiple / pathology. Humans. Leiomyomatosis / pathology. Multiple Endocrine Neoplasia / pathology. Multiple Endocrine Neoplasia Type 2a / pathology. Multiple Endocrine Neoplasia Type 2b / pathology. Mutation. Neurofibromatosis 1 / pathology. Neurofibromatosis 2 / pathology. Pedigree. Peutz-Jeghers Syndrome / pathology. Tuberous Sclerosis / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18452857.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 75
  •  go-up   go-down


52. Giles RH, Lolkema MP, Snijckers CM, Belderbos M, van der Groep P, Mans DA, van Beest M, van Noort M, Goldschmeding R, van Diest PJ, Clevers H, Voest EE: Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis. Oncogene; 2006 May 18;25(21):3065-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activation of the Wnt signaling pathway initiates the transformation of colorectal epithelial cells, although the transition to metastatic cancer requires angiogenesis.
  • Here, we show that VHL expression is regulated by TCF4 and is restricted to the proliferative compartment at the bottom of intestinal crypts.
  • Accordingly, VHL is completely absent from the proliferative intestinal pockets of Tcf4(-/-) perinatal mice.
  • We observed complementary staining of the hypoxia-inducible factor (HIF) 1alpha to VHL in normal intestinal epithelium as well as in all stages of colorectal cancer (CRC).
  • Although we observed upregulated levels of VHL in very early CRC lesions from sporadic and familial adenomatous polyposis patients - presumably due to activated Wnt signaling - a clear reduction of VHL expression is observed in later stages of CRC progression, coinciding with stabilization of HIF1alpha.
  • [MeSH-major] Adenocarcinoma / etiology. Cell Transformation, Neoplastic / genetics. Colorectal Neoplasms / etiology. Hypoxia-Inducible Factor 1, alpha Subunit / physiology. Nerve Tissue Proteins / physiology. TCF Transcription Factors / physiology. Von Hippel-Lindau Tumor Suppressor Protein / physiology. Wnt Proteins / physiology. beta Catenin / physiology
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Adenomatous Polyposis Coli / genetics. Adenomatous Polyposis Coli / metabolism. Adenomatous Polyposis Coli / pathology. Animals. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors. Cell Line. Colon / cytology. Colon / metabolism. Colon / pathology. Colonic Polyps / genetics. Colonic Polyps / metabolism. Colonic Polyps / pathology. Disease Progression. Epithelial Cells / metabolism. Erythropoietin / genetics. Gene Expression Regulation, Neoplastic. Genes, Reporter. Humans. Intestinal Mucosa / cytology. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Kidney. L Cells (Cell Line). Mice. Mice, Knockout. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Promoter Regions, Genetic. Recombinant Fusion Proteins / biosynthesis. Recombinant Fusion Proteins / genetics. Signal Transduction / physiology. Transcription Factor 7-Like 2 Protein. Wnt3 Protein

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16407833.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / CTNNB1 protein, human; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Nerve Tissue Proteins; 0 / Recombinant Fusion Proteins; 0 / TCF Transcription Factors; 0 / TCF7L2 protein, human; 0 / Tcf4 protein, mouse; 0 / Tcf7l2 protein, mouse; 0 / Transcription Factor 7-Like 2 Protein; 0 / Wnt Proteins; 0 / Wnt3 Protein; 0 / beta Catenin; 11096-26-7 / Erythropoietin; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Vhlh protein, mouse; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


53. Li JM, Southerland LT, Lu Y, Darlak KA, Giver CR, McMillin DW, Harris WA, Jaye DL, Waller EK: Activation, immune polarization, and graft-versus-leukemia activity of donor T cells are regulated by specific subsets of donor bone marrow antigen-presenting cells in allogeneic hemopoietic stem cell transplantation. J Immunol; 2009 Dec 15;183(12):7799-809
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation, immune polarization, and graft-versus-leukemia activity of donor T cells are regulated by specific subsets of donor bone marrow antigen-presenting cells in allogeneic hemopoietic stem cell transplantation.
  • We investigated the roles of specific subsets of donor APCs purified from bone marrow in donor T cell activation and graft-vs-leukemia (GvL) activity in murine models of hemopoietic stem cell transplantation.
  • Lineage(-)CD11c(+) APC precursors were separated from donor bone marrow based on expression of CD11b.
  • Transplanting lineage(-)CD11c(+)CD11b(-) APC (CD11b(-) APC) in combination with c-kit(+)Sca-1(+)lineage(-) hemopoietic stem cells (HSC) and congenic donor T cells led to increased donor CD4(+) and CD8(+) T cell proliferation and higher donor T cell chimerism than with transplanting grafts containing HSC, T cells, and lineage(-)CD11c(+)CD11b(+) APCs (CD11b(+) APC), or grafts containing only HSC and T cells.
  • Transplanting CD11b(-) APCs induced Th1/type 1 cytotoxic T lymphocyte donor T cell immune polarization and enhanced GvL activity of donor T cells without increased graft-vs-host disease in both MHC- and minor histocompatibility Ag-mismatched murine hemopoietic stem cell transplantation models, whereas CD11b(+) APCs led to Th2/type 2 cytotoxic T lymphocyte donor T cell immune polarization.
  • Donor CD11b(-) APCs were plasmacytoid dendritic cell progenitors (>90% CD317; PDCA-1(+)) and up-regulated CD80, CD86, and IL-12 during alloantigen presentation, whereas CD11b(+) APCs expressed Gr-1 and up-regulated expression of programmed death ligands-1 and 2 after activation.
  • These results are the first to show that manipulation of the content of donor APCs in allogeneic HSC grafts can regulate donor T cell immunity and enhance GvL without increasing graft-vs-host disease activity.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1140-5 [14871849.001]
  • [Cites] Nat Immunol. 2004 Dec;5(12):1219-26 [15549123.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4330-5 [14962904.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7393-8 [15187116.001]
  • [Cites] J Clin Invest. 2004 Jul;114(2):280-90 [15254595.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Aug;10(8):540-51 [15282532.001]
  • [Cites] J Immunol. 2004 Aug 15;173(4):2632-40 [15294980.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4407-15 [15728131.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2206-14 [15941908.001]
  • [Cites] Trends Immunol. 2005 Oct;26(10):506-9 [16087400.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1244-9 [16227991.001]
  • [Cites] Bone Marrow Transplant. 2005 Dec;36(12):1049-52 [16247431.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4225-33 [16118326.001]
  • [Cites] Nat Immunol. 2006 Jun;7(6):663-71 [16680143.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10729-34 [16807294.001]
  • [Cites] J Immunol. 2006 Oct 1;177(7):4414-25 [16982876.001]
  • [Cites] J Exp Med. 2006 Nov 27;203(12):2627-38 [17116734.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Dec;12(12):1239-49 [17162205.001]
  • [Cites] Adv Exp Med Biol. 2007;590:69-87 [17191378.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jan;13(1):46-55 [17222752.001]
  • [Cites] Nat Immunol. 2007 Jun;8(6):578-83 [17450143.001]
  • [Cites] Blood. 2007 Jul 1;110(1):9-17 [17327406.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4153-60 [17827391.001]
  • [Cites] Exp Hematol. 2008 Oct;36(10):1309-17 [18620796.001]
  • [Cites] Nat Immunol. 2008 Nov;9(11):1253-60 [18836452.001]
  • [Cites] J Immunol. 2008 Nov 1;181(9):5829-35 [18941170.001]
  • [Cites] J Immunol. 2009 Jan 15;182(2):912-20 [19124734.001]
  • [Cites] Blood. 2009 Feb 26;113(9):2088-95 [19144988.001]
  • [Cites] Science. 2009 Apr 17;324(5925):392-7 [19286519.001]
  • [Cites] Blood. 2009 May 28;113(22):5644-9 [19336758.001]
  • [Cites] Blood. 2009 Jun 4;113(23):6038-9 [19498034.001]
  • [Cites] J Exp Med. 2003 Jan 6;197(1):101-9 [12515817.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1453-9 [12393665.001]
  • [Cites] Blood. 2003 Mar 1;101(5):2033-42 [12393418.001]
  • [Cites] J Exp Med. 2003 Aug 18;198(4):615-21 [12925677.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Oct;9(10):616-32 [14569558.001]
  • [Cites] Nat Med. 2004 Sep;10(9):987-92 [15286785.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Feb;78(2):1133-7 [6785748.001]
  • [Cites] J Exp Med. 1994 Apr 1;179(4):1109-18 [8145033.001]
  • [Cites] Transplantation. 1994 Aug 15;58(3):278-87 [7914387.001]
  • [Cites] Cell Immunol. 1996 May 25;170(1):111-9 [8665591.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3230-9 [8963063.001]
  • [Cites] J Immunol. 1997 Jul 15;159(2):565-73 [9218570.001]
  • [Cites] Blood. 1998 Jul 1;92(1):215-22 [9639519.001]
  • [Cites] J Exp Med. 1999 Feb 1;189(3):587-92 [9927520.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1036-41 [9927689.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3222-33 [10556211.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3838-46 [11090068.001]
  • [Cites] Blood. 2001 May 15;97(10):2948-56 [11342416.001]
  • [Cites] Cell. 2001 Aug 10;106(3):259-62 [11509173.001]
  • [Cites] Oncology (Williston Park). 2002 Jan;16(1 Suppl 1):19-26 [11829279.001]
  • [Cites] Nat Rev Immunol. 2002 Mar;2(3):151-61 [11913066.001]
  • [Cites] J Exp Med. 2002 Apr 1;195(7):953-8 [11927638.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4207-15 [12010827.001]
  • [Cites] Blood. 2002 Jul 15;100(2):383-90 [12091326.001]
  • [Cites] J Exp Med. 2002 Nov 18;196(10):1307-19 [12438422.001]
  • [Cites] J Exp Med. 2005 Feb 7;201(3):373-83 [15699072.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2227-34 [15522961.001]
  • [Cites] Annu Rev Immunol. 2005;23:275-306 [15771572.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2787-92 [15598811.001]
  • [Cites] Science. 1999 Jul 16;285(5426):412-5 [10411505.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3829-35 [15297318.001]
  • [Cites] Nat Med. 2004 May;10(5):510-7 [15098028.001]
  • (PMID = 19933853.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL086773; United States / NCI NIH HHS / CA / R01 CA074364; United States / PHS HHS / / NHLBI P01HL086773; United States / NCI NIH HHS / CA / R01 CA-74364-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoantigens
  • [Other-IDs] NLM/ NIHMS549152; NLM/ PMC3908652
  •  go-up   go-down


54. Bauer S, Adrian N, Siebenborn U, Fadle N, Plesko M, Fischer E, Wüest T, Stenner F, Mertens JC, Knuth A, Ritter G, Old LJ, Renner C: Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8. Cancer Immun; 2009;9:2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Polymorphonuclear neutrophils (PMNs) are potent effectors of inflammation and their attempts to respond to cancer are suggested by their systemic, regional and intratumoral activation.
  • We previously reported on the recruitment of CD11b+ leukocytes due to tumor site-specific enrichment of TNF activity after intravenous administration of a dimeric TNF immunokine with specificity for fibroblast activation protein (FAP).
  • With the aim to amplify the TNF-induced and IL-8-mediated chemotactic response, we generated immunocytokines by N-terminal fusion of a human anti-FAP scFv fragment with human IL-8 (IL-8(72)) and its N-terminally truncated form IL-8(3-72).
  • Due to the dramatic difference in chemotaxis induction in vitro, we favored the mature chemokine fused to the anti-FAP scFv for further investigation in vivo.
  • BALB/c nu/nu mice were simultaneously xenografted with FAP-positive or -negative tumors and extended chemo-attraction of PMNs was only detectable in FAP-expressing tissue after intravenous administration of the anti-FAP scFv-IL-8(72) construct.
  • As TNF-activated PMNs are likewise producers and primary targets for IL-8, we investigated the therapeutic efficacy of co-administration of both effectors: Sequential application of scFv-IL-8(72) and dimeric IgG1-TNF fusion proteins significantly enhanced anti-tumor activity when compared either to a single effector treatment regimen or sequential application of non-targeted cytokines, indicating that the tumor-restricted sequential application of IL-8(72) and TNF is a promising approach for cancer therapy.
  • [MeSH-major] Immunotherapy. Interleukin-8 / therapeutic use. Neoplasms / drug therapy. Neoplasms / immunology. Protein Multimerization. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Animals. Antigens. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Chemotaxis / drug effects. Gelatinases. Humans. Kinetics. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / metabolism. Membrane Proteins. Mice. Recombinant Fusion Proteins / pharmacology. Recombinant Fusion Proteins / therapeutic use. Serine Endopeptidases / metabolism. Transfection. Treatment Outcome. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Mar 1;164(5):2769-75 [10679119.001]
  • [Cites] Int J Cancer. 2009 Jul 1;125(1):115-23 [19384924.001]
  • [Cites] J Immunol. 2000 Jun 1;164(11):5961-9 [10820279.001]
  • [Cites] J Urol. 2000 Dec;164(6):2129-33 [11061941.001]
  • [Cites] Biotechnol Bioeng. 2001 Oct 20;75(2):197-203 [11536142.001]
  • [Cites] Oncogene. 2002 Jun 20;21(27):4257-65 [12082613.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] J Urol. 2003 Sep;170(3):964-9 [12913751.001]
  • [Cites] Chem Immunol Allergy. 2003;83:182-203 [12947985.001]
  • [Cites] J Immunol. 2004 Mar 15;172(6):3930-9 [15004201.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):641-8 [15286730.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70 [1103152.001]
  • [Cites] J Immunol. 1987 Feb 1;138(3):963-74 [3805720.001]
  • [Cites] Nature. 1987 Mar 26-Apr 1;326(6111):330-1 [3494200.001]
  • [Cites] Cancer Chemother Pharmacol. 1987;20(2):137-44 [3664933.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):344-50 [3339398.001]
  • [Cites] J Exp Med. 1988 Jun 1;167(6):1883-93 [3260265.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):9199-203 [3057503.001]
  • [Cites] Science. 1991 Oct 4;254(5028):99-102 [1718038.001]
  • [Cites] Biochemistry. 1991 Oct 22;30(42):10117-25 [1931943.001]
  • [Cites] J Biol Chem. 1991 Dec 5;266(34):23128-34 [1744111.001]
  • [Cites] J Cell Biol. 1992 May;117(3):565-72 [1315317.001]
  • [Cites] J Urol. 1992 Jun;147(6):1636-42 [1593713.001]
  • [Cites] JAMA. 1993 Apr 14;269(14):1829-35 [8459516.001]
  • [Cites] Am J Physiol. 1994 Mar;266(3 Pt 1):L238-45 [8166294.001]
  • [Cites] J Urol. 1996 Feb;155(2):483-7 [8558641.001]
  • [Cites] Nucleic Acids Res. 1996 Feb 15;24(4):596-601 [8604299.001]
  • [Cites] Cytokine. 1996 Mar;8(3):214-21 [8833036.001]
  • [Cites] J Immunol Methods. 1998 Apr 1;213(1):41-52 [9671124.001]
  • [Cites] Clin Exp Med. 2004 Oct;4(2):57-64 [15672942.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8486-91 [16322312.001]
  • [Cites] J Immunol Methods. 2006 Mar 20;310(1-2):100-16 [16499921.001]
  • [Cites] Cancer Immun. 2006;6:6 [16551058.001]
  • [Cites] J Immunol. 2006 Aug 15;177(4):2423-30 [16888004.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8250-7 [16912205.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6515-24 [18927291.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2275-83 [19005180.001]
  • [Cites] J Immunol. 2000 Mar 15;164(6):3301-8 [10706723.001]
  • (PMID = 19267427.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Interleukin-8; 0 / Membrane Proteins; 0 / Recombinant Fusion Proteins; 0 / Tumor Necrosis Factor-alpha; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  • [Other-IDs] NLM/ PMC2935764
  •  go-up   go-down


55. Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, Wolff RA, Willett CG: Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol; 2009 Sep 01;27(25):4096-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The primary objective of this study was to assess the 1-year survival of patients with locally advanced, unresectable pancreatic cancer treated with the combination of bevacizumab, capecitabine, and radiation.
  • The median and 1-year survival rates were 11.9 months (95% CI, 9.9 to 14.0 months) and 47% (95% CI, 36% to 57%).
  • Median PFS was 8.6 months (95% CI, 6.9 to 10.5), and RR was 26%.
  • Unacceptable radiotherapy protocol deviations (ie, inappropriately generous volume contoured) correlated with grade 3 or greater gastrointestinal toxicity during chemoradiotherapy (45% v 18%; adjusted odds ratio, 3.7; 95% CI, 0.98 to 14.1; P = .05).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antimetabolites, Antineoplastic / administration & dosage. Bevacizumab. Capecitabine. Chemotherapy, Adjuvant. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Pancreatectomy. Pancreaticoduodenectomy. Radiotherapy, Adjuvant. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Jan 1;61(1):39-44 [11196192.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2666-76 [18160686.001]
  • [Cites] Am J Clin Oncol. 2004 Feb;27(1):51-6 [14758134.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] J Clin Epidemiol. 1988;41(12):1209-13 [3062140.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):427-38 [15952180.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):46-51 [16397214.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1145-51 [16505434.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Abdom Imaging. 2006 Sep-Oct;31(5):568-74 [16465578.001]
  • [Cites] Lancet. 2007 Dec 22;370(9605):2103-11 [18156031.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2413-9 [11289107.001]
  • (PMID = 19636002.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00114179
  • [Grant] United States / NCI NIH HHS / CA / U10 CA32115; United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA37422; United States / NCI NIH HHS / CA / U10 CA037422; United States / NCI NIH HHS / CA / U10 CA021661; United States / NCI NIH HHS / CA / U10 CA032115
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2734421
  •  go-up   go-down


56. Al-Sukhni W, Aronson M, Gallinger S: Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome. Surg Clin North Am; 2008 Aug;88(4):819-44, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome.
  • Familial colorectal cancer (CRC) accounts for 10% to 20% of all cases of CRC.
  • Two major autosomal dominant forms of heritable CRC are familial adenomatous polyposis (FAP) and Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer).
  • Along with the risk for CRC, both syndromes are associated with elevated risk for other tumors.
  • Improved understanding of the genetic basis of these diseases has not only facilitated the identification and screening of at-risk individuals and the development of prophylactic or early-stage intervention strategies but also provided better insight into sporadic CRC.
  • This article reviews the clinical and genetic characteristics of FAP and Lynch syndrome, recommended screening and surveillance practices, and appropriate surgical and nonsurgical interventions.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Genetic Predisposition to Disease
  • [MeSH-minor] Diagnosis, Differential. Humans


57. Mirabella D, Spena R, Scognamiglio G, Luca L, Gracco A, Siciliani G: LED vs halogen light-curing of adhesive-precoated brackets. Angle Orthod; 2008 Sep;78(5):935-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To test the hypothesis that bonding with a blue light-emitting diode (LED) curing unit produces no more failures in adhesive-precoated (APC) orthodontic brackets than bonding carried out by a conventional halogen lamp.
  • MATERIALS AND METHODS: Sixty-five patients were selected for this randomized clinical trial, in which a total of 1152 stainless steel APC brackets were employed.
  • In order to carry out a valid comparison of the bracket failure rate following use of each type of curing unit, each patient's mouth was divided into four quadrants.
  • In 34 of the randomly selected patients, designated group A, the APC brackets of the right maxillary and left mandibular quadrants were bonded using a halogen light, while the remaining quadrants were treated with an LED curing unit.
  • In the other 31 patients, designated group B, halogen light was used to cure the left maxillary and right mandibular quadrants, whereas the APC brackets in the remaining quadrants were bonded using an LED dental curing light.
  • The bonding date, the type of light used for curing, and the date of any bracket failures over a mean period of 8.9 months were recorded for each bracket and, subsequently, the chi-square test, the Yates-corrected chi-square test, the Fisher exact test, Kaplan-Meier survival estimates, and the log-rank test were employed in statistical analyses of the results.
  • RESULTS: No statistically significant difference in bond failure rate was found between APC brackets bonded with the halogen light-curing unit and those cured with LED light.
  • CONCLUSIONS: The hypothesis cannot be rejected since use of an LED curing unit produces similar APC bracket failure rates to use of conventional halogen light, with the advantage of a far shorter curing time (10 seconds).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298197.001).
  • [ISSN] 0003-3219
  • [Journal-full-title] The Angle orthodontist
  • [ISO-abbreviation] Angle Orthod
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Composite Resins; 0 / Resin Cements; 0 / Transbond XT; 12597-68-1 / Stainless Steel
  •  go-up   go-down


58. Baum P, Müller D, Rüger R, Kontermann RE: Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells. J Drug Target; 2007 Jul;15(6):399-406
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells.
  • Fibroblast activation protein (FAP) represents a cell surface antigen selectively expressed by reactive tumor stromal fibroblasts of various cancers.
  • Here, we describe anti-FAP immunoliposomes as carrier systems for active targeting of FAP-expressing cells.
  • As targeting ligand we used single-chain Fv (scFv) molecules cross-reacting with human and mouse FAP.
  • These scFv molecules were genetically modified to express an additional cysteine residue at the C-terminus allowing a defined and site-directed conjugation.
  • Coupling to Mal-PEG(2000)-DSPE containing liposomes resulted in sterically stabilized scFv immunoliposomes showing strong and specific binding to FAP-expressing cells.
  • In addition, we could show that binding to FAP-expressing cells leads to internalization of intact liposomes into the endosomal compartment.
  • Thus, these anti-FAP scFv immunoliposomes should be suitable for target cell-specific delivery and uptake of encapsulated drugs.
  • [MeSH-major] Antigens, Neoplasm / immunology. Biomarkers, Tumor / immunology. Immunoglobulin Fragments / chemistry. Immunoglobulin Variable Region / chemistry. Liposomes / chemistry. Membrane Proteins / immunology. Serine Endopeptidases / immunology. Stromal Cells / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613658.001).
  • [ISSN] 1061-186X
  • [Journal-full-title] Journal of drug targeting
  • [ISO-abbreviation] J Drug Target
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Drug Carriers; 0 / Immunoglobulin Fragments; 0 / Immunoglobulin Variable Region; 0 / Liposomes; 0 / Membrane Proteins; 0 / Phosphatidylethanolamines; 0 / immunoglobulin Fv; 1G4B5265CQ / 1,2-distearoylphosphatidylethanolamine; 30IQX730WE / Polyethylene Glycols; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


59. Imanaka H, Tanaka S, Feng B, Imamura K, Nakanishi K: Cultivation characteristics and gene expression profiles of Aspergillus oryzae by membrane-surface liquid culture, shaking-flask culture, and agar-plate culture. J Biosci Bioeng; 2010 Mar;109(3):267-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We cultivated a filamentous fungus, Aspergillus oryzae IAM 2706 by three different cultivation methods, i.e., shaking-flask culture (SFC), agar-plate culture (APC), and membrane-surface liquid culture (MSLC), to elucidate the differences of its behaviors by different cultivation methods under the same media, by measuring the growth, secretion of proteases and alpha-amylase, secreted protein level, and gene transcriptional profile by the DNA microarray analysis.
  • The protease activities detected by MSLC and APC were much higher than that by SFC, using both modified Czapek-Dox (mCD) and dextrin-peptone-yeast extract (DPY) media.
  • The alpha-amylase activity was detected in MSLC and APC in a much larger extent than that in SFC when DPY medium was used.
  • On the basis of SDS-PAGE analyses and N-terminal amino acid sequences, 6 proteins were identified in the supernatants of the culture broths using DPY medium, among which oryzin (alkaline protease) and alpha-amylase were detected at a much higher extent for APC and MSLC than those for SFC while only oryzin was detected in mCD medium, in accordance with the activity measurements.
  • A microarray analysis for the fungi cultivated by SFC, APC, and MSLC using mCD medium was carried out to elucidate the differences in the gene transcriptional profile by the cultivation methods.
  • The gene transcriptional profile obtained for the MSLC sample showed a similar tendency to the APC sample while it was quite different from that for the SFC sample.
  • Most of the genes specifically transcribed in the MSLC sample versus those in the SFC sample with a 10-fold up-regulation or higher were unknown or predicted proteins.
  • [MeSH-major] Agar / metabolism. Aspergillus oryzae / metabolism. Bioreactors / microbiology. Cell Culture Techniques / methods. Cell Membrane / metabolism. Culture Media / metabolism. Fungal Proteins / metabolism. Gene Expression Regulation, Fungal / physiology

  • Hazardous Substances Data Bank. AGAR-AGAR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 The Society for Biotechnology, Japan. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20159576.001).
  • [ISSN] 1347-4421
  • [Journal-full-title] Journal of bioscience and bioengineering
  • [ISO-abbreviation] J. Biosci. Bioeng.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Culture Media; 0 / Fungal Proteins; 0 / Solutions; 9002-18-0 / Agar
  •  go-up   go-down


60. Kretschmer B, Lüthje K, Ehrlich S, Osterloh A, Piedavent M, Fleischer B, Breloer M: CD83 on murine APC does not function as a costimulatory receptor for T cells. Immunol Lett; 2008 Oct 30;120(1-2):87-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD83 on murine APC does not function as a costimulatory receptor for T cells.
  • The transmembrane glycoprotein CD83 is rapidly upregulated on murine and human DC upon maturation and therefore a costimulatory function for T cell activation has been suggested.
  • Studies employing human APC indeed showed that CD83 expression was positively correlated to the stimulatory capacity of the APC.
  • Murine APC that were CD83 deficient however, did not display a reduced capacity to activate T cells.
  • To elucidate this contradiction, we thoroughly compared the stimulatory capacity of CD83-overexpressing and CD83-deficient APC.
  • Here we show that CD83 expression levels on APC did not affect the capacity of the APC to activate CD8(+) T cells.
  • CD83 expression levels did not significantly affect CD4(+) T cell activation in vivo, but a weak positive correlation of CD83 expression with CD4(+) T cell activation was observed in vitro under suboptimal stimulation conditions.
  • As CD83 expression also positively correlated with MHC-II but not with MHC-I expression, this differential stimulation specifically of CD4(+) T cells could be explained by a higher density of MHC-II peptide complexes on the APC surface.
  • Taken together, our results strongly suggest that CD83 does not deliver crucial costimulatory signals to murine T cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18675848.001).
  • [ISSN] 0165-2478
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD86; 0 / CD83 antigen; 0 / Cd86 protein, mouse; 0 / Histocompatibility Antigens Class II; 0 / Immunoglobulins; 0 / Membrane Glycoproteins; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


61. Clarke DJ, Bachant J: Kinetochore structure and spindle assembly checkpoint signaling in the budding yeast, Saccharomyces cerevisiae. Front Biosci; 2008;13:6787-819
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we review recent developments in our understanding of SAC control with particular emphasis on the role of the kinetochore, the nature of the tension sensing mechanism and the possibility that the SAC encompasses more than just stabilization of securin and/or cyclin-B via inhibition of the APC/C to delay anaphase initiation.
  • [MeSH-minor] Cell Cycle. Chromatids / physiology. Chromosomes, Fungal / genetics. Chromosomes, Fungal / physiology. DNA Topoisomerases, Type II / metabolism. Saccharomyces cerevisiae Proteins / metabolism. Stress, Mechanical

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18508695.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA099033; United States / NIGMS NIH HHS / GM / GM-66190
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromatin; 0 / Saccharomyces cerevisiae Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II
  • [Number-of-references] 326
  •  go-up   go-down


62. Lin H, Yamada Y, Nguyen S, Linhart H, Jackson-Grusby L, Meissner A, Meletis K, Lo G, Jaenisch R: Suppression of intestinal neoplasia by deletion of Dnmt3b. Mol Cell Biol; 2006 Apr;26(8):2976-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of intestinal neoplasia by deletion of Dnmt3b.
  • Aberrant gene silencing accompanied by DNA methylation is associated with neoplastic progression in many tumors that also show global loss of DNA methylation.
  • Using conditional inactivation of de novo methyltransferase Dnmt3b in Apc(Min/+) mice, we demonstrate that the loss of Dnmt3b has no impact on microadenoma formation, which is considered the earliest stage of intestinal tumor formation.
  • Interestingly, many large adenomas showed regions with Dnmt3b inactivation, indicating that Dnmt3b is required for initial outgrowth of macroscopic adenomas but is not required for their maintenance.
  • These results support a role for Dnmt3b in the transition stage between microadenoma formation and macroscopic colonic tumor growth and further suggest that Dnmt3b, and by extension de novo methylation, is not required for maintaining tumor growth after this transition stage has occurred.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13580-5 [16174748.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):6960-5 [15870186.001]
  • [Cites] Mol Cell Biol. 1999 Dec;19(12):8211-8 [10567546.001]
  • [Cites] J Biol Chem. 1999 Dec 31;274(53):38071-82 [10608876.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1172-9 [11222358.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):687-92 [11257100.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18605-13 [11359795.001]
  • [Cites] Mol Cell Biol. 2002 Jan;22(2):480-91 [11756544.001]
  • [Cites] Genesis. 2002 Feb;32(2):184-6 [11857816.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1296-9 [11888894.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):552-6 [11932749.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10060-5 [12110732.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):28176-81 [12015329.001]
  • [Cites] Science. 2003 Mar 14;299(5613):1753-5 [12637750.001]
  • [Cites] Science. 2003 Apr 18;300(5618):455 [12702868.001]
  • [Cites] Science. 2003 Apr 18;300(5618):489-92 [12702876.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3475-88 [12776200.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4723-33 [12879017.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4415-22 [14555514.001]
  • [Cites] Nat Genet. 2004 Jun;36(6):582-4 [15156141.001]
  • [Cites] Mol Cell Biol. 2004 Oct;24(20):9048-58 [15456878.001]
  • [Cites] Nature. 1982 Feb 18;295(5850):620-2 [7057921.001]
  • [Cites] Nature. 1983 Jan 6;301(5895):89-92 [6185846.001]
  • [Cites] J Natl Cancer Inst. 1986 Oct;77(4):967-76 [3463823.001]
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1159-61 [3342396.001]
  • [Cites] Hum Genet. 1989 Sep;83(2):155-8 [2550354.001]
  • [Cites] Cell. 1995 Apr 21;81(2):197-205 [7537636.001]
  • [Cites] J Bone Miner Res. 1995 Oct;10(10):1512-22 [8686507.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13927-31 [9391129.001]
  • [Cites] Nat Genet. 1998 Jul;19(3):219-20 [9662389.001]
  • [Cites] Nat Biotechnol. 1998 Jul;16(7):657-62 [9661200.001]
  • [Cites] Nucleic Acids Res. 1999 Jun 1;27(11):2291-8 [10325416.001]
  • [Cites] J Biol Chem. 2005 Jan 7;280(1):64-72 [15509558.001]
  • [Cites] Science. 2005 Mar 25;307(5717):1976-8 [15731405.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):17986-91 [15757890.001]
  • [Cites] Cell. 2005 May 6;121(3):465-77 [15882627.001]
  • [Cites] Cell. 1999 Oct 29;99(3):247-57 [10555141.001]
  • (PMID = 16581773.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R37 CA 84198; United States / NICHD NIH HHS / HD / R01 HD050760; United States / NCI NIH HHS / CA / R01 CA 87869; United States / NCI NIH HHS / CA / R37 CA084198; United States / NICHD NIH HHS / HD / R01 HD 0445022; United States / NCI NIH HHS / CA / R01 CA087869
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA methyltransferase 3B
  • [Other-IDs] NLM/ PMC1446955
  •  go-up   go-down


63. Chen WT, Khazaie K, Zhang G, Weissleder R, Tung CH: Detection of dysplastic intestinal adenomas using a fluorescent folate imaging probe. Mol Imaging; 2005 Jan-Mar;4(1):67-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of dysplastic intestinal adenomas using a fluorescent folate imaging probe.
  • Activated macrophages overexpress folate receptors and we used this phenomenon to image inflammatory reactions in colon dysplasia using a fluorescent folate probe (FFP).
  • APC(Delta468) mice injected with FFP showed fluorescent adenomas (target-to-background ratio, adenoma vs. adjacent normal mucosa, of 2.46 +/- 0.41), significantly higher (p < .001) than adenomas in animals injected with a non-folate-containing control probe.
  • Taken together, these results indicate that probe potentially can be used to image dysplastic intestinal adenomas in vivo.
  • [MeSH-major] Adenoma / pathology. Flow Cytometry / methods. Folic Acid / analysis. Intestinal Neoplasms / pathology
  • [MeSH-minor] Animals. Antigens, Differentiation / metabolism. Carrier Proteins / metabolism. Fluorescent Dyes. Folate Receptors, GPI-Anchored. Genes, APC. Macrophage-1 Antigen / metabolism. Macrophages / metabolism. Macrophages / pathology. Mice. Mice, Mutant Strains. Receptors, Cell Surface / metabolism

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15967128.001).
  • [ISSN] 1535-3508
  • [Journal-full-title] Molecular imaging
  • [ISO-abbreviation] Mol Imaging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 86355; United States / NCI NIH HHS / CA / R01 CA 104547-01A1; United States / NCI NIH HHS / CA / R01 CA 99385; United States / NCI NIH HHS / CA / R33 CA 88365
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Carrier Proteins; 0 / Fluorescent Dyes; 0 / Folate Receptors, GPI-Anchored; 0 / Macrophage-1 Antigen; 0 / Receptors, Cell Surface; 0 / monocyte-macrophage differentiation antigen; 935E97BOY8 / Folic Acid
  •  go-up   go-down


64. Loeffler M, Krüger JA, Niethammer AG, Reisfeld RA: Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest; 2006 Jul;116(7):1955-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake.
  • Tumor-associated fibroblasts are key regulators of tumorigenesis.
  • These cells are also the primary source of collagen type I, which contributes to decreased chemotherapeutic drug uptake in tumors and plays a significant role in regulating tumor sensitivity to a variety of chemotherapies.
  • To specifically kill tumor-associated fibroblasts, we constructed an oral DNA vaccine targeting fibroblast activation protein (FAP), which is specifically overexpressed by fibroblasts in the tumor stroma.
  • Through CD8+ T cell-mediated killing of tumor-associated fibroblasts, our vaccine successfully suppressed primary tumor cell growth and metastasis of multidrug-resistant murine colon and breast carcinoma.
  • Furthermore, tumor tissue of FAP-vaccinated mice revealed markedly decreased collagen type I expression and up to 70% greater uptake of chemotherapeutic drugs.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Physiol. 2002 Sep;192(3):259-67 [12124771.001]
  • [Cites] J Exp Med. 1992 Jan 1;175(1):139-46 [1309851.001]
  • [Cites] J Lab Clin Med. 2002 Nov;140(5):320-8 [12434133.001]
  • [Cites] Nat Med. 2002 Dec;8(12):1369-75 [12415261.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):17-22 [12559172.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):960-8 [12569594.001]
  • [Cites] Trends Immunol. 2003 Jun;24(6):335-42 [12810110.001]
  • [Cites] J Pathol. 2003 Jul;200(4):500-3 [12845617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8850-5 [12857959.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3A):1969-96 [12894571.001]
  • [Cites] Crit Rev Immunol. 2003;23(1-2):83-107 [12906261.001]
  • [Cites] J Exp Med. 2003 Nov 17;198(10):1487-93 [14623905.001]
  • [Cites] Science. 2004 Feb 6;303(5659):848-51 [14764882.001]
  • [Cites] Leukemia. 2004 Mar;18(3):589-96 [14712286.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):806-13 [15510161.001]
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36505-12 [10593948.001]
  • [Cites] J Immunol. 2000 Jan 15;164(2):762-7 [10623821.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(3):1089-94 [10629066.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):393-8 [10666367.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2497-503 [10811131.001]
  • [Cites] Curr Opin Mol Ther. 2001 Feb;3(1):77-84 [11249735.001]
  • [Cites] FASEB J. 2001 Mar;15(3):758-67 [11259394.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1549-59 [11733570.001]
  • [Cites] Cytokine. 2002 Feb 7;17(3):157-63 [11895334.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6B):4221-9 [11908675.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6896-900 [1379725.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1550-4 [8453622.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5657-61 [7911242.001]
  • [Cites] Nat Med. 1996 Oct;2(10):1096-103 [8837607.001]
  • [Cites] Oncogene. 1997 Feb 27;14(8):977-85 [9050997.001]
  • [Cites] Nature. 1997 Nov 27;390(6658):404-7 [9389480.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):737-42 [9485029.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3660-7 [9721876.001]
  • [Cites] J Leukoc Biol. 1998 Sep;64(3):275-90 [9738653.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1442-8 [9836476.001]
  • [Cites] J Leukoc Biol. 1999 Jan;65(1):6-15 [9886241.001]
  • [Cites] J Leukoc Biol. 1999 Aug;66(2):252-62 [10449163.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11156-63 [16322266.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4767-72 [12183436.001]
  • [Cites] Science. 2002 May 10;296(5570):1046-9 [12004111.001]
  • [Cites] J Clin Invest. 2002 Jun;109(12):1551-9 [12070302.001]
  • [Cites] J Clin Invest. 2002 Jun;109(12):1607-15 [12070308.001]
  • [Cites] Annu Rev Biophys Bioeng. 1974;3(0):293-339 [4607560.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3039-51 [3555767.001]
  • [Cites] Microvasc Res. 1989 Jan;37(1):77-104 [2646512.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3 Suppl):814s-819s [2404582.001]
  • [Cites] Clin Immunol Immunopathol. 1992 Jan;62(1 Pt 2):S47-54 [1728987.001]
  • [ErratumIn] J Clin Invest. 2009 Feb;119(2):421
  • (PMID = 16794736.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA083856; United States / NCI NIH HHS / CA / CA83856
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Collagen Type I; 0 / Membrane Proteins; 0 / Recombinant Fusion Proteins; 0 / Vaccines, DNA; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  • [Other-IDs] NLM/ PMC1481657
  •  go-up   go-down


65. Saito T, Oda Y, Yamamoto H, Kawaguchi K, Tanaka K, Matsuda S, Iwamoto Y, Tsuneyoshi M: Nuclear beta-catenin correlates with cyclin D1 expression in spindle and pleomorphic sarcomas but not in synovial sarcoma. Hum Pathol; 2006 Jun;37(6):689-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear beta-catenin correlates with cyclin D1 expression in spindle and pleomorphic sarcomas but not in synovial sarcoma.
  • Frequent activation of Wnt signaling pathway has been also shown in synovial sarcoma (SS), suggesting a specific role of this pathway in SS.
  • Immunohistochemical detection of nuclear beta-catenin accumulation correlated with cyclin D1 overexpression in spindle cell and pleomorphic sarcomas (P = .037), and the expression of these proteins evenly distributed throughout each section.
  • Cyclin D1 mRNA expression levels were statistically higher in tumors with cyclin D1 overexpression than in tumors without (P = .037), suggesting that cyclin D1 overexpression is due to transcriptional activation.
  • However, these correlations could not be detected in SS.
  • Mutations in exon 3 of the beta-catenin gene and in the mutation cluster region of adenomatous polyposis coli gene were absent in this series of cases.


66. Kroboth K, Newton IP, Kita K, Dikovskaya D, Zumbrunn J, Waterman-Storer CM, Näthke IS: Lack of adenomatous polyposis coli protein correlates with a decrease in cell migration and overall changes in microtubule stability. Mol Biol Cell; 2007 Mar;18(3):910-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of adenomatous polyposis coli protein correlates with a decrease in cell migration and overall changes in microtubule stability.
  • Most sporadic colorectal tumors carry truncation mutations in the adenomatous polyposis coli (APC) gene.
  • The APC protein is involved in many processes that govern gut tissue.
  • In addition to its involvement in the regulation of beta-catenin, APC is a cytoskeletal regulator with direct and indirect effects on microtubules.
  • Cancer-related truncation mutations lack direct and indirect binding sites for microtubules in APC, suggesting that loss of this function contributes to defects in APC-mutant cells.
  • In this study, we show that loss of APC results in disappearance of cellular protrusions and decreased cell migration.
  • Consistent with the ability of APC to affect cell shape, the overexpression of APC in cells can induce cellular protrusions.
  • These data demonstrate that cell migration and microtubule stability are linked to APC status, thereby revealing a weakness in APC-deficient cells with potential therapeutic implications.


67. Romero-Giménez J, Dopeso H, Blanco I, Guerra-Moreno A, Gonzalez S, Vogt S, Aretz S, Schwartz S Jr, Capella G, Arango D: Germline hypermethylation of the APC promoter is not a frequent cause of familial adenomatous polyposis in APC/MUTYH mutation negative families. Int J Cancer; 2008 Mar 15;122(6):1422-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline hypermethylation of the APC promoter is not a frequent cause of familial adenomatous polyposis in APC/MUTYH mutation negative families.
  • Familial adenomatous polyposis (FAP) is an autosomal dominant syndrome predisposing to colorectal cancer and affects 1 in 5-10,000 births.
  • Inheritance of a mutant allele of the adenomatous polyposis coli (APC) gene is the cause of approximately 80% of FAP and 20-30% of an attenuated form of FAP (AFAP), whereas mutations in MUTYH account for a small proportion of the remaining cases.
  • However, the genetic cause of FAP/AFAP in a significant number of families is not known, and cancer risk for individual members of these families cannot be assessed.
  • There is, therefore, an acute need to identify the underlying genetic cause responsible for FAP/AFAP in APC/MUTYH mutation negative families.
  • Moreover, APC promoter hypermethylation is observed in approximately 20% of sporadic colorectal tumors and correlates with the loss of gene expression.
  • In our study, we used bisulfite treatment and direct sequencing of 2 regulatory regions of APC containing a total of 25 CpG dinucleotides, to investigate the possible role of germline hypermethylation of the APC promoter in FAP and AFAP families that were negative for APC and MUTYH mutations.
  • Analysis of 21 FAP and 39 AFAP families did not identify signs of abnormal promoter methylation, indicating that this form of epigenetic silencing is not a common cause of FAP/AFAP.
  • These results substantially contribute to clarify the potential role of germline epimutations as a cause of inherited predisposition to cancer.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. DNA Glycosylases / genetics. DNA Methylation. Genes, APC. Germ-Line Mutation. Promoter Regions, Genetic

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18027849.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / mutY adenine glycosylase
  •  go-up   go-down


68. Walker LR, Bülow S: [Restorative proctocolectomy with an ileoanal pouch. Postoperative course and long-term functional results]. Ugeskr Laeger; 2008 May 12;170(20):1721-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Over the last 25 years restorative proctocolectomy with an ileoanal pouch has been the gold standard in the surgical treatment of ulcerative colitis and in selected patients with familial adenomatous polyposis.
  • MATERIALS AND METHODS: A prospective cohort analysis and a questionnaire in 178 consecutive patients operated since 1987 in Hvidovre Hospital.
  • The late complications comprised reoperation for intestinal bowel obstruction in 10 (6%), pouch fistula in 6 (3%), pouchitis in 22 (12%), and anastomotic stricture in 8 (5%).
  • In our opinion restorative proctocolectomy with an ileoanal pouch is still the gold standard for patients with ulcerative colitis and for selected patients with familial adenomatous polyposis.
  • [MeSH-major] Adenomatous Polyposis Coli / surgery. Colitis, Ulcerative / surgery. Colonic Pouches. Proctocolectomy, Restorative

  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489884.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


69. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR: Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell; 2007 Apr;11(4):321-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Deregulation of these two pathways in the murine ovarian surface epithelium by conditional inactivation of the Pten and Apc tumor suppressor genes results in the formation of adenocarcinomas morphologically similar to human OEAs with 100% penetrance, short latency, and rapid progression to metastatic disease in upwards of 75% of mice.
  • [MeSH-major] Disease Models, Animal. Ovarian Neoplasms / genetics. PTEN Phosphohydrolase / genetics. Phosphatidylinositol 3-Kinases / genetics. Signal Transduction. Wnt1 Protein / genetics. beta Catenin / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenomatous Polyposis Coli Protein / genetics. Adenomatous Polyposis Coli Protein / physiology. Animals. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Epithelium / metabolism. Epithelium / pathology. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Mice. Mutation. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Ovary / metabolism. Ovary / pathology. Survival Rate. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism


70. Wang D, Wang H, Guo Y, Ning W, Katkuri S, Wahli W, Desvergne B, Dey SK, DuBois RN: Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A; 2006 Dec 12;103(50):19069-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we present genetic and pharmacologic evidence demonstrating that deletion of PPARdelta decreases intestinal adenoma growth in Apc(Min/+) mice and inhibits tumor-promoting effects of a PPARdelta agonist GW501516.
  • More importantly, we found that activation of PPARdelta up-regulated VEGF in colon carcinoma cells.
  • VEGF directly promotes colon tumor epithelial cell survival through activation of PI3K-Akt signaling.
  • These results not only highlight concerns about the use of PPARdelta agonists for treatment of metabolic disorders in patients who are at high risk for colorectal cancer, but also support the rationale for developing PPARdelta antagonists for prevention and/or treatment of cancer.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1999 Oct 29;99(3):335-45 [10555149.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):941-51 [16567391.001]
  • [Cites] Biochem Biophys Res Commun. 2000 May 19;271(3):571-4 [10814503.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(14):5119-28 [10866668.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13275-80 [11087869.001]
  • [Cites] J Invest Dermatol. 2000 Dec;115(6):1000-7 [11121133.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2598-603 [11226285.001]
  • [Cites] Cell Growth Differ. 2001 Mar;12(3):129-35 [11306513.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5306-11 [11309497.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10857-62 [11553814.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):303-8 [11756685.001]
  • [Cites] Acta Biochim Pol. 2000;47(4):1147-57 [11996104.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3282-8 [12036946.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):21341-5 [11927585.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):721-33 [12419217.001]
  • [Cites] Cell. 2003 Apr 18;113(2):159-70 [12705865.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Aug 22;308(2):361-8 [12901877.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):257-65 [12943711.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15924-9 [14676330.001]
  • [Cites] Nat Med. 2004 Mar;10(3):245-7 [14758356.001]
  • [Cites] Nat Med. 2004 Apr;10(4):355-61 [15057233.001]
  • [Cites] Nat Med. 2004 May;10(5):481-3 [15048110.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3162-70 [15126355.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):285-95 [15380519.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):3964-8 [7664263.001]
  • [Cites] Nat Med. 1995 Oct;1(10):1024-8 [7489357.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30336-43 [9804796.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):728-33 [9973224.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):16349-54 [10347193.001]
  • [Cites] J Pathol. 1999 Aug;188(4):369-77 [10440746.001]
  • [Cites] Urology. 1999 Sep;54(3):567-72 [10475375.001]
  • [Cites] Oncogene. 2004 Nov 25;23(55):8992-6 [15480419.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1822-9 [15753380.001]
  • [Cites] J Clin Invest. 2005 Aug;115(8):2119-27 [16075056.001]
  • [Cites] Pharmacogenet Genomics. 2006 Jan;16(1):43-50 [16344721.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):937-45 [16355211.001]
  • [Cites] Biochem J. 2006 Apr 1;395(1):81-8 [16343055.001]
  • [Cites] Mol Cell Biol. 2006 Apr;26(8):3266-81 [16581799.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):748-53 [10762747.001]
  • (PMID = 17148604.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 77839; United States / NIDDK NIH HHS / DK / R01 DK 62112; United States / NICHD NIH HHS / HD / R37 HD 12304; United States / NIDDK NIH HHS / DK / R37 DK 47297; United States / NICHD NIH HHS / HD / P30 HD033994; United States / NICHD NIH HHS / HD / R37 HD012304; United States / NCI NIH HHS / CA / P01 CA077839; United States / NCI NIH HHS / CA / P30 CA 068485; United States / NCI NIH HHS / CA / P30 CA068485; United States / NIDDK NIH HHS / DK / R37 DK047297; United States / NIDDK NIH HHS / DK / R01 DK062112; United States / NICHD NIH HHS / HD / U54 HD033994
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GW 501516; 0 / PPAR delta; 0 / Thiazoles; 0 / Vascular Endothelial Growth Factor A; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC1748178
  •  go-up   go-down


71. Schönthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA: Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin Investig Drugs; 2008 Feb;17(2):197-208
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, it was more recently approved as an oral adjunct to prevent colon cancer development in patients with familial adenomatous polyposis and is presently being investigated for its chemotherapeutic potential in the therapy of advanced cancers.
  • However, in laboratory studies it was discovered that celecoxib was able to suppress tumor growth in the absence of any apparent involvement of COX-2, and additional pharmacologic activities associated with this drug were found.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18230053.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 2,5-dimethylcelecoxib; 0 / Antineoplastic Agents; 0 / OSU 03012; 0 / Pyrazoles; 0 / Sulfonamides; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib
  • [Number-of-references] 91
  •  go-up   go-down


72. Quyn AJ, Steele RJ, Carey FA, Näthke IS: Prognostic and therapeutic implications of Apc mutations in colorectal cancer. Surgeon; 2008 Dec;6(6):350-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and therapeutic implications of Apc mutations in colorectal cancer.
  • The adenomatous polyposis coli gene (Apc) is mutated in most colorectal cancers.
  • The multifunctional character of the Apc protein in the regulation of beta-catenin-mediated gene transcription and cytoskeletal proteins has been well described.
  • An important question is how this protein affects the behaviour of cells within a tumour and how its mutational status influences the prognosis for these tumours.
  • Here we provide an overview of the functions of Apc and examine how this information can be used in the prognosis and development of directed therapy in colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / genetics. Genes, APC / physiology
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Aspirin / pharmacology. Cytoskeleton / genetics. Humans. Prognosis. Signal Transduction / drug effects. Signal Transduction / genetics. Wnt Proteins / genetics. beta Catenin / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surgeon. 2008 Dec;6(6):324 [19110817.001]
  • (PMID = 19110823.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Wnt Proteins; 0 / beta Catenin; R16CO5Y76E / Aspirin
  • [Number-of-references] 87
  •  go-up   go-down


73. Saif MW, Podoltsev NA, Rubin MS, Figueroa JA, Lee MY, Kwon J, Rowen E, Yu J, Kerr RO: Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Cancer Invest; 2010 Feb;28(2):186-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To determine in patients, with locally advanced or metastatic pancreatic cancer (APC), efficacy and safety of treatment with intravenous paclitaxel loaded polymeric micelle (GPM).
  • Patients with APC, ECOG performance status < or = 2, no prior chemotherapy and adequate organ function were treated with 3-hour GPM infusions every 3 weeks.
  • Median TTP for patients treated with 300 or 350 mg/m(2) doses was 3.2 months (95% CI, 2.6-4.2).
  • Median progression free survival (PFS) was 2.8 months (95% CI, 1.4-4.0).
  • Median overall survival (OS) was 6.5 months (95% CI, 5.1-7.9).
  • Disease control rate (CR + PR + stable disease) was 60.0%.
  • CONCLUSIONS: Treatment of APC with GPM at a dose of 300 mg/m(2) q 3 weeks was well tolerated and common toxicities were qualitatively similar to Cremophor-based paclitaxel.
  • Future studies of GPM in combination with other agents for treatment of APC are warranted.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19968498.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Micelles; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


74. Rajakannu M, Ananthakrishnan N, Madhavan M: Isolated mesenteric fibromatosis. Trop Gastroenterol; 2008 Jul-Sep;29(3):179-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibromatosis is a rare, locally aggressive but non-metastasising fibrous mass often associated with familial adenomatous polyposis in Gardner's Syndrome (GS).
  • We report the case of a 40-year-old lady who underwent laparotomy for a large isolated abdominal mass three years after a Whipple's procedure for adenocarcinoma of the distal common bile duct.
  • This case is peculiar in that mesenteric fibromatosis occurred in a patient with prior history of periampullary carcinoma and without history of familial adenomatous polyposis.
  • [MeSH-major] Fibroma / diagnosis. Jejunal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Fibromatosis.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19115615.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


75. Szczepański M, Stelmachowska M, Stryczyński L, Golusiński W, Samara H, Mozer-Lisewska I, Zeromski J: Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. Eur Arch Otorhinolaryngol; 2007 May;264(5):525-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Toll-like receptors 1-13 (TLRs) are crucial for activation of innate immunity and secondarily for the induction of acquired response.
  • Ligand binding to TLR leads to the activation of several genes, predominantly proinflammatory ones such as IL-1 and TNF-alpha and maturation of professional antigen presenting cells (APC) i.e., dendritic cells.
  • It can cause better tumor antigen presentation by APC.
  • Immunohistochemistry and indirect immunoflourescence on frozen tissue sections.
  • It is of interest that TLRs tested were expressed not only on cells of inflammatory infiltrate, but also on tumor cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):15028-34 [11836257.001]
  • [Cites] J Immunol. 2000 Jan 15;164(2):558-61 [10623794.001]
  • [Cites] J Biol Chem. 2004 Sep 24;279(39):40882-9 [15247273.001]
  • [Cites] Scand J Immunol. 2005 Oct;62(4):407-12 [16253129.001]
  • [Cites] Cancer Immunol Immunother. 2004 Oct;53(10):865-78 [15118842.001]
  • [Cites] Eur J Immunol. 2002 Nov;32(11):3235-45 [12555669.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5429-32 [10554011.001]
  • [Cites] Nature. 1997 Jul 24;388(6640):394-7 [9237759.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5009-14 [15958541.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6478-87 [14559840.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Jul;263(7):603-7 [16538507.001]
  • [Cites] Lab Invest. 2006 Jan;86(1):9-22 [16357866.001]
  • [Cites] Nat Rev Immunol. 2004 Sep;4(9):675-87 [15343367.001]
  • [Cites] Semin Cancer Biol. 2006 Feb;16(1):3-15 [16153857.001]
  • [Cites] Cancer Detect Prev. 1998;22(6):549-55 [9824379.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1515-20 [10749115.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):777-85 [15289883.001]
  • [Cites] Clin Cancer Res. 1996 Jan;2(1):161-73 [9816103.001]
  • [Cites] Curr Opin Immunol. 2002 Jun;14(3):380-3 [11973138.001]
  • (PMID = 17165086.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD11; 0 / Antigens, CD3; 0 / HLA-DR Antigens; 0 / Interleukin-1; 0 / Toll-Like Receptor 2; 0 / Toll-Like Receptor 3; 0 / Toll-Like Receptor 4; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


76. Cai SR, Yu JK, Jiang WZ, Zhang SZ, Zheng S: [Application of serum protein markers to distinguish familial adenomatous polyposis (FAP) and sporadic colorectal adenomas]. Zhonghua Zhong Liu Za Zhi; 2009 Mar;31(3):192-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of serum protein markers to distinguish familial adenomatous polyposis (FAP) and sporadic colorectal adenomas].
  • OBJECTIVE: To screen out specifically-expressed serum protein markers in familial adenomatous polyposis (FAP) and to establish a serum protein fingerprint diagnostic model for distinguishing FAP from sporadic colorectal adenomas.
  • METHODS: Serum samples were collected from 19 FAP cases and 16 sporadic colorectal adenomas with informed consent.
  • Serum protein fingerprint profiles were detected by SELDI-TOF-MS with CM 10 protein chip to screen out FAP adenoma-related serum protein markers, and support vector machine (SVG) technique was used to establish the diagnostic model to distinguish FAP from sporadic colorectal adenomas.
  • RESULTS: Six differently-expressed protein peaks (P < 0.01) were detected.
  • Among them proteins of 5640, 3160, 4180 and 4290 m/z were highly expressed in FAP adenomas, and proteins of 3940 and 3400 m/z were highly expressed in sporadic colorectal adenomas.
  • The accuracy of diagnostic model established with SVG to distinguish FAP adenomas and sporadic colorectal adenomas was 94.7% and 93.7%, respectively.
  • CONCLUSION: SELDI-TOF-MS can be effectively used to screen out the differentially expressed serum protein markers in FAP adenomas and sporadic colorectal adenomas, and a diagnostic model build by SVG to distinguish them has been successfully established.
  • Therefore, a useful breakthrough point for research on molecular mechanisms of FAP pathogenesis is provided.
  • [MeSH-major] Adenoma / metabolism. Adenomatous Polyposis Coli / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Gene Expression Profiling
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Protein Array Analysis. Proteomics. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615258.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


77. Lee SH, Ahn BK, Chang HK, Baek SU: Adenocarcinoma in ileal pouch after proctocolectomy for familial adenomatous polyposis: report of a case. J Korean Med Sci; 2009 Oct;24(5):985-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in ileal pouch after proctocolectomy for familial adenomatous polyposis: report of a case.
  • Restorative proctocolectomy with ileal pouch-anal anastomosis is one of the surgical treatments of choice for patients with familial adenomatous polyposis.
  • Although the risk of cancer developing in an ileal pouch is not yet clear, a few cases of adenocarcinoma arising in an ileal pouch have been reported.
  • A 56-yr-old woman was diagnosed as having familial adenomatous polyposis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenomatous Polyposis Coli / surgery. Colonic Pouches / pathology. Colorectal Neoplasms / diagnosis. Proctocolectomy, Restorative

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2000 Nov;47(5):732-4 [11034594.001]
  • [Cites] Med Princ Pract. 2006;15(1):83-6 [16340235.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):487-99 [11330575.001]
  • [Cites] Gastroenterology. 2001 Aug;121(2):275-81 [11487537.001]
  • [Cites] Dis Colon Rectum. 2001 Nov;44(11):1714-5 [11711749.001]
  • [Cites] Int J Colorectal Dis. 2002 Mar;17(2):92-7 [12014427.001]
  • [Cites] Dis Colon Rectum. 2003 Jan;46(1):6-13 [12544515.001]
  • [Cites] Dis Colon Rectum. 2003 Feb;46(2):156-9 [12576887.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1418-23; discussion 1422-3 [14530685.001]
  • [Cites] Colorectal Dis. 2003 Nov;5(6):592-4 [14617250.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):530-4 [14978621.001]
  • [Cites] Dis Colon Rectum. 1983 Dec;26(12):768-71 [6641457.001]
  • [Cites] Ann Surg. 1989 Sep;210(3):268-71; discussion 272-3 [2549890.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):90-5; discussion 95-6 [1987862.001]
  • [Cites] Dis Colon Rectum. 1994 Aug;37(8):824-8 [8055729.001]
  • [Cites] Dis Colon Rectum. 1994 Dec;37(12):1281-5 [7995159.001]
  • [Cites] Gut. 1994 Dec;35(12):1721-7 [7829009.001]
  • [Cites] Gastroenterology. 1995 Oct;109(4):1090-7 [7557073.001]
  • [Cites] Br J Surg. 1996 Apr;83(4):506 [8665242.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):995-9 [8712299.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1487-92 [9136826.001]
  • [Cites] Indian J Cancer. 1997 Mar;34(1):16-9 [9491657.001]
  • [Cites] Int J Colorectal Dis. 1998;13(5-6):196-207 [9870162.001]
  • [Cites] J Gastrointest Surg. 2005 May-Jun;9(5):695-702 [15862266.001]
  • [Cites] Dis Colon Rectum. 2005 Apr;48(4):816-23 [15747076.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):360-4 [11224623.001]
  • (PMID = 19795007.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2752792
  • [Keywords] NOTNLM ; Adenocarcinoma / Adenomatous Polyposis Coli / Ileal Pouches
  •  go-up   go-down


78. Mahalingam D, Kelly KR, Swords RT, Carew J, Nawrocki ST, Giles FJ: Emerging drugs in the treatment of pancreatic cancer. Expert Opin Emerg Drugs; 2009 Jun;14(2):311-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging drugs in the treatment of pancreatic cancer.
  • BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer-related death in the US.
  • However, there is a growing belief that novel biological agents could improve survival of patients with this cancer.
  • Gemcitabine-based chemotherapy remains the cornerstone treatment for advanced pancreatic cancers.
  • So far, the current targeted agents that have been used in combination with gemcitabine have failed to improve clinical outcomes.
  • This failure may stem from the heterogeneous molecular pathogenesis of pancreatic cancers, which involves several oncogenic pathways and defined genetic mutations.
  • OBJECTIVE: The aims of this review are: i) to define the existing treatments available at present for patients with pancreatic cancers in the neo-adjuvant, adjuvant, locally advanced and metastatic settings;.
  • ii) to highlight the molecular heterogeneity of the cancers and the rationale for targeting specific oncogenic pathways;.
  • iii) to give an overview of targeted agents that may potentially have an impact in the treatment of pancreatic cancers.
  • CONCLUSIONS: Molecular pathogenesis of pancreatic cancer involves several pathways and defined genetic mutations.
  • Targeting these complex molecular pathways with a combination of novel biological and chemotherapeutic agents could potentially improve patient outcome.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drugs, Investigational / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant / trends. Drug Delivery Systems. Humans. Mutation. Oncogenes / physiology. Signal Transduction / drug effects. Signal Transduction / physiology


79. Ma JG, Yasue H, Eyer KE, Hiraiwa H, Shimogiri T, Meyers SN, Beever JE, Schook LB, Beattie CW, Liu WS: An integrated RH map of porcine chromosome 10. BMC Genomics; 2009;10:211
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An integrated RH map of porcine chromosome 10.
  • BACKGROUND: Whole genome radiation hybrid (WG-RH) maps serve as "scaffolds" to significantly improve the orientation of small bacterial artificial chromosome (BAC) contigs, order genes within the contigs and assist assembly of a sequence-ready map for virtually any species.
  • Here, we report the construction of a porcine: human comparative map for pig (Sus scrofa) chromosome 10 (SSC10) using the IMNpRH2(12,000-rad) porcine WG-RH panel, integrated with the IMpRH(7000-rad) WG-RH, genetic and BAC fingerprinted contig (FPC) maps.
  • RESULTS: Map vectors from the IMNpRH2(12,000-rad) and IMpRH(7,000-rad) panels were merged to construct parallel framework (FW) maps, within which FW markers common to both panels have an identical order.
  • This strategy reduced map discrepancies between the two panels and significantly improved map accuracy.
  • One linkage group covers SSC10p with accumulated map distances of 738.2 cR(7,000) and 1814.5 cR(12,000), respectively.
  • The second group covers SSC10q at map distances of 1336.9 cR(7,000) and 3353.6 cR(12,000), yielding an overall average map resolution of 16.4 kb/cR(12,000) or 393.5 kb per marker on SSC10.
  • This represents an approximately 2.5-fold increase in map resolution over the IMpRH(7,000-rad) panel.
  • Based on 127 porcine markers that have homologous sequences in the human genome, a detailed comparative map between SSC10 and human (Homo sapiens) chromosome (HSA) 1, 9 and 10 was built.
  • CONCLUSION: This initial comparative RH map of SSC10 refines the syntenic regions between SSC10 and HSA1, 9 and 10.
  • It integrates the IMNpRH2(12,000-rad) and IMpRH(7,000-rad), genetic and BAC FPC maps and provides a scaffold to close potential gaps between contigs prior to genome sequencing and assembly.
  • This map is also useful in fine mapping of QTLs on SSC10.

  • Genetic Alliance. consumer health - Chromosome 10.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Int Conf Intell Syst Mol Biol. 1997;5:258-67 [9322047.001]
  • [Cites] Nihon Juigaku Zasshi. 1988 Apr;50(2):341-5 [3386091.001]
  • [Cites] Cytogenet Cell Genet. 1998;82(3-4):182-8 [9858812.001]
  • [Cites] Mamm Genome. 1999 Aug;10(8):824-30 [10430669.001]
  • [Cites] Anim Genet. 2005 Feb;36(1):76-86 [15670138.001]
  • [Cites] Cytogenet Genome Res. 2006;112(1-2):121-5 [16276100.001]
  • [Cites] Anim Genet. 2005 Dec;36(6):540-2 [16293146.001]
  • [Cites] Genomics. 2005 Dec;86(6):739-52 [16246521.001]
  • [Cites] Genomics. 2005 Dec;86(6):731-8 [16289748.001]
  • [Cites] Mamm Genome. 2006 Aug;17(8):878-85 [16897346.001]
  • [Cites] BMC Vet Res. 2006;2:28 [16970816.001]
  • [Cites] Genome Biol. 2007;8(7):R139 [17625002.001]
  • [Cites] Mamm Genome. 2008 Jan;19(1):51-60 [18188646.001]
  • [Cites] Anim Genet. 2008 Apr;39(2):130-40 [18307580.001]
  • [Cites] Cytogenet Genome Res. 2008;120(1-2):157-63 [18467842.001]
  • [Cites] Genome Res. 2000 May;10(5):691-702 [10810092.001]
  • [Cites] Science. 2001 Feb 16;291(5507):1304-51 [11181995.001]
  • [Cites] Mamm Genome. 2001 May;12(5):366-70 [11331944.001]
  • [Cites] Mamm Genome. 2001 Jul;12(7):518-23 [11420614.001]
  • [Cites] Cytogenet Cell Genet. 2001;94(1-2):84-5 [11701961.001]
  • [Cites] Anim Genet. 2002 Jun;33(3):178-85 [12030920.001]
  • [Cites] Mamm Genome. 2002 Aug;13(8):469-74 [12226714.001]
  • [Cites] Mamm Genome. 2002 Oct;13(10):578-87 [12420136.001]
  • [Cites] Cytogenet Genome Res. 2002;97(3-4):219-28 [12438716.001]
  • [Cites] Anim Genet. 2002 Dec;33(6):477-85 [12464033.001]
  • [Cites] Mamm Genome. 2003 Jan;14(1):71-80 [12532270.001]
  • [Cites] Anim Genet. 2003 Feb;34(1):42-6 [12580785.001]
  • [Cites] Anim Genet. 2003 Jun;34(3):216-20 [12755823.001]
  • [Cites] BMC Genomics. 2003 May 13;4(1):20 [12744726.001]
  • [Cites] J Vet Med Sci. 2004 Jan;66(1):15-23 [14960805.001]
  • [Cites] Cytogenet Genome Res. 2003;102(1-4):121-7 [14970690.001]
  • [Cites] Anim Genet. 2004 Aug;35(4):338-43 [15265077.001]
  • [Cites] Hereditas. 1988;109(2):151-7 [3230021.001]
  • [Cites] Science. 1990 Oct 12;250(4978):245-50 [2218528.001]
  • [Cites] Cytometry. 1992;13(7):703-10 [1451601.001]
  • [Cites] Hum Genet. 1995 Sep;96(3):335-8 [7649552.001]
  • [Cites] Anim Genet. 1995 Oct;26(5):293-8 [7486245.001]
  • [Cites] Mamm Genome. 1996 Apr;7(4):285-90 [8661700.001]
  • [Cites] Genomics. 1996 Sep 1;36(2):252-62 [8812451.001]
  • [Cites] Anim Genet. 2004 Oct;35(5):367-78 [15373740.001]
  • [Cites] Can J Genet Cytol. 1980;22(1):103-16 [7388680.001]
  • [Cites] C R Acad Sci III. 1984;298(14):383-6 [6428712.001]
  • [Cites] Adv Vet Med. 1997;40:157-89 [9395733.001]
  • (PMID = 19426492.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC2689272
  •  go-up   go-down


80. Hara T, Nagata M, Yamashita Y, Fujimoto K, Muraki Y, Yasuda Y, Kurahashi T: [Usefulness of S-1/gemcitabine combination therapy for advanced pancreatic cancer]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1233-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Usefulness of S-1/gemcitabine combination therapy for advanced pancreatic cancer].
  • Combination chemotherapy with S-1 and gemcitabine(GEM)was given to patients with advanced pancreatic cancer and favorable results were obtained.
  • They were administered S-1 at a dose of 80-100 mg/day for 2 weeks and GEM at a dose of 1,000-1,200 mg/body on days 8 and 15 followed by a 2-week recovery period.
  • One course consisted of a 2-week treatment period and a recovery period; this course was repeated in all of these patients.
  • The 3 types of patients have survived for a year and five months, a year and three months, and nine months, respectively, after diagnosis.
  • Combination therapy with S-1 and GEM can be provided for a long-term treatment with few adverse reactions on an outpatient basis.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633271.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


81. Barone M, Scavo MP, Papagni S, Piscitelli D, Guido R, Di Lena M, Comelli MC, Di Leo A: ERβ expression in normal, adenomatous and carcinomatous tissues of patients with familial adenomatous polyposis. Scand J Gastroenterol; 2010 Nov;45(11):1320-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ERβ expression in normal, adenomatous and carcinomatous tissues of patients with familial adenomatous polyposis.
  • OBJECTIVES: The APC gene mutation triggers familial adenomatous polyposis (FAP) and approximately 80% of sporadic colorectal cancers.
  • FAP summarizes the natural history of colorectal cancer because low- and high-grade dysplastic lesions and adenocarcinoma are simultaneously present in the same patients free from individual and environmental variability factors.
  • Estrogen receptor beta (ERβ) has recently been suggested as the most likely mediator of estrogen-related anti-carcinogenic effects in Apc(Min-/+) mice and humans.
  • In this study we assessed the ERβ expression in the intestinal mucosa of FAP patients to verify its possible involvement in tumor progression in colorectal cancer.
  • MATERIAL AND METHODS: ERβ and ERα expression, cell proliferation (Ki-67) and apoptosis (TUNEL), were evaluated on archival biopsy material from six patients with FAP who underwent colectomy.
  • RESULTS: A progressive significant decrease of ERβ expression was observed in the different stages of the disease as compared to normal mucosa (p < 0.001).
  • CONCLUSIONS: ERβ expression is related to the severity of the disease, supporting the role of ERβ as a relevant biomarker of tumor progression and possible chemopreventive target in patients at risk of colonic neoplasia.
  • [MeSH-major] Adenocarcinoma / genetics. Adenomatous Polyposis Coli / genetics. Colon, Descending / metabolism. Colorectal Neoplasms / genetics. DNA, Neoplasm. Estrogen Receptor beta / genetics. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adult. Apoptosis. Biopsy. Cell Proliferation. Disease Progression. Female. Humans. In Situ Nick-End Labeling. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Male. Prognosis. Severity of Illness Index


82. Moschos J, Tzilves D, Paikos D, Tagarakis G, Pilpilidis I, Antonopoulos Z, Kadis S, Katsos I, Tarpagos A: Large mesenteric gastrointestinal stromal tumor in a patient with familial adenomatous polyposis syndrome. Wien Klin Wochenschr; 2006 Jun;118(11-12):355-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large mesenteric gastrointestinal stromal tumor in a patient with familial adenomatous polyposis syndrome.
  • We report a case of a 30-year-old man who presented with severe debilitation, anemia and diarrhea over two months.
  • Colonoscopy revealed many (>100) polyps (familial adenomatous polyposis syndrome).
  • Abdominal CT scan showed a large mass at the left upper abdomen in conjunction with the splenic flexure.
  • We describe for the first time in medical literature the coexistence of familial adenomatous polyposis syndrome and GIST in a 30-year-old man.
  • [MeSH-major] Adenomatous Polyposis Coli / complications. Adenomatous Polyposis Coli / diagnosis. Gastrointestinal Stromal Tumors / complications. Gastrointestinal Stromal Tumors / diagnosis. Mesentery / pathology
  • [MeSH-minor] Adult. Humans. Male. Rare Diseases / diagnosis. Syndrome

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):630-5 [14675690.001]
  • [Cites] Histol Histopathol. 2000 Oct;15(4):1293-301 [11005253.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Br J Surg. 1987 May;74(5):377-80 [3036290.001]
  • [Cites] Eur Radiol. 2002 Dec;12 Suppl 3:S82-5 [12522611.001]
  • [Cites] Turk J Gastroenterol. 2004 Sep;15(3):187-91 [15492920.001]
  • [Cites] Wien Klin Wochenschr. 2001 Jun 15;113(11-12):446-50 [11467091.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Surgery. 1989 May;105(5):668-70 [2539653.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):655-64 [12424067.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):682-6 [10782147.001]
  • [Cites] Gut. 1994 Mar;35(3):377-81 [8150351.001]
  • [Cites] Hum Pathol. 1978 May;9(3):269-83 [26633.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1149-53 [7577011.001]
  • [Cites] Eur J Surg Oncol. 1992 Dec;18(6):580-4 [1478290.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):318-9 [11231473.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1109-18 [10478672.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2005 Jan;34(1):11-4 [15796875.001]
  • (PMID = 16855925.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


83. Buckman SA, Heise CP: Nutrition considerations surrounding restorative proctocolectomy. Nutr Clin Pract; 2010 Jun;25(3):250-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Restorative proctocolectomy with ileal pouch-anal anastomosis has become the surgical treatment of choice for patients with ulcerative colitis and familial polyposis coli syndromes.
  • Pouch construction uses the distal 30-40 cm of ileum, and there exists a potential for postoperative nutrition consequences.
  • Patients who have undergone an ileal pouch-anal anastomosis procedure often describe specific food sensitivities that may require diet alteration, even more so than do patients with permanent ileostomy.
  • [MeSH-minor] Adenomatous Polyposis Coli / surgery. Anal Canal / surgery. Anemia, Iron-Deficiency / etiology. Colitis, Ulcerative / surgery. Diet. Dietary Supplements. Electrolytes / pharmacokinetics. Humans. Ileostomy. Intestinal Absorption. Pouchitis / etiology. Pouchitis / prevention & control. Probiotics. Trace Elements / pharmacokinetics. Vitamin B 12 Deficiency / etiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20581318.001).
  • [ISSN] 1941-2452
  • [Journal-full-title] Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
  • [ISO-abbreviation] Nutr Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Electrolytes; 0 / Trace Elements
  •  go-up   go-down


84. Abdelrazeq AS, Scott N, Thorn C, Verbeke CS, Ambrose NS, Botterill ID, Jayne DG: The impact of spontaneous tumour perforation on outcome following colon cancer surgery. Colorectal Dis; 2008 Oct;10(8):775-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of spontaneous tumour perforation on outcome following colon cancer surgery.
  • OBJECTIVE: The impact of spontaneous tumour perforation on survival following surgery for colon cancer is unclear.
  • METHOD: A prospective histological database was searched for all patients undergoing resection for adenocarcinoma of the colon between 1996 and 2002.
  • Patients with synchronous colonic and rectal cancers, familial polyposis, inflammatory bowel disease, iatrogenic or remote colonic perforation were excluded.
  • Data were analysed for differences in demographics, histological variables, operative mortality, disease-free and overall survival.
  • Patients with perforated cancers were more likely to present with metastatic disease and undergo emergency surgery with a higher 30-day mortality.
  • There was a trend towards reduced overall survival in the perforated group (P = 0.06), but no difference in disease-free survival (P = 0.43).
  • CONCLUSION: Both perforated and nonperforated T4 colon cancers have a poor prognosis.
  • Spontaneous perforation of the cancer is associated with reduced overall survival, due to higher 30-day mortality, but in itself does not appear to significantly impact on disease-free survival.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Cause of Death. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Intestinal Perforation / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Colectomy / adverse effects. Colectomy / methods. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Postoperative Complications / diagnosis. Postoperative Complications / mortality. Probability. Prognosis. Proportional Hazards Models. Prospective Studies. Registries. Risk Assessment. Sex Factors. Statistics, Nonparametric. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18266887.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


85. Scott EN, Garcea G, Doucas H, Steward WP, Dennison AR, Berry DP: Surgical bypass vs. endoscopic stenting for pancreatic ductal adenocarcinoma. HPB (Oxford); 2009 Mar;11(2):118-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Methods of palliation in such patients with locally advanced disease comprise endoscopic placement of a biliary endoprosthesis or surgical bypass.
  • RESULTS: We identified a total of 56 patients, of whom 33 underwent endoscopic stenting and 23 underwent a surgical bypass consisting of a hepaticojejunostomy-en-Y and a gastrojejunostomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1994 Jan;219(1):18-24 [7507656.001]
  • [Cites] Am J Surg. 1994 Jan;167(1):208-12; discussion 212-3 [7508687.001]
  • [Cites] Lancet. 1994 Dec 17;344(8938):1655-60 [7996958.001]
  • [Cites] Eur J Surg Oncol. 1993 Aug;19(4):342-7 [7689488.001]
  • [Cites] Ann Surg. 1993 Apr;217(4):356-68 [7682052.001]
  • [Cites] Am J Surg. 1993 Dec;166(6):626-30; discussion 630-1 [7903846.001]
  • [Cites] J Natl Med Assoc. 1991 May;83(5):405-8 [1714964.001]
  • [Cites] Br J Surg. 1992 Jan;79(1):8-20 [1371087.001]
  • [Cites] Gut. 1989 Aug;30(8):1132-5 [2475392.001]
  • [Cites] Br J Surg. 1988 Dec;75(12):1166-8 [2466520.001]
  • [Cites] Acta Chir Scand. 1986 Apr;152:297-300 [3739536.001]
  • [Cites] Lancet. 1986 Jan 11;1(8472):69-71 [2417075.001]
  • [Cites] Ann Surg. 1990 Aug;212(2):132-9 [1695834.001]
  • [Cites] Gut. 1982 May;23(5):371-5 [7076014.001]
  • [Cites] Cancer. 1982 Dec 1;50(11 Suppl):2689-98 [6182980.001]
  • [Cites] Ann Intern Med. 1978 Nov;89(5 Pt 1):589-3 [82416.001]
  • [Cites] Gut. 1977 Jul;18(7):580-96 [326643.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1282-5 [15362733.001]
  • [Cites] Eur Rev Med Pharmacol Sci. 2003 Nov-Dec;7(6):175-80 [15206487.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Apr 15;19(8):901-5 [15080851.001]
  • [Cites] J Clin Gastroenterol. 2004 Jan;38(1):59-67 [14679329.001]
  • [Cites] Gastrointest Endosc. 2003 Aug;58(2):213-9 [12872088.001]
  • [Cites] Eur J Surg Oncol. 2003 May;29(4):368-73 [12711291.001]
  • [Cites] Hepatogastroenterology. 2003 Jan-Feb;50(49):250-3 [12630033.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(4):367-73 [11521183.001]
  • [Cites] Swiss Surg. 2000;6(5):283-8 [11077497.001]
  • [Cites] Dig Surg. 2000;17(2):143-6 [10781977.001]
  • [Cites] Int J Pancreatol. 2000 Feb;27(1):51-8 [10811023.001]
  • [Cites] Liver Transpl. 2000 May;6(3):302-8 [10827230.001]
  • [Cites] World J Surg. 2000 Jan;24(1):60-4; discussion 64-5 [10594205.001]
  • [Cites] Eur J Surg Oncol. 2007 Sep;33(7):892-7 [17398060.001]
  • [Cites] J Gastrointest Surg. 2006 Feb;10(2):286-91 [16455463.001]
  • [Cites] Asian J Surg. 2005 Oct;28(4):262-5 [16234076.001]
  • [Cites] Gastrointest Endosc. 2004 Dec;60(6):1010-7 [15605026.001]
  • [Cites] Am Surg. 1999 Oct;65(10):955-8 [10515542.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):322-8; discussion 328-30 [10493479.001]
  • [Cites] J R Coll Surg Edinb. 1999 Aug;44(4):231-5 [10453145.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:269-72 [10436838.001]
  • [Cites] J R Coll Surg Edinb. 1997 Aug;42(4):238-43 [9276557.001]
  • [Cites] Br J Surg. 1997 Oct;84(10):1402-6 [9361599.001]
  • [Cites] Ann Surg Oncol. 1996 Sep;3(5):470-5 [8876889.001]
  • [Cites] Am Surg. 1996 Jul;62(7):582-8 [8651556.001]
  • [Cites] Ann Surg. 1996 Jun;223(6):718-25; discussion 725-8 [8645045.001]
  • [Cites] Eur J Surg Oncol. 1995 Apr;21(2):176-82 [7536691.001]
  • (PMID = 19590634.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2697879
  • [Keywords] NOTNLM ; biliary bypass / biliary stent / pancreatic cancer / surgical bypass / survival
  •  go-up   go-down


86. González MA, Menéndez R, Ayala JM, Herrero M, Cuesta J, Domínguez A, Martínez M, Graña JL, Pozo F: [Intra-abdominal desmoid tumor]. Cir Esp; 2005 Jun;77(6):362-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aggressive fibromatosis (desmoid tumor) are rare connective tissue tumors that occur sporadically or in association with familial adenomatous polyposis.
  • Biopsy is required to establish the diagnosis.

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420952.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


87. Mahjoub T, Mtiraoui N, Tamim H, Hizem S, Finan RR, Nsiri B, Almawi WY: Association between adverse pregnancy outcomes and maternal factor V G1691A (Leiden) and prothrombin G20210A genotypes in women with a history of recurrent idiopathic miscarriages. Am J Hematol; 2005 Sep;80(1):12-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • APC resistance (APCR) was detected functionally (measuring the activated clotting time triggered by activated factor X in presence of a fixed amount of purified APC), and FV-Leiden and PRT G20210A genotypes were assessed by PCR.
  • The frequency of the mutant FV (0.1400 vs. 0.0276; P < 0.001) but not PRT 20210 (0.0100 vs. 0.0225; P = 0.159) allele was higher in patients than controls, respectively.
  • APC resistance with factor V Leiden was seen in 27% of patients compared to 11.5% of controls, while APC resistance without factor V Leiden was seen in 12.5% of patients compared to 9.5% of controls.
  • APC resistance and FV Leiden, as well as combination of both, are common thrombotic defects seen in women with idiopathic recurrent pregnancy loss, thus testing for these is recommended in women who have experienced recurrent miscarriages.

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Prothrombin.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16138341.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / factor V Leiden; 9001-24-5 / Factor V; 9001-26-7 / Prothrombin
  •  go-up   go-down


88. Deriy L, Ogawa H, Gao GP, Galili U: In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the alpha1,3galactosyltransferase gene. Cancer Gene Ther; 2005 Jun;12(6):528-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Poor uptake by antigen-presenting cells (APC) is a major reason for low immunogenicity of autologous tumor vaccines.
  • Anti-Gal binds to alpha-gal epitopes (Galalpha1-3Galbeta1-4GlcNAc-R) on vaccinating tumor cells and opsonizes them for effective uptake by APC.
  • Immunization with AdalphaGT transduced autologous tumor cells may serve as adjuvant immunotherapy delivered after completion of standard therapy.
  • This method may complement another gene therapy method in which GM-CSF-secreting vaccinating tumor cells recruit APC to vaccination sites.
  • Anti-Gal-opsonized vaccinating tumor cells will be effectively internalized by GM-CSF recruited APC and transported to draining lymph nodes for processing and presentation of tumor antigens.
  • The subsequent uptake of anti-Gal-opsonized tumor membranes by APC results in their effective transportation to lymph nodes where processed tumor antigens may elicit a protective antitumor immune response.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15818383.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 85868
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Immunodominant Epitopes; EC 2.4.1.- / Galactosyltransferases; EC 2.4.1.133 / alpha 1,3 galactosyltransferase, mouse
  •  go-up